CCJM delivers practical clinical articles relevant to internists, cardiologists, endocrinologists, and other specialists, all written by known experts.

Theme
medstat_ccjm
Top Sections
CME
Reviews
1-Minute Consult
The Clinical Picture
Smart Testing
Symptoms to Diagnosis
ccjm
Main menu
CCJM Main Menu
Explore menu
CCJM Explore Menu
Proclivity ID
18804001
Unpublish
Negative Keywords
gaming
gambling
compulsive behaviors
ammunition
assault rifle
black jack
Boko Haram
bondage
child abuse
cocaine
Daech
drug paraphernalia
explosion
gun
human trafficking
ISIL
ISIS
Islamic caliphate
Islamic state
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
pedophile
pedophilia
poker
porn
pornography
psychedelic drug
recreational drug
sex slave rings
slot machine
terrorism
terrorist
Texas hold 'em
UFC
substance abuse
abuseed
abuseer
abusees
abuseing
abusely
abuses
aeolus
aeolused
aeoluser
aeoluses
aeolusing
aeolusly
aeoluss
ahole
aholeed
aholeer
aholees
aholeing
aholely
aholes
alcohol
alcoholed
alcoholer
alcoholes
alcoholing
alcoholly
alcohols
allman
allmaned
allmaner
allmanes
allmaning
allmanly
allmans
alted
altes
alting
altly
alts
analed
analer
anales
analing
anally
analprobe
analprobeed
analprobeer
analprobees
analprobeing
analprobely
analprobes
anals
anilingus
anilingused
anilinguser
anilinguses
anilingusing
anilingusly
anilinguss
anus
anused
anuser
anuses
anusing
anusly
anuss
areola
areolaed
areolaer
areolaes
areolaing
areolaly
areolas
areole
areoleed
areoleer
areolees
areoleing
areolely
areoles
arian
arianed
arianer
arianes
arianing
arianly
arians
aryan
aryaned
aryaner
aryanes
aryaning
aryanly
aryans
asiaed
asiaer
asiaes
asiaing
asialy
asias
ass
ass hole
ass lick
ass licked
ass licker
ass lickes
ass licking
ass lickly
ass licks
assbang
assbanged
assbangeded
assbangeder
assbangedes
assbangeding
assbangedly
assbangeds
assbanger
assbanges
assbanging
assbangly
assbangs
assbangsed
assbangser
assbangses
assbangsing
assbangsly
assbangss
assed
asser
asses
assesed
asseser
asseses
assesing
assesly
assess
assfuck
assfucked
assfucker
assfuckered
assfuckerer
assfuckeres
assfuckering
assfuckerly
assfuckers
assfuckes
assfucking
assfuckly
assfucks
asshat
asshated
asshater
asshates
asshating
asshatly
asshats
assholeed
assholeer
assholees
assholeing
assholely
assholes
assholesed
assholeser
assholeses
assholesing
assholesly
assholess
assing
assly
assmaster
assmastered
assmasterer
assmasteres
assmastering
assmasterly
assmasters
assmunch
assmunched
assmuncher
assmunches
assmunching
assmunchly
assmunchs
asss
asswipe
asswipeed
asswipeer
asswipees
asswipeing
asswipely
asswipes
asswipesed
asswipeser
asswipeses
asswipesing
asswipesly
asswipess
azz
azzed
azzer
azzes
azzing
azzly
azzs
babeed
babeer
babees
babeing
babely
babes
babesed
babeser
babeses
babesing
babesly
babess
ballsac
ballsaced
ballsacer
ballsaces
ballsacing
ballsack
ballsacked
ballsacker
ballsackes
ballsacking
ballsackly
ballsacks
ballsacly
ballsacs
ballsed
ballser
ballses
ballsing
ballsly
ballss
barf
barfed
barfer
barfes
barfing
barfly
barfs
bastard
bastarded
bastarder
bastardes
bastarding
bastardly
bastards
bastardsed
bastardser
bastardses
bastardsing
bastardsly
bastardss
bawdy
bawdyed
bawdyer
bawdyes
bawdying
bawdyly
bawdys
beaner
beanered
beanerer
beaneres
beanering
beanerly
beaners
beardedclam
beardedclamed
beardedclamer
beardedclames
beardedclaming
beardedclamly
beardedclams
beastiality
beastialityed
beastialityer
beastialityes
beastialitying
beastialityly
beastialitys
beatch
beatched
beatcher
beatches
beatching
beatchly
beatchs
beater
beatered
beaterer
beateres
beatering
beaterly
beaters
beered
beerer
beeres
beering
beerly
beeyotch
beeyotched
beeyotcher
beeyotches
beeyotching
beeyotchly
beeyotchs
beotch
beotched
beotcher
beotches
beotching
beotchly
beotchs
biatch
biatched
biatcher
biatches
biatching
biatchly
biatchs
big tits
big titsed
big titser
big titses
big titsing
big titsly
big titss
bigtits
bigtitsed
bigtitser
bigtitses
bigtitsing
bigtitsly
bigtitss
bimbo
bimboed
bimboer
bimboes
bimboing
bimboly
bimbos
bisexualed
bisexualer
bisexuales
bisexualing
bisexually
bisexuals
bitch
bitched
bitcheded
bitcheder
bitchedes
bitcheding
bitchedly
bitcheds
bitcher
bitches
bitchesed
bitcheser
bitcheses
bitchesing
bitchesly
bitchess
bitching
bitchly
bitchs
bitchy
bitchyed
bitchyer
bitchyes
bitchying
bitchyly
bitchys
bleached
bleacher
bleaches
bleaching
bleachly
bleachs
blow job
blow jobed
blow jober
blow jobes
blow jobing
blow jobly
blow jobs
blowed
blower
blowes
blowing
blowjob
blowjobed
blowjober
blowjobes
blowjobing
blowjobly
blowjobs
blowjobsed
blowjobser
blowjobses
blowjobsing
blowjobsly
blowjobss
blowly
blows
boink
boinked
boinker
boinkes
boinking
boinkly
boinks
bollock
bollocked
bollocker
bollockes
bollocking
bollockly
bollocks
bollocksed
bollockser
bollockses
bollocksing
bollocksly
bollockss
bollok
bolloked
bolloker
bollokes
bolloking
bollokly
bolloks
boner
bonered
bonerer
boneres
bonering
bonerly
boners
bonersed
bonerser
bonerses
bonersing
bonersly
bonerss
bong
bonged
bonger
bonges
bonging
bongly
bongs
boob
boobed
boober
boobes
boobies
boobiesed
boobieser
boobieses
boobiesing
boobiesly
boobiess
boobing
boobly
boobs
boobsed
boobser
boobses
boobsing
boobsly
boobss
booby
boobyed
boobyer
boobyes
boobying
boobyly
boobys
booger
boogered
boogerer
boogeres
boogering
boogerly
boogers
bookie
bookieed
bookieer
bookiees
bookieing
bookiely
bookies
bootee
booteeed
booteeer
booteees
booteeing
booteely
bootees
bootie
bootieed
bootieer
bootiees
bootieing
bootiely
booties
booty
bootyed
bootyer
bootyes
bootying
bootyly
bootys
boozeed
boozeer
boozees
boozeing
boozely
boozer
boozered
boozerer
boozeres
boozering
boozerly
boozers
boozes
boozy
boozyed
boozyer
boozyes
boozying
boozyly
boozys
bosomed
bosomer
bosomes
bosoming
bosomly
bosoms
bosomy
bosomyed
bosomyer
bosomyes
bosomying
bosomyly
bosomys
bugger
buggered
buggerer
buggeres
buggering
buggerly
buggers
bukkake
bukkakeed
bukkakeer
bukkakees
bukkakeing
bukkakely
bukkakes
bull shit
bull shited
bull shiter
bull shites
bull shiting
bull shitly
bull shits
bullshit
bullshited
bullshiter
bullshites
bullshiting
bullshitly
bullshits
bullshitsed
bullshitser
bullshitses
bullshitsing
bullshitsly
bullshitss
bullshitted
bullshitteded
bullshitteder
bullshittedes
bullshitteding
bullshittedly
bullshitteds
bullturds
bullturdsed
bullturdser
bullturdses
bullturdsing
bullturdsly
bullturdss
bung
bunged
bunger
bunges
bunging
bungly
bungs
busty
bustyed
bustyer
bustyes
bustying
bustyly
bustys
butt
butt fuck
butt fucked
butt fucker
butt fuckes
butt fucking
butt fuckly
butt fucks
butted
buttes
buttfuck
buttfucked
buttfucker
buttfuckered
buttfuckerer
buttfuckeres
buttfuckering
buttfuckerly
buttfuckers
buttfuckes
buttfucking
buttfuckly
buttfucks
butting
buttly
buttplug
buttpluged
buttpluger
buttpluges
buttpluging
buttplugly
buttplugs
butts
caca
cacaed
cacaer
cacaes
cacaing
cacaly
cacas
cahone
cahoneed
cahoneer
cahonees
cahoneing
cahonely
cahones
cameltoe
cameltoeed
cameltoeer
cameltoees
cameltoeing
cameltoely
cameltoes
carpetmuncher
carpetmunchered
carpetmuncherer
carpetmuncheres
carpetmunchering
carpetmuncherly
carpetmunchers
cawk
cawked
cawker
cawkes
cawking
cawkly
cawks
chinc
chinced
chincer
chinces
chincing
chincly
chincs
chincsed
chincser
chincses
chincsing
chincsly
chincss
chink
chinked
chinker
chinkes
chinking
chinkly
chinks
chode
chodeed
chodeer
chodees
chodeing
chodely
chodes
chodesed
chodeser
chodeses
chodesing
chodesly
chodess
clit
clited
cliter
clites
cliting
clitly
clitoris
clitorised
clitoriser
clitorises
clitorising
clitorisly
clitoriss
clitorus
clitorused
clitoruser
clitoruses
clitorusing
clitorusly
clitoruss
clits
clitsed
clitser
clitses
clitsing
clitsly
clitss
clitty
clittyed
clittyer
clittyes
clittying
clittyly
clittys
cocain
cocaine
cocained
cocaineed
cocaineer
cocainees
cocaineing
cocainely
cocainer
cocaines
cocaining
cocainly
cocains
cock
cock sucker
cock suckered
cock suckerer
cock suckeres
cock suckering
cock suckerly
cock suckers
cockblock
cockblocked
cockblocker
cockblockes
cockblocking
cockblockly
cockblocks
cocked
cocker
cockes
cockholster
cockholstered
cockholsterer
cockholsteres
cockholstering
cockholsterly
cockholsters
cocking
cockknocker
cockknockered
cockknockerer
cockknockeres
cockknockering
cockknockerly
cockknockers
cockly
cocks
cocksed
cockser
cockses
cocksing
cocksly
cocksmoker
cocksmokered
cocksmokerer
cocksmokeres
cocksmokering
cocksmokerly
cocksmokers
cockss
cocksucker
cocksuckered
cocksuckerer
cocksuckeres
cocksuckering
cocksuckerly
cocksuckers
coital
coitaled
coitaler
coitales
coitaling
coitally
coitals
commie
commieed
commieer
commiees
commieing
commiely
commies
condomed
condomer
condomes
condoming
condomly
condoms
coon
cooned
cooner
coones
cooning
coonly
coons
coonsed
coonser
coonses
coonsing
coonsly
coonss
corksucker
corksuckered
corksuckerer
corksuckeres
corksuckering
corksuckerly
corksuckers
cracked
crackwhore
crackwhoreed
crackwhoreer
crackwhorees
crackwhoreing
crackwhorely
crackwhores
crap
craped
craper
crapes
craping
craply
crappy
crappyed
crappyer
crappyes
crappying
crappyly
crappys
cum
cumed
cumer
cumes
cuming
cumly
cummin
cummined
cumminer
cummines
cumming
cumminged
cumminger
cumminges
cumminging
cummingly
cummings
cummining
cumminly
cummins
cums
cumshot
cumshoted
cumshoter
cumshotes
cumshoting
cumshotly
cumshots
cumshotsed
cumshotser
cumshotses
cumshotsing
cumshotsly
cumshotss
cumslut
cumsluted
cumsluter
cumslutes
cumsluting
cumslutly
cumsluts
cumstain
cumstained
cumstainer
cumstaines
cumstaining
cumstainly
cumstains
cunilingus
cunilingused
cunilinguser
cunilinguses
cunilingusing
cunilingusly
cunilinguss
cunnilingus
cunnilingused
cunnilinguser
cunnilinguses
cunnilingusing
cunnilingusly
cunnilinguss
cunny
cunnyed
cunnyer
cunnyes
cunnying
cunnyly
cunnys
cunt
cunted
cunter
cuntes
cuntface
cuntfaceed
cuntfaceer
cuntfacees
cuntfaceing
cuntfacely
cuntfaces
cunthunter
cunthuntered
cunthunterer
cunthunteres
cunthuntering
cunthunterly
cunthunters
cunting
cuntlick
cuntlicked
cuntlicker
cuntlickered
cuntlickerer
cuntlickeres
cuntlickering
cuntlickerly
cuntlickers
cuntlickes
cuntlicking
cuntlickly
cuntlicks
cuntly
cunts
cuntsed
cuntser
cuntses
cuntsing
cuntsly
cuntss
dago
dagoed
dagoer
dagoes
dagoing
dagoly
dagos
dagosed
dagoser
dagoses
dagosing
dagosly
dagoss
dammit
dammited
dammiter
dammites
dammiting
dammitly
dammits
damn
damned
damneded
damneder
damnedes
damneding
damnedly
damneds
damner
damnes
damning
damnit
damnited
damniter
damnites
damniting
damnitly
damnits
damnly
damns
dick
dickbag
dickbaged
dickbager
dickbages
dickbaging
dickbagly
dickbags
dickdipper
dickdippered
dickdipperer
dickdipperes
dickdippering
dickdipperly
dickdippers
dicked
dicker
dickes
dickface
dickfaceed
dickfaceer
dickfacees
dickfaceing
dickfacely
dickfaces
dickflipper
dickflippered
dickflipperer
dickflipperes
dickflippering
dickflipperly
dickflippers
dickhead
dickheaded
dickheader
dickheades
dickheading
dickheadly
dickheads
dickheadsed
dickheadser
dickheadses
dickheadsing
dickheadsly
dickheadss
dicking
dickish
dickished
dickisher
dickishes
dickishing
dickishly
dickishs
dickly
dickripper
dickrippered
dickripperer
dickripperes
dickrippering
dickripperly
dickrippers
dicks
dicksipper
dicksippered
dicksipperer
dicksipperes
dicksippering
dicksipperly
dicksippers
dickweed
dickweeded
dickweeder
dickweedes
dickweeding
dickweedly
dickweeds
dickwhipper
dickwhippered
dickwhipperer
dickwhipperes
dickwhippering
dickwhipperly
dickwhippers
dickzipper
dickzippered
dickzipperer
dickzipperes
dickzippering
dickzipperly
dickzippers
diddle
diddleed
diddleer
diddlees
diddleing
diddlely
diddles
dike
dikeed
dikeer
dikees
dikeing
dikely
dikes
dildo
dildoed
dildoer
dildoes
dildoing
dildoly
dildos
dildosed
dildoser
dildoses
dildosing
dildosly
dildoss
diligaf
diligafed
diligafer
diligafes
diligafing
diligafly
diligafs
dillweed
dillweeded
dillweeder
dillweedes
dillweeding
dillweedly
dillweeds
dimwit
dimwited
dimwiter
dimwites
dimwiting
dimwitly
dimwits
dingle
dingleed
dingleer
dinglees
dingleing
dinglely
dingles
dipship
dipshiped
dipshiper
dipshipes
dipshiping
dipshiply
dipships
dizzyed
dizzyer
dizzyes
dizzying
dizzyly
dizzys
doggiestyleed
doggiestyleer
doggiestylees
doggiestyleing
doggiestylely
doggiestyles
doggystyleed
doggystyleer
doggystylees
doggystyleing
doggystylely
doggystyles
dong
donged
donger
donges
donging
dongly
dongs
doofus
doofused
doofuser
doofuses
doofusing
doofusly
doofuss
doosh
dooshed
doosher
dooshes
dooshing
dooshly
dooshs
dopeyed
dopeyer
dopeyes
dopeying
dopeyly
dopeys
douchebag
douchebaged
douchebager
douchebages
douchebaging
douchebagly
douchebags
douchebagsed
douchebagser
douchebagses
douchebagsing
douchebagsly
douchebagss
doucheed
doucheer
douchees
doucheing
douchely
douches
douchey
doucheyed
doucheyer
doucheyes
doucheying
doucheyly
doucheys
drunk
drunked
drunker
drunkes
drunking
drunkly
drunks
dumass
dumassed
dumasser
dumasses
dumassing
dumassly
dumasss
dumbass
dumbassed
dumbasser
dumbasses
dumbassesed
dumbasseser
dumbasseses
dumbassesing
dumbassesly
dumbassess
dumbassing
dumbassly
dumbasss
dummy
dummyed
dummyer
dummyes
dummying
dummyly
dummys
dyke
dykeed
dykeer
dykees
dykeing
dykely
dykes
dykesed
dykeser
dykeses
dykesing
dykesly
dykess
erotic
eroticed
eroticer
erotices
eroticing
eroticly
erotics
extacy
extacyed
extacyer
extacyes
extacying
extacyly
extacys
extasy
extasyed
extasyer
extasyes
extasying
extasyly
extasys
fack
facked
facker
fackes
facking
fackly
facks
fag
faged
fager
fages
fagg
fagged
faggeded
faggeder
faggedes
faggeding
faggedly
faggeds
fagger
fagges
fagging
faggit
faggited
faggiter
faggites
faggiting
faggitly
faggits
faggly
faggot
faggoted
faggoter
faggotes
faggoting
faggotly
faggots
faggs
faging
fagly
fagot
fagoted
fagoter
fagotes
fagoting
fagotly
fagots
fags
fagsed
fagser
fagses
fagsing
fagsly
fagss
faig
faiged
faiger
faiges
faiging
faigly
faigs
faigt
faigted
faigter
faigtes
faigting
faigtly
faigts
fannybandit
fannybandited
fannybanditer
fannybandites
fannybanditing
fannybanditly
fannybandits
farted
farter
fartes
farting
fartknocker
fartknockered
fartknockerer
fartknockeres
fartknockering
fartknockerly
fartknockers
fartly
farts
felch
felched
felcher
felchered
felcherer
felcheres
felchering
felcherly
felchers
felches
felching
felchinged
felchinger
felchinges
felchinging
felchingly
felchings
felchly
felchs
fellate
fellateed
fellateer
fellatees
fellateing
fellately
fellates
fellatio
fellatioed
fellatioer
fellatioes
fellatioing
fellatioly
fellatios
feltch
feltched
feltcher
feltchered
feltcherer
feltcheres
feltchering
feltcherly
feltchers
feltches
feltching
feltchly
feltchs
feom
feomed
feomer
feomes
feoming
feomly
feoms
fisted
fisteded
fisteder
fistedes
fisteding
fistedly
fisteds
fisting
fistinged
fistinger
fistinges
fistinging
fistingly
fistings
fisty
fistyed
fistyer
fistyes
fistying
fistyly
fistys
floozy
floozyed
floozyer
floozyes
floozying
floozyly
floozys
foad
foaded
foader
foades
foading
foadly
foads
fondleed
fondleer
fondlees
fondleing
fondlely
fondles
foobar
foobared
foobarer
foobares
foobaring
foobarly
foobars
freex
freexed
freexer
freexes
freexing
freexly
freexs
frigg
frigga
friggaed
friggaer
friggaes
friggaing
friggaly
friggas
frigged
frigger
frigges
frigging
friggly
friggs
fubar
fubared
fubarer
fubares
fubaring
fubarly
fubars
fuck
fuckass
fuckassed
fuckasser
fuckasses
fuckassing
fuckassly
fuckasss
fucked
fuckeded
fuckeder
fuckedes
fuckeding
fuckedly
fuckeds
fucker
fuckered
fuckerer
fuckeres
fuckering
fuckerly
fuckers
fuckes
fuckface
fuckfaceed
fuckfaceer
fuckfacees
fuckfaceing
fuckfacely
fuckfaces
fuckin
fuckined
fuckiner
fuckines
fucking
fuckinged
fuckinger
fuckinges
fuckinging
fuckingly
fuckings
fuckining
fuckinly
fuckins
fuckly
fucknugget
fucknuggeted
fucknuggeter
fucknuggetes
fucknuggeting
fucknuggetly
fucknuggets
fucknut
fucknuted
fucknuter
fucknutes
fucknuting
fucknutly
fucknuts
fuckoff
fuckoffed
fuckoffer
fuckoffes
fuckoffing
fuckoffly
fuckoffs
fucks
fucksed
fuckser
fuckses
fucksing
fucksly
fuckss
fucktard
fucktarded
fucktarder
fucktardes
fucktarding
fucktardly
fucktards
fuckup
fuckuped
fuckuper
fuckupes
fuckuping
fuckuply
fuckups
fuckwad
fuckwaded
fuckwader
fuckwades
fuckwading
fuckwadly
fuckwads
fuckwit
fuckwited
fuckwiter
fuckwites
fuckwiting
fuckwitly
fuckwits
fudgepacker
fudgepackered
fudgepackerer
fudgepackeres
fudgepackering
fudgepackerly
fudgepackers
fuk
fuked
fuker
fukes
fuking
fukly
fuks
fvck
fvcked
fvcker
fvckes
fvcking
fvckly
fvcks
fxck
fxcked
fxcker
fxckes
fxcking
fxckly
fxcks
gae
gaeed
gaeer
gaees
gaeing
gaely
gaes
gai
gaied
gaier
gaies
gaiing
gaily
gais
ganja
ganjaed
ganjaer
ganjaes
ganjaing
ganjaly
ganjas
gayed
gayer
gayes
gaying
gayly
gays
gaysed
gayser
gayses
gaysing
gaysly
gayss
gey
geyed
geyer
geyes
geying
geyly
geys
gfc
gfced
gfcer
gfces
gfcing
gfcly
gfcs
gfy
gfyed
gfyer
gfyes
gfying
gfyly
gfys
ghay
ghayed
ghayer
ghayes
ghaying
ghayly
ghays
ghey
gheyed
gheyer
gheyes
gheying
gheyly
gheys
gigolo
gigoloed
gigoloer
gigoloes
gigoloing
gigololy
gigolos
goatse
goatseed
goatseer
goatsees
goatseing
goatsely
goatses
godamn
godamned
godamner
godamnes
godamning
godamnit
godamnited
godamniter
godamnites
godamniting
godamnitly
godamnits
godamnly
godamns
goddam
goddamed
goddamer
goddames
goddaming
goddamly
goddammit
goddammited
goddammiter
goddammites
goddammiting
goddammitly
goddammits
goddamn
goddamned
goddamner
goddamnes
goddamning
goddamnly
goddamns
goddams
goldenshower
goldenshowered
goldenshowerer
goldenshoweres
goldenshowering
goldenshowerly
goldenshowers
gonad
gonaded
gonader
gonades
gonading
gonadly
gonads
gonadsed
gonadser
gonadses
gonadsing
gonadsly
gonadss
gook
gooked
gooker
gookes
gooking
gookly
gooks
gooksed
gookser
gookses
gooksing
gooksly
gookss
gringo
gringoed
gringoer
gringoes
gringoing
gringoly
gringos
gspot
gspoted
gspoter
gspotes
gspoting
gspotly
gspots
gtfo
gtfoed
gtfoer
gtfoes
gtfoing
gtfoly
gtfos
guido
guidoed
guidoer
guidoes
guidoing
guidoly
guidos
handjob
handjobed
handjober
handjobes
handjobing
handjobly
handjobs
hard on
hard oned
hard oner
hard ones
hard oning
hard only
hard ons
hardknight
hardknighted
hardknighter
hardknightes
hardknighting
hardknightly
hardknights
hebe
hebeed
hebeer
hebees
hebeing
hebely
hebes
heeb
heebed
heeber
heebes
heebing
heebly
heebs
hell
helled
heller
helles
helling
hellly
hells
hemp
hemped
hemper
hempes
hemping
hemply
hemps
heroined
heroiner
heroines
heroining
heroinly
heroins
herp
herped
herper
herpes
herpesed
herpeser
herpeses
herpesing
herpesly
herpess
herping
herply
herps
herpy
herpyed
herpyer
herpyes
herpying
herpyly
herpys
hitler
hitlered
hitlerer
hitleres
hitlering
hitlerly
hitlers
hived
hiver
hives
hiving
hivly
hivs
hobag
hobaged
hobager
hobages
hobaging
hobagly
hobags
homey
homeyed
homeyer
homeyes
homeying
homeyly
homeys
homo
homoed
homoer
homoes
homoey
homoeyed
homoeyer
homoeyes
homoeying
homoeyly
homoeys
homoing
homoly
homos
honky
honkyed
honkyer
honkyes
honkying
honkyly
honkys
hooch
hooched
hoocher
hooches
hooching
hoochly
hoochs
hookah
hookahed
hookaher
hookahes
hookahing
hookahly
hookahs
hooker
hookered
hookerer
hookeres
hookering
hookerly
hookers
hoor
hoored
hoorer
hoores
hooring
hoorly
hoors
hootch
hootched
hootcher
hootches
hootching
hootchly
hootchs
hooter
hootered
hooterer
hooteres
hootering
hooterly
hooters
hootersed
hooterser
hooterses
hootersing
hootersly
hooterss
horny
hornyed
hornyer
hornyes
hornying
hornyly
hornys
houstoned
houstoner
houstones
houstoning
houstonly
houstons
hump
humped
humpeded
humpeder
humpedes
humpeding
humpedly
humpeds
humper
humpes
humping
humpinged
humpinger
humpinges
humpinging
humpingly
humpings
humply
humps
husbanded
husbander
husbandes
husbanding
husbandly
husbands
hussy
hussyed
hussyer
hussyes
hussying
hussyly
hussys
hymened
hymener
hymenes
hymening
hymenly
hymens
inbred
inbreded
inbreder
inbredes
inbreding
inbredly
inbreds
incest
incested
incester
incestes
incesting
incestly
incests
injun
injuned
injuner
injunes
injuning
injunly
injuns
jackass
jackassed
jackasser
jackasses
jackassing
jackassly
jackasss
jackhole
jackholeed
jackholeer
jackholees
jackholeing
jackholely
jackholes
jackoff
jackoffed
jackoffer
jackoffes
jackoffing
jackoffly
jackoffs
jap
japed
japer
japes
japing
japly
japs
japsed
japser
japses
japsing
japsly
japss
jerkoff
jerkoffed
jerkoffer
jerkoffes
jerkoffing
jerkoffly
jerkoffs
jerks
jism
jismed
jismer
jismes
jisming
jismly
jisms
jiz
jized
jizer
jizes
jizing
jizly
jizm
jizmed
jizmer
jizmes
jizming
jizmly
jizms
jizs
jizz
jizzed
jizzeded
jizzeder
jizzedes
jizzeding
jizzedly
jizzeds
jizzer
jizzes
jizzing
jizzly
jizzs
junkie
junkieed
junkieer
junkiees
junkieing
junkiely
junkies
junky
junkyed
junkyer
junkyes
junkying
junkyly
junkys
kike
kikeed
kikeer
kikees
kikeing
kikely
kikes
kikesed
kikeser
kikeses
kikesing
kikesly
kikess
killed
killer
killes
killing
killly
kills
kinky
kinkyed
kinkyer
kinkyes
kinkying
kinkyly
kinkys
kkk
kkked
kkker
kkkes
kkking
kkkly
kkks
klan
klaned
klaner
klanes
klaning
klanly
klans
knobend
knobended
knobender
knobendes
knobending
knobendly
knobends
kooch
kooched
koocher
kooches
koochesed
koocheser
koocheses
koochesing
koochesly
koochess
kooching
koochly
koochs
kootch
kootched
kootcher
kootches
kootching
kootchly
kootchs
kraut
krauted
krauter
krautes
krauting
krautly
krauts
kyke
kykeed
kykeer
kykees
kykeing
kykely
kykes
lech
leched
lecher
leches
leching
lechly
lechs
leper
lepered
leperer
leperes
lepering
leperly
lepers
lesbiansed
lesbianser
lesbianses
lesbiansing
lesbiansly
lesbianss
lesbo
lesboed
lesboer
lesboes
lesboing
lesboly
lesbos
lesbosed
lesboser
lesboses
lesbosing
lesbosly
lesboss
lez
lezbianed
lezbianer
lezbianes
lezbianing
lezbianly
lezbians
lezbiansed
lezbianser
lezbianses
lezbiansing
lezbiansly
lezbianss
lezbo
lezboed
lezboer
lezboes
lezboing
lezboly
lezbos
lezbosed
lezboser
lezboses
lezbosing
lezbosly
lezboss
lezed
lezer
lezes
lezing
lezly
lezs
lezzie
lezzieed
lezzieer
lezziees
lezzieing
lezziely
lezzies
lezziesed
lezzieser
lezzieses
lezziesing
lezziesly
lezziess
lezzy
lezzyed
lezzyer
lezzyes
lezzying
lezzyly
lezzys
lmaoed
lmaoer
lmaoes
lmaoing
lmaoly
lmaos
lmfao
lmfaoed
lmfaoer
lmfaoes
lmfaoing
lmfaoly
lmfaos
loined
loiner
loines
loining
loinly
loins
loinsed
loinser
loinses
loinsing
loinsly
loinss
lubeed
lubeer
lubees
lubeing
lubely
lubes
lusty
lustyed
lustyer
lustyes
lustying
lustyly
lustys
massa
massaed
massaer
massaes
massaing
massaly
massas
masterbate
masterbateed
masterbateer
masterbatees
masterbateing
masterbately
masterbates
masterbating
masterbatinged
masterbatinger
masterbatinges
masterbatinging
masterbatingly
masterbatings
masterbation
masterbationed
masterbationer
masterbationes
masterbationing
masterbationly
masterbations
masturbate
masturbateed
masturbateer
masturbatees
masturbateing
masturbately
masturbates
masturbating
masturbatinged
masturbatinger
masturbatinges
masturbatinging
masturbatingly
masturbatings
masturbation
masturbationed
masturbationer
masturbationes
masturbationing
masturbationly
masturbations
methed
mether
methes
mething
methly
meths
militaryed
militaryer
militaryes
militarying
militaryly
militarys
mofo
mofoed
mofoer
mofoes
mofoing
mofoly
mofos
molest
molested
molester
molestes
molesting
molestly
molests
moolie
moolieed
moolieer
mooliees
moolieing
mooliely
moolies
moron
moroned
moroner
morones
moroning
moronly
morons
motherfucka
motherfuckaed
motherfuckaer
motherfuckaes
motherfuckaing
motherfuckaly
motherfuckas
motherfucker
motherfuckered
motherfuckerer
motherfuckeres
motherfuckering
motherfuckerly
motherfuckers
motherfucking
motherfuckinged
motherfuckinger
motherfuckinges
motherfuckinging
motherfuckingly
motherfuckings
mtherfucker
mtherfuckered
mtherfuckerer
mtherfuckeres
mtherfuckering
mtherfuckerly
mtherfuckers
mthrfucker
mthrfuckered
mthrfuckerer
mthrfuckeres
mthrfuckering
mthrfuckerly
mthrfuckers
mthrfucking
mthrfuckinged
mthrfuckinger
mthrfuckinges
mthrfuckinging
mthrfuckingly
mthrfuckings
muff
muffdiver
muffdivered
muffdiverer
muffdiveres
muffdivering
muffdiverly
muffdivers
muffed
muffer
muffes
muffing
muffly
muffs
murdered
murderer
murderes
murdering
murderly
murders
muthafuckaz
muthafuckazed
muthafuckazer
muthafuckazes
muthafuckazing
muthafuckazly
muthafuckazs
muthafucker
muthafuckered
muthafuckerer
muthafuckeres
muthafuckering
muthafuckerly
muthafuckers
mutherfucker
mutherfuckered
mutherfuckerer
mutherfuckeres
mutherfuckering
mutherfuckerly
mutherfuckers
mutherfucking
mutherfuckinged
mutherfuckinger
mutherfuckinges
mutherfuckinging
mutherfuckingly
mutherfuckings
muthrfucking
muthrfuckinged
muthrfuckinger
muthrfuckinges
muthrfuckinging
muthrfuckingly
muthrfuckings
nad
naded
nader
nades
nading
nadly
nads
nadsed
nadser
nadses
nadsing
nadsly
nadss
nakeded
nakeder
nakedes
nakeding
nakedly
nakeds
napalm
napalmed
napalmer
napalmes
napalming
napalmly
napalms
nappy
nappyed
nappyer
nappyes
nappying
nappyly
nappys
nazi
nazied
nazier
nazies
naziing
nazily
nazis
nazism
nazismed
nazismer
nazismes
nazisming
nazismly
nazisms
negro
negroed
negroer
negroes
negroing
negroly
negros
nigga
niggaed
niggaer
niggaes
niggah
niggahed
niggaher
niggahes
niggahing
niggahly
niggahs
niggaing
niggaly
niggas
niggased
niggaser
niggases
niggasing
niggasly
niggass
niggaz
niggazed
niggazer
niggazes
niggazing
niggazly
niggazs
nigger
niggered
niggerer
niggeres
niggering
niggerly
niggers
niggersed
niggerser
niggerses
niggersing
niggersly
niggerss
niggle
niggleed
niggleer
nigglees
niggleing
nigglely
niggles
niglet
nigleted
nigleter
nigletes
nigleting
nigletly
niglets
nimrod
nimroded
nimroder
nimrodes
nimroding
nimrodly
nimrods
ninny
ninnyed
ninnyer
ninnyes
ninnying
ninnyly
ninnys
nooky
nookyed
nookyer
nookyes
nookying
nookyly
nookys
nuccitelli
nuccitellied
nuccitellier
nuccitellies
nuccitelliing
nuccitellily
nuccitellis
nympho
nymphoed
nymphoer
nymphoes
nymphoing
nympholy
nymphos
opium
opiumed
opiumer
opiumes
opiuming
opiumly
opiums
orgies
orgiesed
orgieser
orgieses
orgiesing
orgiesly
orgiess
orgy
orgyed
orgyer
orgyes
orgying
orgyly
orgys
paddy
paddyed
paddyer
paddyes
paddying
paddyly
paddys
paki
pakied
pakier
pakies
pakiing
pakily
pakis
pantie
pantieed
pantieer
pantiees
pantieing
pantiely
panties
pantiesed
pantieser
pantieses
pantiesing
pantiesly
pantiess
panty
pantyed
pantyer
pantyes
pantying
pantyly
pantys
pastie
pastieed
pastieer
pastiees
pastieing
pastiely
pasties
pasty
pastyed
pastyer
pastyes
pastying
pastyly
pastys
pecker
peckered
peckerer
peckeres
peckering
peckerly
peckers
pedo
pedoed
pedoer
pedoes
pedoing
pedoly
pedophile
pedophileed
pedophileer
pedophilees
pedophileing
pedophilely
pedophiles
pedophilia
pedophiliac
pedophiliaced
pedophiliacer
pedophiliaces
pedophiliacing
pedophiliacly
pedophiliacs
pedophiliaed
pedophiliaer
pedophiliaes
pedophiliaing
pedophilialy
pedophilias
pedos
penial
penialed
penialer
peniales
penialing
penially
penials
penile
penileed
penileer
penilees
penileing
penilely
peniles
penis
penised
peniser
penises
penising
penisly
peniss
perversion
perversioned
perversioner
perversiones
perversioning
perversionly
perversions
peyote
peyoteed
peyoteer
peyotees
peyoteing
peyotely
peyotes
phuck
phucked
phucker
phuckes
phucking
phuckly
phucks
pillowbiter
pillowbitered
pillowbiterer
pillowbiteres
pillowbitering
pillowbiterly
pillowbiters
pimp
pimped
pimper
pimpes
pimping
pimply
pimps
pinko
pinkoed
pinkoer
pinkoes
pinkoing
pinkoly
pinkos
pissed
pisseded
pisseder
pissedes
pisseding
pissedly
pisseds
pisser
pisses
pissing
pissly
pissoff
pissoffed
pissoffer
pissoffes
pissoffing
pissoffly
pissoffs
pisss
polack
polacked
polacker
polackes
polacking
polackly
polacks
pollock
pollocked
pollocker
pollockes
pollocking
pollockly
pollocks
poon
pooned
pooner
poones
pooning
poonly
poons
poontang
poontanged
poontanger
poontanges
poontanging
poontangly
poontangs
porn
porned
porner
pornes
porning
pornly
porno
pornoed
pornoer
pornoes
pornography
pornographyed
pornographyer
pornographyes
pornographying
pornographyly
pornographys
pornoing
pornoly
pornos
porns
prick
pricked
pricker
prickes
pricking
prickly
pricks
prig
priged
priger
priges
priging
prigly
prigs
prostitute
prostituteed
prostituteer
prostitutees
prostituteing
prostitutely
prostitutes
prude
prudeed
prudeer
prudees
prudeing
prudely
prudes
punkass
punkassed
punkasser
punkasses
punkassing
punkassly
punkasss
punky
punkyed
punkyer
punkyes
punkying
punkyly
punkys
puss
pussed
pusser
pusses
pussies
pussiesed
pussieser
pussieses
pussiesing
pussiesly
pussiess
pussing
pussly
pusss
pussy
pussyed
pussyer
pussyes
pussying
pussyly
pussypounder
pussypoundered
pussypounderer
pussypounderes
pussypoundering
pussypounderly
pussypounders
pussys
puto
putoed
putoer
putoes
putoing
putoly
putos
queaf
queafed
queafer
queafes
queafing
queafly
queafs
queef
queefed
queefer
queefes
queefing
queefly
queefs
queer
queered
queerer
queeres
queering
queerly
queero
queeroed
queeroer
queeroes
queeroing
queeroly
queeros
queers
queersed
queerser
queerses
queersing
queersly
queerss
quicky
quickyed
quickyer
quickyes
quickying
quickyly
quickys
quim
quimed
quimer
quimes
quiming
quimly
quims
racy
racyed
racyer
racyes
racying
racyly
racys
rape
raped
rapeded
rapeder
rapedes
rapeding
rapedly
rapeds
rapeed
rapeer
rapees
rapeing
rapely
raper
rapered
raperer
raperes
rapering
raperly
rapers
rapes
rapist
rapisted
rapister
rapistes
rapisting
rapistly
rapists
raunch
raunched
rauncher
raunches
raunching
raunchly
raunchs
rectus
rectused
rectuser
rectuses
rectusing
rectusly
rectuss
reefer
reefered
reeferer
reeferes
reefering
reeferly
reefers
reetard
reetarded
reetarder
reetardes
reetarding
reetardly
reetards
reich
reiched
reicher
reiches
reiching
reichly
reichs
retard
retarded
retardeded
retardeder
retardedes
retardeding
retardedly
retardeds
retarder
retardes
retarding
retardly
retards
rimjob
rimjobed
rimjober
rimjobes
rimjobing
rimjobly
rimjobs
ritard
ritarded
ritarder
ritardes
ritarding
ritardly
ritards
rtard
rtarded
rtarder
rtardes
rtarding
rtardly
rtards
rum
rumed
rumer
rumes
ruming
rumly
rump
rumped
rumper
rumpes
rumping
rumply
rumprammer
rumprammered
rumprammerer
rumprammeres
rumprammering
rumprammerly
rumprammers
rumps
rums
ruski
ruskied
ruskier
ruskies
ruskiing
ruskily
ruskis
sadism
sadismed
sadismer
sadismes
sadisming
sadismly
sadisms
sadist
sadisted
sadister
sadistes
sadisting
sadistly
sadists
scag
scaged
scager
scages
scaging
scagly
scags
scantily
scantilyed
scantilyer
scantilyes
scantilying
scantilyly
scantilys
schlong
schlonged
schlonger
schlonges
schlonging
schlongly
schlongs
scrog
scroged
scroger
scroges
scroging
scrogly
scrogs
scrot
scrote
scroted
scroteed
scroteer
scrotees
scroteing
scrotely
scroter
scrotes
scroting
scrotly
scrots
scrotum
scrotumed
scrotumer
scrotumes
scrotuming
scrotumly
scrotums
scrud
scruded
scruder
scrudes
scruding
scrudly
scruds
scum
scumed
scumer
scumes
scuming
scumly
scums
seaman
seamaned
seamaner
seamanes
seamaning
seamanly
seamans
seamen
seamened
seamener
seamenes
seamening
seamenly
seamens
seduceed
seduceer
seducees
seduceing
seducely
seduces
semen
semened
semener
semenes
semening
semenly
semens
shamedame
shamedameed
shamedameer
shamedamees
shamedameing
shamedamely
shamedames
shit
shite
shiteater
shiteatered
shiteaterer
shiteateres
shiteatering
shiteaterly
shiteaters
shited
shiteed
shiteer
shitees
shiteing
shitely
shiter
shites
shitface
shitfaceed
shitfaceer
shitfacees
shitfaceing
shitfacely
shitfaces
shithead
shitheaded
shitheader
shitheades
shitheading
shitheadly
shitheads
shithole
shitholeed
shitholeer
shitholees
shitholeing
shitholely
shitholes
shithouse
shithouseed
shithouseer
shithousees
shithouseing
shithousely
shithouses
shiting
shitly
shits
shitsed
shitser
shitses
shitsing
shitsly
shitss
shitt
shitted
shitteded
shitteder
shittedes
shitteding
shittedly
shitteds
shitter
shittered
shitterer
shitteres
shittering
shitterly
shitters
shittes
shitting
shittly
shitts
shitty
shittyed
shittyer
shittyes
shittying
shittyly
shittys
shiz
shized
shizer
shizes
shizing
shizly
shizs
shooted
shooter
shootes
shooting
shootly
shoots
sissy
sissyed
sissyer
sissyes
sissying
sissyly
sissys
skag
skaged
skager
skages
skaging
skagly
skags
skank
skanked
skanker
skankes
skanking
skankly
skanks
slave
slaveed
slaveer
slavees
slaveing
slavely
slaves
sleaze
sleazeed
sleazeer
sleazees
sleazeing
sleazely
sleazes
sleazy
sleazyed
sleazyer
sleazyes
sleazying
sleazyly
sleazys
slut
slutdumper
slutdumpered
slutdumperer
slutdumperes
slutdumpering
slutdumperly
slutdumpers
sluted
sluter
slutes
sluting
slutkiss
slutkissed
slutkisser
slutkisses
slutkissing
slutkissly
slutkisss
slutly
sluts
slutsed
slutser
slutses
slutsing
slutsly
slutss
smegma
smegmaed
smegmaer
smegmaes
smegmaing
smegmaly
smegmas
smut
smuted
smuter
smutes
smuting
smutly
smuts
smutty
smuttyed
smuttyer
smuttyes
smuttying
smuttyly
smuttys
snatch
snatched
snatcher
snatches
snatching
snatchly
snatchs
sniper
snipered
sniperer
sniperes
snipering
sniperly
snipers
snort
snorted
snorter
snortes
snorting
snortly
snorts
snuff
snuffed
snuffer
snuffes
snuffing
snuffly
snuffs
sodom
sodomed
sodomer
sodomes
sodoming
sodomly
sodoms
spic
spiced
spicer
spices
spicing
spick
spicked
spicker
spickes
spicking
spickly
spicks
spicly
spics
spik
spoof
spoofed
spoofer
spoofes
spoofing
spoofly
spoofs
spooge
spoogeed
spoogeer
spoogees
spoogeing
spoogely
spooges
spunk
spunked
spunker
spunkes
spunking
spunkly
spunks
steamyed
steamyer
steamyes
steamying
steamyly
steamys
stfu
stfued
stfuer
stfues
stfuing
stfuly
stfus
stiffy
stiffyed
stiffyer
stiffyes
stiffying
stiffyly
stiffys
stoneded
stoneder
stonedes
stoneding
stonedly
stoneds
stupided
stupider
stupides
stupiding
stupidly
stupids
suckeded
suckeder
suckedes
suckeding
suckedly
suckeds
sucker
suckes
sucking
suckinged
suckinger
suckinges
suckinging
suckingly
suckings
suckly
sucks
sumofabiatch
sumofabiatched
sumofabiatcher
sumofabiatches
sumofabiatching
sumofabiatchly
sumofabiatchs
tard
tarded
tarder
tardes
tarding
tardly
tards
tawdry
tawdryed
tawdryer
tawdryes
tawdrying
tawdryly
tawdrys
teabagging
teabagginged
teabagginger
teabagginges
teabagginging
teabaggingly
teabaggings
terd
terded
terder
terdes
terding
terdly
terds
teste
testee
testeed
testeeed
testeeer
testeees
testeeing
testeely
testeer
testees
testeing
testely
testes
testesed
testeser
testeses
testesing
testesly
testess
testicle
testicleed
testicleer
testiclees
testicleing
testiclely
testicles
testis
testised
testiser
testises
testising
testisly
testiss
thrusted
thruster
thrustes
thrusting
thrustly
thrusts
thug
thuged
thuger
thuges
thuging
thugly
thugs
tinkle
tinkleed
tinkleer
tinklees
tinkleing
tinklely
tinkles
tit
tited
titer
tites
titfuck
titfucked
titfucker
titfuckes
titfucking
titfuckly
titfucks
titi
titied
titier
tities
titiing
titily
titing
titis
titly
tits
titsed
titser
titses
titsing
titsly
titss
tittiefucker
tittiefuckered
tittiefuckerer
tittiefuckeres
tittiefuckering
tittiefuckerly
tittiefuckers
titties
tittiesed
tittieser
tittieses
tittiesing
tittiesly
tittiess
titty
tittyed
tittyer
tittyes
tittyfuck
tittyfucked
tittyfucker
tittyfuckered
tittyfuckerer
tittyfuckeres
tittyfuckering
tittyfuckerly
tittyfuckers
tittyfuckes
tittyfucking
tittyfuckly
tittyfucks
tittying
tittyly
tittys
toke
tokeed
tokeer
tokees
tokeing
tokely
tokes
toots
tootsed
tootser
tootses
tootsing
tootsly
tootss
tramp
tramped
tramper
trampes
tramping
tramply
tramps
transsexualed
transsexualer
transsexuales
transsexualing
transsexually
transsexuals
trashy
trashyed
trashyer
trashyes
trashying
trashyly
trashys
tubgirl
tubgirled
tubgirler
tubgirles
tubgirling
tubgirlly
tubgirls
turd
turded
turder
turdes
turding
turdly
turds
tush
tushed
tusher
tushes
tushing
tushly
tushs
twat
twated
twater
twates
twating
twatly
twats
twatsed
twatser
twatses
twatsing
twatsly
twatss
undies
undiesed
undieser
undieses
undiesing
undiesly
undiess
unweded
unweder
unwedes
unweding
unwedly
unweds
uzi
uzied
uzier
uzies
uziing
uzily
uzis
vag
vaged
vager
vages
vaging
vagly
vags
valium
valiumed
valiumer
valiumes
valiuming
valiumly
valiums
venous
virgined
virginer
virgines
virgining
virginly
virgins
vixen
vixened
vixener
vixenes
vixening
vixenly
vixens
vodkaed
vodkaer
vodkaes
vodkaing
vodkaly
vodkas
voyeur
voyeured
voyeurer
voyeures
voyeuring
voyeurly
voyeurs
vulgar
vulgared
vulgarer
vulgares
vulgaring
vulgarly
vulgars
wang
wanged
wanger
wanges
wanging
wangly
wangs
wank
wanked
wanker
wankered
wankerer
wankeres
wankering
wankerly
wankers
wankes
wanking
wankly
wanks
wazoo
wazooed
wazooer
wazooes
wazooing
wazooly
wazoos
wedgie
wedgieed
wedgieer
wedgiees
wedgieing
wedgiely
wedgies
weeded
weeder
weedes
weeding
weedly
weeds
weenie
weenieed
weenieer
weeniees
weenieing
weeniely
weenies
weewee
weeweeed
weeweeer
weeweees
weeweeing
weeweely
weewees
weiner
weinered
weinerer
weineres
weinering
weinerly
weiners
weirdo
weirdoed
weirdoer
weirdoes
weirdoing
weirdoly
weirdos
wench
wenched
wencher
wenches
wenching
wenchly
wenchs
wetback
wetbacked
wetbacker
wetbackes
wetbacking
wetbackly
wetbacks
whitey
whiteyed
whiteyer
whiteyes
whiteying
whiteyly
whiteys
whiz
whized
whizer
whizes
whizing
whizly
whizs
whoralicious
whoralicioused
whoraliciouser
whoraliciouses
whoraliciousing
whoraliciously
whoraliciouss
whore
whorealicious
whorealicioused
whorealiciouser
whorealiciouses
whorealiciousing
whorealiciously
whorealiciouss
whored
whoreded
whoreder
whoredes
whoreding
whoredly
whoreds
whoreed
whoreer
whorees
whoreface
whorefaceed
whorefaceer
whorefacees
whorefaceing
whorefacely
whorefaces
whorehopper
whorehoppered
whorehopperer
whorehopperes
whorehoppering
whorehopperly
whorehoppers
whorehouse
whorehouseed
whorehouseer
whorehousees
whorehouseing
whorehousely
whorehouses
whoreing
whorely
whores
whoresed
whoreser
whoreses
whoresing
whoresly
whoress
whoring
whoringed
whoringer
whoringes
whoringing
whoringly
whorings
wigger
wiggered
wiggerer
wiggeres
wiggering
wiggerly
wiggers
woody
woodyed
woodyer
woodyes
woodying
woodyly
woodys
wop
woped
woper
wopes
woping
woply
wops
wtf
wtfed
wtfer
wtfes
wtfing
wtfly
wtfs
xxx
xxxed
xxxer
xxxes
xxxing
xxxly
xxxs
yeasty
yeastyed
yeastyer
yeastyes
yeastying
yeastyly
yeastys
yobbo
yobboed
yobboer
yobboes
yobboing
yobboly
yobbos
zoophile
zoophileed
zoophileer
zoophilees
zoophileing
zoophilely
zoophiles
anal
ass
ass lick
balls
ballsac
bisexual
bleach
causas
cheap
cost of miracles
cunt
display network stats
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gfc
humira AND expensive
illegal
madvocate
masturbation
nuccitelli
overdose
porn
shit
snort
texarkana
direct\-acting antivirals
assistance
ombitasvir
support path
harvoni
abbvie
direct-acting antivirals
paritaprevir
advocacy
ledipasvir
vpak
ritonavir with dasabuvir
program
gilead
greedy
financial
needy
fake-ovir
viekira pak
v pak
sofosbuvir
support
oasis
discount
dasabuvir
protest
ritonavir
Negative Keywords Excluded Elements
header[@id='header']
section[contains(@class, 'nav-hidden')]
footer[@id='footer']
div[contains(@class, 'pane-pub-article-cleveland-clinic')]
div[contains(@class, 'pane-pub-home-cleveland-clinic')]
div[contains(@class, 'pane-pub-topic-cleveland-clinic')]
div[contains(@class, 'panel-panel-inner')]
div[contains(@class, 'pane-node-field-article-topics')]
section[contains(@class, 'footer-nav-section-wrapper')]
Altmetric
DSM Affiliated
Display in offset block
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Society
Slot System
Featured Buckets
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
LayerRx MD-IQ Id
773
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC
Use larger logo size
Off
publication_blueconic_enabled
Off
Show More Destinations Menu
Disable Adhesion on Publication
Off
Restore Menu Label on Mobile Navigation
Disable Facebook Pixel from Publication
Exclude this publication from publication selection on articles and quiz

Stress in medicine: Strategies for caregivers, patients, clinicians—Promoting better outcomes with stress and anxiety reduction

Article Type
Changed
Tue, 10/02/2018 - 09:31
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Promoting better outcomes with stress and anxiety reduction

The traditional paradigm for cardiac care has emphasized the use of technology to treat disease. Our focus on technologies such as echocardiography, advanced imaging instrumentation, and cardiac catheterization mirrors the preoccupation of society as a whole with technologic advances.

Attention has only recently been given to the patient’s emotional experience and how this might relate to outcomes, recovery, and healing. An expanded paradigm of cardiac care incorporates pain relief, emotional support, spiritual healing, and a caring environment. These elements of patient-centered care aim to relieve stress and anxiety in order to achieve a better clinical outcome.

PATIENT-CENTERED CARE

The importance of patient-centered care is illustrated by the results of a 2007 survey in which 41% of patients cited elements of the patient experience as factors that most influenced their choice of hospital.1 Accepted wisdom on patient choice has historically centered on medical factors such as clinical reputation, physician recommendations, and hospital location, each of which was cited by 18% to 21% of the patients surveyed. Elements of the patient experience cited in the study include stress-reducing factors such as the appearance of the room, ease of scheduling, an environment that supports family needs, convenience and comfort of common areas, on-time performance, and simple registration procedures.

Székely et al2 found in a 4-year followup study that high levels of preoperative anxiety predicted greater mortality and cardiovascular morbidity following cardiac surgery. In a study by Tully et al,3 preoperative anxiety was also predictive of hospital readmission following cardiac surgery. Preoperative stress and anxiety are reliable predictors of postoperative distress.4

The variety and relative efficacy of interventions to reduce stress and anxiety are not well studied. Voss et al5 showed that cardiac surgery patients who were played soothing music experienced significantly reduced anxiety, pain, pain distress, and length of hospital stay. One Cleveland Clinic study of massage therapy, however, was unable to demonstrate a statistically significant therapeutic benefit, despite patient satisfaction with the therapy.6

THE ADVENT OF HEALING SERVICES

Identifying patients who exhibit significant preoperative stress and providing, as part of an expanded cardiac care paradigm, emotional care both pre- and postoperatively may ameliorate clinical outcomes. As such, the Heart and Vascular Institute at the Cleveland Clinic formed a healing services division, based on the concept that healing is more than simply physical recovery from a particular procedure. The division’s mission statement is: “To enhance the patient experience by promoting healing through a comprehensive set of coordinated services addressing the holistic needs of the patient.”

A healing services menu is offered to each patient (Table). Referral for these services can come from the patient, family, physicians, or nurses. Of the first 898 patients admitted for heart surgery who were offered healing services on the third or fourth postoperative day, 582 chose one or more of the services (average, 2.7 interventions; total interventions, 1,514), most frequently spiritual or holistic nursing care. Ninety-three percent of these patients felt the services were helpful, and 90% said that they would recommend them to others. A personal connection between the patient and family and caregivers fosters feelings of a healing partnership that lessens stress and anxiety.

At the Cleveland Clinic, healing services are now integrated with standard services to enhance the cardiac care paradigm. Our standard medical services focus on areas of communication and pain control, both of which affect anxiety and stress. The need for enhanced communication is significant: 75% of patients admitted to a Chicago hospital were unable to name a single doctor assigned to their care, and of the remaining 25%, only 40% of responders were correct.7

It is worth noting that communicating more information to a patient is not necessarily better. Patients given detailed preoperative information about their disease and the potential complications of their cardiac surgery had levels of preoperative, perioperative, and postoperative stress, anxiety, and depression similar to those who received routine medical information.8,9 On the other hand, patients desire information about their postoperative plan of care while they are experiencing it, and value communication with physicians, nurses, healing services personnel, and other caregivers when it is presented in a calm and forthright manner. Communications should emphasize that the entire clinical team is there to help the patient get better.

THE FIFTH VITAL SIGN

Pain control is an aspect of care that was long ignored. The goal of the pain control task force at the Cleveland Clinic is the development of effective, efficient, and compassionate pain management.

The fifth vital sign, one that escapes the electronic medical record, can be addressed by this question: “How are you feeling?” Treating pain will reduce stress and anxiety. Before surgery, pain management priorities are discussed with patients, and at each daily encounter the goal is to set, refine, and exceed expectations for pain control through discussion and frequent pain assessments.

Reducing anxiety and stress is the goal of both standard care services and healing services, resulting in more satisfied patients with better clinical outcomes.

CASE: “YOU AND THE TEAM MADE ME GET OUTOF BED AND MOVE FORWARD”

Bobbi is a 78-year-old woman who was initially recovering well following cardiac surgery, including valve surgery, but had to return to the intensive care unit, which is difficult for patients. She was subsequently returned to the floor but was reluctant to walk and progressed slowly, despite normal electrocardiogram, radiographs, and blood panel results. We discovered that her husband was in hospice care in another state, causing Bobbi anxiety as she expressed concern over being her husband’s caregiver while being weakened physically herself. She was fearful of moving forward and her recovery stalled.

The primary care nurse referred her to the healing services team. The healing services team provided support for her anxiety and stress, and reviewed options for managing her husband’s care. She participated in Reiki, spiritual support, and social work services. During her admission her husband died, so the team provided appropriate support.

When asked about her experience upon leavingthe hospital, Bobbi did not mention her surgeon or the success of her heart valve procedure, but commented instead on the healing services team that enabled her to get through the experience.

References
  1. Grote KD, Newman JRS, Sutaria SS. A better hospital experience. The McKinsey Quarterly. November 2007.
  2. Székely A, Balog P, Benkö E, et al. Anxiety predicts mortality and morbidity after coronary artery and valve surgery—a 4-year followup study. Psychosom Med 2007; 69:625–631.
  3. Tully PJ, Baker RA, Turnbull D, Winefield H. The role of depression and anxiety symptoms in hospital readmissions after cardiac surgery. J Behav Med 2008; 31:281–290.
  4. Vingerhoets G. Perioperative anxiety and depression in open-heart surgery. Psychosomatics 1998; 39:30–37.
  5. Voss JA, Good M, Yates B, Baun MM, Thompson A, Hertzog M. Sedative music reduces anxiety and pain during chair rest after open-heart surgery. Pain 2004; 112:197–203.
  6. Albert NM, Gillinov AM, Lytle BW, Feng J, Cwynar R, Blackstone EH. A randomized trial of massage therapy after heart surgery. Heart Lung 2009; 38:480–490.
  7. Arora V, Gangireddy S, Mehrotra A, Ginde R, Tormey M, Meltzer D. Ability of hospitalized patients to identify their in-hospital physicians. Arch Intern Med 2009; 169:199–201.
  8. Ivarsson B, Larsson S, Lührs C, Sjöberg T. Extended written pre-operative information about possible complications at cardiac surgery—do the patients want to know? Eur J Cardiothorac Surg 2005; 28:407–414.
  9. Bergmann P, Huber S, Mächler H, et al. The influence of medical information on the perioperative course of stress in cardiac surgery patients. Anesth Analg 2001; 93:1093–1099.  
Article PDF
Author and Disclosure Information

A. Marc Gillinov, MD
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

Correspondence: A. Marc Gillinov, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue, J4-1, Cleveland, OH 44195; gillinom@ccf.org

Dr. Gillinov reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gillinov's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gillinov.

Publications
Page Number
S56-S58
Author and Disclosure Information

A. Marc Gillinov, MD
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

Correspondence: A. Marc Gillinov, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue, J4-1, Cleveland, OH 44195; gillinom@ccf.org

Dr. Gillinov reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gillinov's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gillinov.

Author and Disclosure Information

A. Marc Gillinov, MD
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

Correspondence: A. Marc Gillinov, MD, Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, 9500 Euclid Avenue, J4-1, Cleveland, OH 44195; gillinom@ccf.org

Dr. Gillinov reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gillinov's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gillinov.

Article PDF
Article PDF

The traditional paradigm for cardiac care has emphasized the use of technology to treat disease. Our focus on technologies such as echocardiography, advanced imaging instrumentation, and cardiac catheterization mirrors the preoccupation of society as a whole with technologic advances.

Attention has only recently been given to the patient’s emotional experience and how this might relate to outcomes, recovery, and healing. An expanded paradigm of cardiac care incorporates pain relief, emotional support, spiritual healing, and a caring environment. These elements of patient-centered care aim to relieve stress and anxiety in order to achieve a better clinical outcome.

PATIENT-CENTERED CARE

The importance of patient-centered care is illustrated by the results of a 2007 survey in which 41% of patients cited elements of the patient experience as factors that most influenced their choice of hospital.1 Accepted wisdom on patient choice has historically centered on medical factors such as clinical reputation, physician recommendations, and hospital location, each of which was cited by 18% to 21% of the patients surveyed. Elements of the patient experience cited in the study include stress-reducing factors such as the appearance of the room, ease of scheduling, an environment that supports family needs, convenience and comfort of common areas, on-time performance, and simple registration procedures.

Székely et al2 found in a 4-year followup study that high levels of preoperative anxiety predicted greater mortality and cardiovascular morbidity following cardiac surgery. In a study by Tully et al,3 preoperative anxiety was also predictive of hospital readmission following cardiac surgery. Preoperative stress and anxiety are reliable predictors of postoperative distress.4

The variety and relative efficacy of interventions to reduce stress and anxiety are not well studied. Voss et al5 showed that cardiac surgery patients who were played soothing music experienced significantly reduced anxiety, pain, pain distress, and length of hospital stay. One Cleveland Clinic study of massage therapy, however, was unable to demonstrate a statistically significant therapeutic benefit, despite patient satisfaction with the therapy.6

THE ADVENT OF HEALING SERVICES

Identifying patients who exhibit significant preoperative stress and providing, as part of an expanded cardiac care paradigm, emotional care both pre- and postoperatively may ameliorate clinical outcomes. As such, the Heart and Vascular Institute at the Cleveland Clinic formed a healing services division, based on the concept that healing is more than simply physical recovery from a particular procedure. The division’s mission statement is: “To enhance the patient experience by promoting healing through a comprehensive set of coordinated services addressing the holistic needs of the patient.”

A healing services menu is offered to each patient (Table). Referral for these services can come from the patient, family, physicians, or nurses. Of the first 898 patients admitted for heart surgery who were offered healing services on the third or fourth postoperative day, 582 chose one or more of the services (average, 2.7 interventions; total interventions, 1,514), most frequently spiritual or holistic nursing care. Ninety-three percent of these patients felt the services were helpful, and 90% said that they would recommend them to others. A personal connection between the patient and family and caregivers fosters feelings of a healing partnership that lessens stress and anxiety.

At the Cleveland Clinic, healing services are now integrated with standard services to enhance the cardiac care paradigm. Our standard medical services focus on areas of communication and pain control, both of which affect anxiety and stress. The need for enhanced communication is significant: 75% of patients admitted to a Chicago hospital were unable to name a single doctor assigned to their care, and of the remaining 25%, only 40% of responders were correct.7

It is worth noting that communicating more information to a patient is not necessarily better. Patients given detailed preoperative information about their disease and the potential complications of their cardiac surgery had levels of preoperative, perioperative, and postoperative stress, anxiety, and depression similar to those who received routine medical information.8,9 On the other hand, patients desire information about their postoperative plan of care while they are experiencing it, and value communication with physicians, nurses, healing services personnel, and other caregivers when it is presented in a calm and forthright manner. Communications should emphasize that the entire clinical team is there to help the patient get better.

THE FIFTH VITAL SIGN

Pain control is an aspect of care that was long ignored. The goal of the pain control task force at the Cleveland Clinic is the development of effective, efficient, and compassionate pain management.

The fifth vital sign, one that escapes the electronic medical record, can be addressed by this question: “How are you feeling?” Treating pain will reduce stress and anxiety. Before surgery, pain management priorities are discussed with patients, and at each daily encounter the goal is to set, refine, and exceed expectations for pain control through discussion and frequent pain assessments.

Reducing anxiety and stress is the goal of both standard care services and healing services, resulting in more satisfied patients with better clinical outcomes.

CASE: “YOU AND THE TEAM MADE ME GET OUTOF BED AND MOVE FORWARD”

Bobbi is a 78-year-old woman who was initially recovering well following cardiac surgery, including valve surgery, but had to return to the intensive care unit, which is difficult for patients. She was subsequently returned to the floor but was reluctant to walk and progressed slowly, despite normal electrocardiogram, radiographs, and blood panel results. We discovered that her husband was in hospice care in another state, causing Bobbi anxiety as she expressed concern over being her husband’s caregiver while being weakened physically herself. She was fearful of moving forward and her recovery stalled.

The primary care nurse referred her to the healing services team. The healing services team provided support for her anxiety and stress, and reviewed options for managing her husband’s care. She participated in Reiki, spiritual support, and social work services. During her admission her husband died, so the team provided appropriate support.

When asked about her experience upon leavingthe hospital, Bobbi did not mention her surgeon or the success of her heart valve procedure, but commented instead on the healing services team that enabled her to get through the experience.

The traditional paradigm for cardiac care has emphasized the use of technology to treat disease. Our focus on technologies such as echocardiography, advanced imaging instrumentation, and cardiac catheterization mirrors the preoccupation of society as a whole with technologic advances.

Attention has only recently been given to the patient’s emotional experience and how this might relate to outcomes, recovery, and healing. An expanded paradigm of cardiac care incorporates pain relief, emotional support, spiritual healing, and a caring environment. These elements of patient-centered care aim to relieve stress and anxiety in order to achieve a better clinical outcome.

PATIENT-CENTERED CARE

The importance of patient-centered care is illustrated by the results of a 2007 survey in which 41% of patients cited elements of the patient experience as factors that most influenced their choice of hospital.1 Accepted wisdom on patient choice has historically centered on medical factors such as clinical reputation, physician recommendations, and hospital location, each of which was cited by 18% to 21% of the patients surveyed. Elements of the patient experience cited in the study include stress-reducing factors such as the appearance of the room, ease of scheduling, an environment that supports family needs, convenience and comfort of common areas, on-time performance, and simple registration procedures.

Székely et al2 found in a 4-year followup study that high levels of preoperative anxiety predicted greater mortality and cardiovascular morbidity following cardiac surgery. In a study by Tully et al,3 preoperative anxiety was also predictive of hospital readmission following cardiac surgery. Preoperative stress and anxiety are reliable predictors of postoperative distress.4

The variety and relative efficacy of interventions to reduce stress and anxiety are not well studied. Voss et al5 showed that cardiac surgery patients who were played soothing music experienced significantly reduced anxiety, pain, pain distress, and length of hospital stay. One Cleveland Clinic study of massage therapy, however, was unable to demonstrate a statistically significant therapeutic benefit, despite patient satisfaction with the therapy.6

THE ADVENT OF HEALING SERVICES

Identifying patients who exhibit significant preoperative stress and providing, as part of an expanded cardiac care paradigm, emotional care both pre- and postoperatively may ameliorate clinical outcomes. As such, the Heart and Vascular Institute at the Cleveland Clinic formed a healing services division, based on the concept that healing is more than simply physical recovery from a particular procedure. The division’s mission statement is: “To enhance the patient experience by promoting healing through a comprehensive set of coordinated services addressing the holistic needs of the patient.”

A healing services menu is offered to each patient (Table). Referral for these services can come from the patient, family, physicians, or nurses. Of the first 898 patients admitted for heart surgery who were offered healing services on the third or fourth postoperative day, 582 chose one or more of the services (average, 2.7 interventions; total interventions, 1,514), most frequently spiritual or holistic nursing care. Ninety-three percent of these patients felt the services were helpful, and 90% said that they would recommend them to others. A personal connection between the patient and family and caregivers fosters feelings of a healing partnership that lessens stress and anxiety.

At the Cleveland Clinic, healing services are now integrated with standard services to enhance the cardiac care paradigm. Our standard medical services focus on areas of communication and pain control, both of which affect anxiety and stress. The need for enhanced communication is significant: 75% of patients admitted to a Chicago hospital were unable to name a single doctor assigned to their care, and of the remaining 25%, only 40% of responders were correct.7

It is worth noting that communicating more information to a patient is not necessarily better. Patients given detailed preoperative information about their disease and the potential complications of their cardiac surgery had levels of preoperative, perioperative, and postoperative stress, anxiety, and depression similar to those who received routine medical information.8,9 On the other hand, patients desire information about their postoperative plan of care while they are experiencing it, and value communication with physicians, nurses, healing services personnel, and other caregivers when it is presented in a calm and forthright manner. Communications should emphasize that the entire clinical team is there to help the patient get better.

THE FIFTH VITAL SIGN

Pain control is an aspect of care that was long ignored. The goal of the pain control task force at the Cleveland Clinic is the development of effective, efficient, and compassionate pain management.

The fifth vital sign, one that escapes the electronic medical record, can be addressed by this question: “How are you feeling?” Treating pain will reduce stress and anxiety. Before surgery, pain management priorities are discussed with patients, and at each daily encounter the goal is to set, refine, and exceed expectations for pain control through discussion and frequent pain assessments.

Reducing anxiety and stress is the goal of both standard care services and healing services, resulting in more satisfied patients with better clinical outcomes.

CASE: “YOU AND THE TEAM MADE ME GET OUTOF BED AND MOVE FORWARD”

Bobbi is a 78-year-old woman who was initially recovering well following cardiac surgery, including valve surgery, but had to return to the intensive care unit, which is difficult for patients. She was subsequently returned to the floor but was reluctant to walk and progressed slowly, despite normal electrocardiogram, radiographs, and blood panel results. We discovered that her husband was in hospice care in another state, causing Bobbi anxiety as she expressed concern over being her husband’s caregiver while being weakened physically herself. She was fearful of moving forward and her recovery stalled.

The primary care nurse referred her to the healing services team. The healing services team provided support for her anxiety and stress, and reviewed options for managing her husband’s care. She participated in Reiki, spiritual support, and social work services. During her admission her husband died, so the team provided appropriate support.

When asked about her experience upon leavingthe hospital, Bobbi did not mention her surgeon or the success of her heart valve procedure, but commented instead on the healing services team that enabled her to get through the experience.

References
  1. Grote KD, Newman JRS, Sutaria SS. A better hospital experience. The McKinsey Quarterly. November 2007.
  2. Székely A, Balog P, Benkö E, et al. Anxiety predicts mortality and morbidity after coronary artery and valve surgery—a 4-year followup study. Psychosom Med 2007; 69:625–631.
  3. Tully PJ, Baker RA, Turnbull D, Winefield H. The role of depression and anxiety symptoms in hospital readmissions after cardiac surgery. J Behav Med 2008; 31:281–290.
  4. Vingerhoets G. Perioperative anxiety and depression in open-heart surgery. Psychosomatics 1998; 39:30–37.
  5. Voss JA, Good M, Yates B, Baun MM, Thompson A, Hertzog M. Sedative music reduces anxiety and pain during chair rest after open-heart surgery. Pain 2004; 112:197–203.
  6. Albert NM, Gillinov AM, Lytle BW, Feng J, Cwynar R, Blackstone EH. A randomized trial of massage therapy after heart surgery. Heart Lung 2009; 38:480–490.
  7. Arora V, Gangireddy S, Mehrotra A, Ginde R, Tormey M, Meltzer D. Ability of hospitalized patients to identify their in-hospital physicians. Arch Intern Med 2009; 169:199–201.
  8. Ivarsson B, Larsson S, Lührs C, Sjöberg T. Extended written pre-operative information about possible complications at cardiac surgery—do the patients want to know? Eur J Cardiothorac Surg 2005; 28:407–414.
  9. Bergmann P, Huber S, Mächler H, et al. The influence of medical information on the perioperative course of stress in cardiac surgery patients. Anesth Analg 2001; 93:1093–1099.  
References
  1. Grote KD, Newman JRS, Sutaria SS. A better hospital experience. The McKinsey Quarterly. November 2007.
  2. Székely A, Balog P, Benkö E, et al. Anxiety predicts mortality and morbidity after coronary artery and valve surgery—a 4-year followup study. Psychosom Med 2007; 69:625–631.
  3. Tully PJ, Baker RA, Turnbull D, Winefield H. The role of depression and anxiety symptoms in hospital readmissions after cardiac surgery. J Behav Med 2008; 31:281–290.
  4. Vingerhoets G. Perioperative anxiety and depression in open-heart surgery. Psychosomatics 1998; 39:30–37.
  5. Voss JA, Good M, Yates B, Baun MM, Thompson A, Hertzog M. Sedative music reduces anxiety and pain during chair rest after open-heart surgery. Pain 2004; 112:197–203.
  6. Albert NM, Gillinov AM, Lytle BW, Feng J, Cwynar R, Blackstone EH. A randomized trial of massage therapy after heart surgery. Heart Lung 2009; 38:480–490.
  7. Arora V, Gangireddy S, Mehrotra A, Ginde R, Tormey M, Meltzer D. Ability of hospitalized patients to identify their in-hospital physicians. Arch Intern Med 2009; 169:199–201.
  8. Ivarsson B, Larsson S, Lührs C, Sjöberg T. Extended written pre-operative information about possible complications at cardiac surgery—do the patients want to know? Eur J Cardiothorac Surg 2005; 28:407–414.
  9. Bergmann P, Huber S, Mächler H, et al. The influence of medical information on the perioperative course of stress in cardiac surgery patients. Anesth Analg 2001; 93:1093–1099.  
Page Number
S56-S58
Page Number
S56-S58
Publications
Publications
Article Type
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Promoting better outcomes with stress and anxiety reduction
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Promoting better outcomes with stress and anxiety reduction
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S56-S58
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Stress in medicine: Strategies for caregivers, patients, clinicians—Addressing the impact of clinician stress

Article Type
Changed
Tue, 10/02/2018 - 09:31
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Addressing the impact of clinician stress

The impact of clinician stress on the health care system is significant. It can adversely affect the patient experience, compromise patient safety, hinder the delivery of care in a manner that is inconsistent with producing quality outcomes, and increase the overall cost of care.

CLINICIAN STRESS IS PREVALENT

Models of health care that restore human interaction are desperately needed. Clinicians today are overwhelmed by performance assessments that are based on length of stay, use of evidence-based medication regimens, and morbidity and mortality outcomes. Yet clinicians have few opportunities to establish more than cursory relationships with their patients—relationships that would permit better understanding of patients’ emotional well-being and that would optimize the overall healing experience.

Shanafelt et al1 surveyed 7,905 surgeons and found that clinician stress is pervasive: 64% indicated that their work schedule left inadequate time for their personal or family life, 40% reported burnout, and 30% screened positive for symptoms of depression. Another survey of 763 practicing physicians in California found that 53% reported moderate to severe levels of stress.2 Nonphysician clinicians have significant levels of stress as well, with one survey of nurses finding that, of those who quit the profession, 26% cited stress as the cause.3

THE EFFECT OF CLINICIAN STRESSON QUALITY OF CARE

In the Shanafelt et al study, high levels of emotional exhaustion correlated positively with major medical errors over the previous 3 months.1 Nearly 9% of the surgeons surveyed reported making a stress-related major medical mistake in the past 3 months; among those surgeons with high levels of emotional exhaustion, that figure was nearly 15%. This study also found that every 1-point increase in the emotional exhaustion scale (range, 0 to 54) was associated with a 5% increase in the likelihood of reporting a medical error.1

In a study of internal medicine residents, fatigue and distress were associated with medical errors, which were reported by 39% of respondents.4

STRESS AND COMMUNICATION

Stress can damage the physician-nurse relationship, with a significant impact not only on clinicians, but also on delivery of care. The associated breakdowns in communication can negatively affect several areas, including critical care transitions and timely delivery of care. Stress also affects morale, job satisfaction, and job retention.5

Figure. An analysis by the Agency for Healthcare Research and Quality concluded that communication was the most frequent contributor to 3,548 sentinel clinical events (eg, wrong-site surgery, medication errors) that occurred from 1995 through 2005.6
In an examination of sentinel events in US health care, the Agency for Healthcare Research and Quality determined that a communication breakdown was the most common root cause of sentinel events in wrong-site surgery, delays in treatment, and medication errors, and the second most common cause (behind orientation/training) of adverse postoperative events.6 When root causes of all clinical categories of sentinel events were tallied, communication was found to be the most frequent contributor (training, patient assessment, and staffing were next) (Figure).6 The quality of the communication among physicians and nurses is a major influence on overall patient satisfaction and a patient’s willingness to recommend the hospital to others.

ADDRESSING THE IMPACT OF CLINICIAN STRESS

The traditional response to complaints registered by patients has been behavioral coaching, disruptive-behavior programs, and the punitive use of satisfaction metrics, which are incorporated into the physician’s annual evaluation. These approaches do little to address the cause of the stress and can inculcate cynicism instead.

A more useful approach is to define and strive for an optimal working environment for clinicians, thereby promoting an enhanced patient experience. This approach attempts to restore balance to both the business and art of medicine and may incorporate biofeedback and other healing services to clinicians as tools to minimize and manage stress.

The business of medicine may be restored by enhancing the culture and climate of the hospital, improving communication and collaboration, reducing administrative tasks, restoring authority and autonomy, and eliminating punitive practices. The art of medicine may be restored by valuing the sacred relationship between clinician and patient, learning to listen more carefully to the patient, creating better healing environments, providing emotional support, and supporting caregivers.

References
  1. Shanafelt TD, Balch CM, Bechamps G, et al. Burnout and medical errors among American surgeons. Ann Surg 2010; 251:995–1000.
  2. Beck M. Checking up on the doctor. What patients can learn from the ways physicians take care of themselves. Wall Street Journal. May 25, 2010. http://online.wsj.com/article/SB10001424052748704113504575264364125574500.html?KEYWORDS=Checking+up+on+the+doctor. Accessed April 27, 2011. 
  3. Reineck C, Furino A. Nursing career fulfillment: statistics and statements from registered nurses. Nursing Economics 2005; 23:25–30. 
  4. West CP, Tan AD, Habermann TM, Sloan JA, Shanafelt TD. Association of resident fatigue and distress with perceived medical errors. JAMA 2009; 302:1294–1300.
  5. Rosenstein AH. Nurse-physician relationships: Impact on nurses atisfaction and retention. Am J Nursing 2002; 102:26–34.
  6. Hickam DH, Severance S, Feldstein A, et al; Oregon Health & Science University Evidence-based Practice Center. The effect of health care working conditions on patient safety. Agency for Healthcare Research and Quality publication 03-E031. http://www.ahrq.gov/downloads/pub/evidence/pdf/work/work.pdf. Published May 2003. Accessed April 27, 2011.
Article PDF
Author and Disclosure Information

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Correspondence: M. Bridget Duffy, MD, ExperiaHealth, 2250 Hyde St., Suite 2, San Francisco, CA 94109; bduffy@experiahealth.com

Dr. Duffy reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Duffy's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Duffy.

Publications
Page Number
S58-S59
Author and Disclosure Information

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Correspondence: M. Bridget Duffy, MD, ExperiaHealth, 2250 Hyde St., Suite 2, San Francisco, CA 94109; bduffy@experiahealth.com

Dr. Duffy reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Duffy's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Duffy.

Author and Disclosure Information

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Correspondence: M. Bridget Duffy, MD, ExperiaHealth, 2250 Hyde St., Suite 2, San Francisco, CA 94109; bduffy@experiahealth.com

Dr. Duffy reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Duffy's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Duffy.

Article PDF
Article PDF

The impact of clinician stress on the health care system is significant. It can adversely affect the patient experience, compromise patient safety, hinder the delivery of care in a manner that is inconsistent with producing quality outcomes, and increase the overall cost of care.

CLINICIAN STRESS IS PREVALENT

Models of health care that restore human interaction are desperately needed. Clinicians today are overwhelmed by performance assessments that are based on length of stay, use of evidence-based medication regimens, and morbidity and mortality outcomes. Yet clinicians have few opportunities to establish more than cursory relationships with their patients—relationships that would permit better understanding of patients’ emotional well-being and that would optimize the overall healing experience.

Shanafelt et al1 surveyed 7,905 surgeons and found that clinician stress is pervasive: 64% indicated that their work schedule left inadequate time for their personal or family life, 40% reported burnout, and 30% screened positive for symptoms of depression. Another survey of 763 practicing physicians in California found that 53% reported moderate to severe levels of stress.2 Nonphysician clinicians have significant levels of stress as well, with one survey of nurses finding that, of those who quit the profession, 26% cited stress as the cause.3

THE EFFECT OF CLINICIAN STRESSON QUALITY OF CARE

In the Shanafelt et al study, high levels of emotional exhaustion correlated positively with major medical errors over the previous 3 months.1 Nearly 9% of the surgeons surveyed reported making a stress-related major medical mistake in the past 3 months; among those surgeons with high levels of emotional exhaustion, that figure was nearly 15%. This study also found that every 1-point increase in the emotional exhaustion scale (range, 0 to 54) was associated with a 5% increase in the likelihood of reporting a medical error.1

In a study of internal medicine residents, fatigue and distress were associated with medical errors, which were reported by 39% of respondents.4

STRESS AND COMMUNICATION

Stress can damage the physician-nurse relationship, with a significant impact not only on clinicians, but also on delivery of care. The associated breakdowns in communication can negatively affect several areas, including critical care transitions and timely delivery of care. Stress also affects morale, job satisfaction, and job retention.5

Figure. An analysis by the Agency for Healthcare Research and Quality concluded that communication was the most frequent contributor to 3,548 sentinel clinical events (eg, wrong-site surgery, medication errors) that occurred from 1995 through 2005.6
In an examination of sentinel events in US health care, the Agency for Healthcare Research and Quality determined that a communication breakdown was the most common root cause of sentinel events in wrong-site surgery, delays in treatment, and medication errors, and the second most common cause (behind orientation/training) of adverse postoperative events.6 When root causes of all clinical categories of sentinel events were tallied, communication was found to be the most frequent contributor (training, patient assessment, and staffing were next) (Figure).6 The quality of the communication among physicians and nurses is a major influence on overall patient satisfaction and a patient’s willingness to recommend the hospital to others.

ADDRESSING THE IMPACT OF CLINICIAN STRESS

The traditional response to complaints registered by patients has been behavioral coaching, disruptive-behavior programs, and the punitive use of satisfaction metrics, which are incorporated into the physician’s annual evaluation. These approaches do little to address the cause of the stress and can inculcate cynicism instead.

A more useful approach is to define and strive for an optimal working environment for clinicians, thereby promoting an enhanced patient experience. This approach attempts to restore balance to both the business and art of medicine and may incorporate biofeedback and other healing services to clinicians as tools to minimize and manage stress.

The business of medicine may be restored by enhancing the culture and climate of the hospital, improving communication and collaboration, reducing administrative tasks, restoring authority and autonomy, and eliminating punitive practices. The art of medicine may be restored by valuing the sacred relationship between clinician and patient, learning to listen more carefully to the patient, creating better healing environments, providing emotional support, and supporting caregivers.

The impact of clinician stress on the health care system is significant. It can adversely affect the patient experience, compromise patient safety, hinder the delivery of care in a manner that is inconsistent with producing quality outcomes, and increase the overall cost of care.

CLINICIAN STRESS IS PREVALENT

Models of health care that restore human interaction are desperately needed. Clinicians today are overwhelmed by performance assessments that are based on length of stay, use of evidence-based medication regimens, and morbidity and mortality outcomes. Yet clinicians have few opportunities to establish more than cursory relationships with their patients—relationships that would permit better understanding of patients’ emotional well-being and that would optimize the overall healing experience.

Shanafelt et al1 surveyed 7,905 surgeons and found that clinician stress is pervasive: 64% indicated that their work schedule left inadequate time for their personal or family life, 40% reported burnout, and 30% screened positive for symptoms of depression. Another survey of 763 practicing physicians in California found that 53% reported moderate to severe levels of stress.2 Nonphysician clinicians have significant levels of stress as well, with one survey of nurses finding that, of those who quit the profession, 26% cited stress as the cause.3

THE EFFECT OF CLINICIAN STRESSON QUALITY OF CARE

In the Shanafelt et al study, high levels of emotional exhaustion correlated positively with major medical errors over the previous 3 months.1 Nearly 9% of the surgeons surveyed reported making a stress-related major medical mistake in the past 3 months; among those surgeons with high levels of emotional exhaustion, that figure was nearly 15%. This study also found that every 1-point increase in the emotional exhaustion scale (range, 0 to 54) was associated with a 5% increase in the likelihood of reporting a medical error.1

In a study of internal medicine residents, fatigue and distress were associated with medical errors, which were reported by 39% of respondents.4

STRESS AND COMMUNICATION

Stress can damage the physician-nurse relationship, with a significant impact not only on clinicians, but also on delivery of care. The associated breakdowns in communication can negatively affect several areas, including critical care transitions and timely delivery of care. Stress also affects morale, job satisfaction, and job retention.5

Figure. An analysis by the Agency for Healthcare Research and Quality concluded that communication was the most frequent contributor to 3,548 sentinel clinical events (eg, wrong-site surgery, medication errors) that occurred from 1995 through 2005.6
In an examination of sentinel events in US health care, the Agency for Healthcare Research and Quality determined that a communication breakdown was the most common root cause of sentinel events in wrong-site surgery, delays in treatment, and medication errors, and the second most common cause (behind orientation/training) of adverse postoperative events.6 When root causes of all clinical categories of sentinel events were tallied, communication was found to be the most frequent contributor (training, patient assessment, and staffing were next) (Figure).6 The quality of the communication among physicians and nurses is a major influence on overall patient satisfaction and a patient’s willingness to recommend the hospital to others.

ADDRESSING THE IMPACT OF CLINICIAN STRESS

The traditional response to complaints registered by patients has been behavioral coaching, disruptive-behavior programs, and the punitive use of satisfaction metrics, which are incorporated into the physician’s annual evaluation. These approaches do little to address the cause of the stress and can inculcate cynicism instead.

A more useful approach is to define and strive for an optimal working environment for clinicians, thereby promoting an enhanced patient experience. This approach attempts to restore balance to both the business and art of medicine and may incorporate biofeedback and other healing services to clinicians as tools to minimize and manage stress.

The business of medicine may be restored by enhancing the culture and climate of the hospital, improving communication and collaboration, reducing administrative tasks, restoring authority and autonomy, and eliminating punitive practices. The art of medicine may be restored by valuing the sacred relationship between clinician and patient, learning to listen more carefully to the patient, creating better healing environments, providing emotional support, and supporting caregivers.

References
  1. Shanafelt TD, Balch CM, Bechamps G, et al. Burnout and medical errors among American surgeons. Ann Surg 2010; 251:995–1000.
  2. Beck M. Checking up on the doctor. What patients can learn from the ways physicians take care of themselves. Wall Street Journal. May 25, 2010. http://online.wsj.com/article/SB10001424052748704113504575264364125574500.html?KEYWORDS=Checking+up+on+the+doctor. Accessed April 27, 2011. 
  3. Reineck C, Furino A. Nursing career fulfillment: statistics and statements from registered nurses. Nursing Economics 2005; 23:25–30. 
  4. West CP, Tan AD, Habermann TM, Sloan JA, Shanafelt TD. Association of resident fatigue and distress with perceived medical errors. JAMA 2009; 302:1294–1300.
  5. Rosenstein AH. Nurse-physician relationships: Impact on nurses atisfaction and retention. Am J Nursing 2002; 102:26–34.
  6. Hickam DH, Severance S, Feldstein A, et al; Oregon Health & Science University Evidence-based Practice Center. The effect of health care working conditions on patient safety. Agency for Healthcare Research and Quality publication 03-E031. http://www.ahrq.gov/downloads/pub/evidence/pdf/work/work.pdf. Published May 2003. Accessed April 27, 2011.
References
  1. Shanafelt TD, Balch CM, Bechamps G, et al. Burnout and medical errors among American surgeons. Ann Surg 2010; 251:995–1000.
  2. Beck M. Checking up on the doctor. What patients can learn from the ways physicians take care of themselves. Wall Street Journal. May 25, 2010. http://online.wsj.com/article/SB10001424052748704113504575264364125574500.html?KEYWORDS=Checking+up+on+the+doctor. Accessed April 27, 2011. 
  3. Reineck C, Furino A. Nursing career fulfillment: statistics and statements from registered nurses. Nursing Economics 2005; 23:25–30. 
  4. West CP, Tan AD, Habermann TM, Sloan JA, Shanafelt TD. Association of resident fatigue and distress with perceived medical errors. JAMA 2009; 302:1294–1300.
  5. Rosenstein AH. Nurse-physician relationships: Impact on nurses atisfaction and retention. Am J Nursing 2002; 102:26–34.
  6. Hickam DH, Severance S, Feldstein A, et al; Oregon Health & Science University Evidence-based Practice Center. The effect of health care working conditions on patient safety. Agency for Healthcare Research and Quality publication 03-E031. http://www.ahrq.gov/downloads/pub/evidence/pdf/work/work.pdf. Published May 2003. Accessed April 27, 2011.
Page Number
S58-S59
Page Number
S58-S59
Publications
Publications
Article Type
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Addressing the impact of clinician stress
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Addressing the impact of clinician stress
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S58-S59
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback in the treatment of stress

Article Type
Changed
Tue, 10/02/2018 - 09:32
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback in the treatment of stress

Traditionally, biofeedback was considered to be a stress management technique that targeted sympathetic nervous system (SNS) overdrive with an adrenal medullary system backup. Recent advances in autonomic physiology, however, have clarified that except in extreme situations, the SNS is not the key factor in day-to-day stress. Rather, the parasympathetic branch of the autonomic nervous system appears to be a more likely candidate for mediating routine stress because, unlike the SNS, which has slow-acting neurotransmitters (ie, catecholamines), the parasympathetic nervous system has the fast-acting transmitter acetylcholine.

VAGAL WITHDRAWAL: AN ALTERNATIVE TO SYMPATHETIC ACTIVATION

Porges1 first proposed the concept of vagal withdrawal as an indicator of stress and stress vulnerability; this contrasts with the idea that the stress response is a consequence of sympathetic activation and the hypothalamic-pituitary-adrenal axis response. In the vagal withdrawal model, the response to stress is stabilization of the sympathetic system followed by termination of parasympathetic activity, manifested as cardiac acceleration.

Respiratory sinus arrhythmia (RSA), or the variability in heart rate as it synchronizes with breathing, is considered an index of parasympathetic tone. In the laboratory, slow atropine infusion produces a transient paradoxical vagomimetic effect characterized by an initial increase in RSA, followed by a flattening and then a rise in the heart rate.2 This phenomenon has been measured in people during times of routine stress, such as when worrying about being late for an appointment. In such individuals, biofeedback training can result in recovery of normal RSA shortly after an episode of anxiety.

Historically, the focus of biofeedback was to cultivate low arousal, presumably reducing SNS activity, through the use of finger temperature, skin conductance training, and profound muscle relaxation. More sophisticated ways to look at both branches of the autonomic nervous system have since emerged that allow for sampling of the beat-by-beat changes in heart rate.

HEART RATE VARIABILITY BIOFEEDBACK

The concept of modifying the respiration rate (paced breathing) originated some 2,500 years ago as a component of meditation. It is being revisited today in the form of heart rate variability (HRV) biofeedback training, which is being used as a stress-management tool and a method to correct disorders in which autonomic regulation is thought to be important. HRV biofeedback involves training to increase the amplitude of HRV rhythms and thus improve autonomic homeostasis.

Normal HRV has a pattern of overlapping oscillatory frequency components, including:

  • a high-frequency rhythm, 0.15 to 0.4 Hz, which is the RSA;
  • a low-frequency rhythm, 0.05 to 0.15 Hz, associated with blood pressure oscillations; and
  • a very-low-frequency rhythm, 0.005 to 0.05 Hz, which may regulate vascular tone and body temperature.

The goal of HRV biofeedback is to achieve respiratory rates at which resonance occurs between cardiac rhythms associated with respiration (RSA, or high-frequency oscillations) and those caused by baroreflex activity (low-frequency oscillations).

Spectral analysis has demonstrated that nearly all of the activity with HRV biofeedback occurs at a low-frequency band. The reason is that activity in the low-frequency band is related more to baroreflex activity than to HRV compared with other ranges of frequency. Breathing rates that correspond to baroreflex effects, called resonance frequency breathing, represent resonance in the cardiovascular system. Several devices are available whose mechanisms are based on the concept of achieving resonance frequency breathing. One such device is a slow-breathing monitor (Resp-e-rate) that has been approved by the US Food and Drug Administration for the adjunctive treatment of hypertension.

Figure. Patients who underwent heart-rate variability (HRV) biofeedback training achieved near-normal standard deviation of normal-to-normal QRS complexes (SDNN) after 18 weeks. The SDNN, which is the primary measure used to quantify a change in HRV, declined in patients in the control group.3
Biofeedback has demonstrated success in several clinical trials targeting populations with autonomically mediated disorders. Del Pozo et al3 conducted a randomized study of HRV biofeedback in patients with coronary artery disease. Patients in the active intervention group underwent HRV biofeedback training that included breathing practice at home for 20 minutes per day. The standard deviation of normal-to-normal QRS complexes (SDNN), which is the primary measure used to quantify a change in HRV, improved from a mean of 28.0 msec to 42.0 msec after 18 weeks in the treatment group, and declined from a mean of 33.0 msec to 30.7 msec in the controls (Figure).

Improved HRV may suggest an improved risk status: Kleiger et al4 found that the relative risk of mortality was 5.3 times greater for people with SDNN of less than 50 msec compared with those whose SDNN was greater than 100 msec. In Del Pozo’s study, eight of 30 patients in the intervention group achieved an SDNN of greater than 50 msec (vs 0 at pretreatment) compared with three of 31 controls (vs two at pretreatment).3 As an additional benefit of HRV biofeedback, patients in the intervention group who entered the study with hypertension all became normotensive.

In a meta-analysis, van Dixhoorn and White5 found fewer cardiac events, fewer episodes of angina, and less occurrence of arrhythmia and exercise-induced ischemia from intensive supervised relaxation therapy in patients with ischemic heart disease. Improvements in scales of depression and anxiety were also observed with relaxation therapy.

Other studies have shown biofeedback to have beneficial effects based on the Posttraumatic Stress Disorder Checklist, the Hamilton Depression Rating Scale, and, in patients with mild to moderate heartfailure, the 6-minute walk test.6–8

The proposed mechanism for the beneficial effects of biofeedback found in clinical trials is improvement in baroreflex function, producing greater reflex efficiency and improved modulation of autonomic activity.

CONCLUSION

A shift in emphasis to vagal withdrawal has led to new forms of biofeedback that probably potentiate many of the same mechanisms thought to be present in Eastern practices such as yoga and tai chi. Results from small-scale trials have been promising for HRV biofeedback as a means of modifying responses to stress and promoting homeostatic processes that reduce the intensity of symptoms and improve surrogate markers associated with a number of disorders.

References
  1. Porges SW. Cardiac vagal tone: a physiological index of stress. Neurosci Biobehav Rev 1995; 19:225–233.
  2. Médigue C, Girard A, Laude D, Monti A, Wargon M, ElghoziJ-L. Relationship between pulse interval and respiratory sinusarrhythmia: a time- and frequency-domain analysis of the effects ofatropine. Eur J Physiol 2001; 441:650–655.
  3. Del Pozo JM, Gevirtz RN, Scher B, Guarneri E. Biofeedbacktreatment increases heart rate variability in patients withknown coronary artery disease. Am Heart J 2004; 147:e11. http://download.journals.elsevierhealth.com/pdfs/journals/0002-8703/PIIS0002870303007191.pdf. Accessed May 2, 2011.
  4. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart ratevariability and its association with increased mortality after acutemyocardial infarciton. Am J Cardiol 1987; 59:256–262.
  5. van Dixhoorn JV, White A. Relaxation therapy for rehabilitationand prevention in ischaemic heart disease: a systematic review andmeta-analysis. Eur J Cardiovasc Prev Rehabil 2005; 12:193–202.
  6. Karavidas MK, Lehrer PM, Vaschillo E, et al. Preliminary resultsof an open label study of heart rate variability biofeedback for thetreatment of major depression. Appl Psychophysiol Biofeedback2007; 32:19–30.
  7. Zucker TL, Samuelson KW, Muench F, Greenberg MA, GevirtzRN. The effects of respiratory sinus arrhythmia biofeedback onheart rate variability and posttraumatic stress disorder symptoms: apilot study. Appl Psychophysiol Biofeedback 2009; 34:135–143.
  8. Swanson KS, Gevirtz RN, Brown M, Spira J, Guarneri E, StoletniyL. The effect of biofeedback on function in patients with heartfailure. Appl Psychophysiol Biofeedback 2009; 34:71–91.
Article PDF
Author and Disclosure Information

Richard N. Gevirtz, PhD
Professor of Health Psychology at the California School of Professional Psychology, Alliant International University, San Diego, CA

Correspondence: Richard Gevirtz, PhD, California School of Professional Psychology, Alliant International University, 10455 Pomerado Road, San Diego, CA 92131; rgevirtz@alliant.edu

Dr. Gevirtz reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gevirtz's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gevirtz.

Publications
Page Number
S59-S61
Author and Disclosure Information

Richard N. Gevirtz, PhD
Professor of Health Psychology at the California School of Professional Psychology, Alliant International University, San Diego, CA

Correspondence: Richard Gevirtz, PhD, California School of Professional Psychology, Alliant International University, 10455 Pomerado Road, San Diego, CA 92131; rgevirtz@alliant.edu

Dr. Gevirtz reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gevirtz's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gevirtz.

Author and Disclosure Information

Richard N. Gevirtz, PhD
Professor of Health Psychology at the California School of Professional Psychology, Alliant International University, San Diego, CA

Correspondence: Richard Gevirtz, PhD, California School of Professional Psychology, Alliant International University, 10455 Pomerado Road, San Diego, CA 92131; rgevirtz@alliant.edu

Dr. Gevirtz reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Gevirtz's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Gevirtz.

Article PDF
Article PDF

Traditionally, biofeedback was considered to be a stress management technique that targeted sympathetic nervous system (SNS) overdrive with an adrenal medullary system backup. Recent advances in autonomic physiology, however, have clarified that except in extreme situations, the SNS is not the key factor in day-to-day stress. Rather, the parasympathetic branch of the autonomic nervous system appears to be a more likely candidate for mediating routine stress because, unlike the SNS, which has slow-acting neurotransmitters (ie, catecholamines), the parasympathetic nervous system has the fast-acting transmitter acetylcholine.

VAGAL WITHDRAWAL: AN ALTERNATIVE TO SYMPATHETIC ACTIVATION

Porges1 first proposed the concept of vagal withdrawal as an indicator of stress and stress vulnerability; this contrasts with the idea that the stress response is a consequence of sympathetic activation and the hypothalamic-pituitary-adrenal axis response. In the vagal withdrawal model, the response to stress is stabilization of the sympathetic system followed by termination of parasympathetic activity, manifested as cardiac acceleration.

Respiratory sinus arrhythmia (RSA), or the variability in heart rate as it synchronizes with breathing, is considered an index of parasympathetic tone. In the laboratory, slow atropine infusion produces a transient paradoxical vagomimetic effect characterized by an initial increase in RSA, followed by a flattening and then a rise in the heart rate.2 This phenomenon has been measured in people during times of routine stress, such as when worrying about being late for an appointment. In such individuals, biofeedback training can result in recovery of normal RSA shortly after an episode of anxiety.

Historically, the focus of biofeedback was to cultivate low arousal, presumably reducing SNS activity, through the use of finger temperature, skin conductance training, and profound muscle relaxation. More sophisticated ways to look at both branches of the autonomic nervous system have since emerged that allow for sampling of the beat-by-beat changes in heart rate.

HEART RATE VARIABILITY BIOFEEDBACK

The concept of modifying the respiration rate (paced breathing) originated some 2,500 years ago as a component of meditation. It is being revisited today in the form of heart rate variability (HRV) biofeedback training, which is being used as a stress-management tool and a method to correct disorders in which autonomic regulation is thought to be important. HRV biofeedback involves training to increase the amplitude of HRV rhythms and thus improve autonomic homeostasis.

Normal HRV has a pattern of overlapping oscillatory frequency components, including:

  • a high-frequency rhythm, 0.15 to 0.4 Hz, which is the RSA;
  • a low-frequency rhythm, 0.05 to 0.15 Hz, associated with blood pressure oscillations; and
  • a very-low-frequency rhythm, 0.005 to 0.05 Hz, which may regulate vascular tone and body temperature.

The goal of HRV biofeedback is to achieve respiratory rates at which resonance occurs between cardiac rhythms associated with respiration (RSA, or high-frequency oscillations) and those caused by baroreflex activity (low-frequency oscillations).

Spectral analysis has demonstrated that nearly all of the activity with HRV biofeedback occurs at a low-frequency band. The reason is that activity in the low-frequency band is related more to baroreflex activity than to HRV compared with other ranges of frequency. Breathing rates that correspond to baroreflex effects, called resonance frequency breathing, represent resonance in the cardiovascular system. Several devices are available whose mechanisms are based on the concept of achieving resonance frequency breathing. One such device is a slow-breathing monitor (Resp-e-rate) that has been approved by the US Food and Drug Administration for the adjunctive treatment of hypertension.

Figure. Patients who underwent heart-rate variability (HRV) biofeedback training achieved near-normal standard deviation of normal-to-normal QRS complexes (SDNN) after 18 weeks. The SDNN, which is the primary measure used to quantify a change in HRV, declined in patients in the control group.3
Biofeedback has demonstrated success in several clinical trials targeting populations with autonomically mediated disorders. Del Pozo et al3 conducted a randomized study of HRV biofeedback in patients with coronary artery disease. Patients in the active intervention group underwent HRV biofeedback training that included breathing practice at home for 20 minutes per day. The standard deviation of normal-to-normal QRS complexes (SDNN), which is the primary measure used to quantify a change in HRV, improved from a mean of 28.0 msec to 42.0 msec after 18 weeks in the treatment group, and declined from a mean of 33.0 msec to 30.7 msec in the controls (Figure).

Improved HRV may suggest an improved risk status: Kleiger et al4 found that the relative risk of mortality was 5.3 times greater for people with SDNN of less than 50 msec compared with those whose SDNN was greater than 100 msec. In Del Pozo’s study, eight of 30 patients in the intervention group achieved an SDNN of greater than 50 msec (vs 0 at pretreatment) compared with three of 31 controls (vs two at pretreatment).3 As an additional benefit of HRV biofeedback, patients in the intervention group who entered the study with hypertension all became normotensive.

In a meta-analysis, van Dixhoorn and White5 found fewer cardiac events, fewer episodes of angina, and less occurrence of arrhythmia and exercise-induced ischemia from intensive supervised relaxation therapy in patients with ischemic heart disease. Improvements in scales of depression and anxiety were also observed with relaxation therapy.

Other studies have shown biofeedback to have beneficial effects based on the Posttraumatic Stress Disorder Checklist, the Hamilton Depression Rating Scale, and, in patients with mild to moderate heartfailure, the 6-minute walk test.6–8

The proposed mechanism for the beneficial effects of biofeedback found in clinical trials is improvement in baroreflex function, producing greater reflex efficiency and improved modulation of autonomic activity.

CONCLUSION

A shift in emphasis to vagal withdrawal has led to new forms of biofeedback that probably potentiate many of the same mechanisms thought to be present in Eastern practices such as yoga and tai chi. Results from small-scale trials have been promising for HRV biofeedback as a means of modifying responses to stress and promoting homeostatic processes that reduce the intensity of symptoms and improve surrogate markers associated with a number of disorders.

Traditionally, biofeedback was considered to be a stress management technique that targeted sympathetic nervous system (SNS) overdrive with an adrenal medullary system backup. Recent advances in autonomic physiology, however, have clarified that except in extreme situations, the SNS is not the key factor in day-to-day stress. Rather, the parasympathetic branch of the autonomic nervous system appears to be a more likely candidate for mediating routine stress because, unlike the SNS, which has slow-acting neurotransmitters (ie, catecholamines), the parasympathetic nervous system has the fast-acting transmitter acetylcholine.

VAGAL WITHDRAWAL: AN ALTERNATIVE TO SYMPATHETIC ACTIVATION

Porges1 first proposed the concept of vagal withdrawal as an indicator of stress and stress vulnerability; this contrasts with the idea that the stress response is a consequence of sympathetic activation and the hypothalamic-pituitary-adrenal axis response. In the vagal withdrawal model, the response to stress is stabilization of the sympathetic system followed by termination of parasympathetic activity, manifested as cardiac acceleration.

Respiratory sinus arrhythmia (RSA), or the variability in heart rate as it synchronizes with breathing, is considered an index of parasympathetic tone. In the laboratory, slow atropine infusion produces a transient paradoxical vagomimetic effect characterized by an initial increase in RSA, followed by a flattening and then a rise in the heart rate.2 This phenomenon has been measured in people during times of routine stress, such as when worrying about being late for an appointment. In such individuals, biofeedback training can result in recovery of normal RSA shortly after an episode of anxiety.

Historically, the focus of biofeedback was to cultivate low arousal, presumably reducing SNS activity, through the use of finger temperature, skin conductance training, and profound muscle relaxation. More sophisticated ways to look at both branches of the autonomic nervous system have since emerged that allow for sampling of the beat-by-beat changes in heart rate.

HEART RATE VARIABILITY BIOFEEDBACK

The concept of modifying the respiration rate (paced breathing) originated some 2,500 years ago as a component of meditation. It is being revisited today in the form of heart rate variability (HRV) biofeedback training, which is being used as a stress-management tool and a method to correct disorders in which autonomic regulation is thought to be important. HRV biofeedback involves training to increase the amplitude of HRV rhythms and thus improve autonomic homeostasis.

Normal HRV has a pattern of overlapping oscillatory frequency components, including:

  • a high-frequency rhythm, 0.15 to 0.4 Hz, which is the RSA;
  • a low-frequency rhythm, 0.05 to 0.15 Hz, associated with blood pressure oscillations; and
  • a very-low-frequency rhythm, 0.005 to 0.05 Hz, which may regulate vascular tone and body temperature.

The goal of HRV biofeedback is to achieve respiratory rates at which resonance occurs between cardiac rhythms associated with respiration (RSA, or high-frequency oscillations) and those caused by baroreflex activity (low-frequency oscillations).

Spectral analysis has demonstrated that nearly all of the activity with HRV biofeedback occurs at a low-frequency band. The reason is that activity in the low-frequency band is related more to baroreflex activity than to HRV compared with other ranges of frequency. Breathing rates that correspond to baroreflex effects, called resonance frequency breathing, represent resonance in the cardiovascular system. Several devices are available whose mechanisms are based on the concept of achieving resonance frequency breathing. One such device is a slow-breathing monitor (Resp-e-rate) that has been approved by the US Food and Drug Administration for the adjunctive treatment of hypertension.

Figure. Patients who underwent heart-rate variability (HRV) biofeedback training achieved near-normal standard deviation of normal-to-normal QRS complexes (SDNN) after 18 weeks. The SDNN, which is the primary measure used to quantify a change in HRV, declined in patients in the control group.3
Biofeedback has demonstrated success in several clinical trials targeting populations with autonomically mediated disorders. Del Pozo et al3 conducted a randomized study of HRV biofeedback in patients with coronary artery disease. Patients in the active intervention group underwent HRV biofeedback training that included breathing practice at home for 20 minutes per day. The standard deviation of normal-to-normal QRS complexes (SDNN), which is the primary measure used to quantify a change in HRV, improved from a mean of 28.0 msec to 42.0 msec after 18 weeks in the treatment group, and declined from a mean of 33.0 msec to 30.7 msec in the controls (Figure).

Improved HRV may suggest an improved risk status: Kleiger et al4 found that the relative risk of mortality was 5.3 times greater for people with SDNN of less than 50 msec compared with those whose SDNN was greater than 100 msec. In Del Pozo’s study, eight of 30 patients in the intervention group achieved an SDNN of greater than 50 msec (vs 0 at pretreatment) compared with three of 31 controls (vs two at pretreatment).3 As an additional benefit of HRV biofeedback, patients in the intervention group who entered the study with hypertension all became normotensive.

In a meta-analysis, van Dixhoorn and White5 found fewer cardiac events, fewer episodes of angina, and less occurrence of arrhythmia and exercise-induced ischemia from intensive supervised relaxation therapy in patients with ischemic heart disease. Improvements in scales of depression and anxiety were also observed with relaxation therapy.

Other studies have shown biofeedback to have beneficial effects based on the Posttraumatic Stress Disorder Checklist, the Hamilton Depression Rating Scale, and, in patients with mild to moderate heartfailure, the 6-minute walk test.6–8

The proposed mechanism for the beneficial effects of biofeedback found in clinical trials is improvement in baroreflex function, producing greater reflex efficiency and improved modulation of autonomic activity.

CONCLUSION

A shift in emphasis to vagal withdrawal has led to new forms of biofeedback that probably potentiate many of the same mechanisms thought to be present in Eastern practices such as yoga and tai chi. Results from small-scale trials have been promising for HRV biofeedback as a means of modifying responses to stress and promoting homeostatic processes that reduce the intensity of symptoms and improve surrogate markers associated with a number of disorders.

References
  1. Porges SW. Cardiac vagal tone: a physiological index of stress. Neurosci Biobehav Rev 1995; 19:225–233.
  2. Médigue C, Girard A, Laude D, Monti A, Wargon M, ElghoziJ-L. Relationship between pulse interval and respiratory sinusarrhythmia: a time- and frequency-domain analysis of the effects ofatropine. Eur J Physiol 2001; 441:650–655.
  3. Del Pozo JM, Gevirtz RN, Scher B, Guarneri E. Biofeedbacktreatment increases heart rate variability in patients withknown coronary artery disease. Am Heart J 2004; 147:e11. http://download.journals.elsevierhealth.com/pdfs/journals/0002-8703/PIIS0002870303007191.pdf. Accessed May 2, 2011.
  4. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart ratevariability and its association with increased mortality after acutemyocardial infarciton. Am J Cardiol 1987; 59:256–262.
  5. van Dixhoorn JV, White A. Relaxation therapy for rehabilitationand prevention in ischaemic heart disease: a systematic review andmeta-analysis. Eur J Cardiovasc Prev Rehabil 2005; 12:193–202.
  6. Karavidas MK, Lehrer PM, Vaschillo E, et al. Preliminary resultsof an open label study of heart rate variability biofeedback for thetreatment of major depression. Appl Psychophysiol Biofeedback2007; 32:19–30.
  7. Zucker TL, Samuelson KW, Muench F, Greenberg MA, GevirtzRN. The effects of respiratory sinus arrhythmia biofeedback onheart rate variability and posttraumatic stress disorder symptoms: apilot study. Appl Psychophysiol Biofeedback 2009; 34:135–143.
  8. Swanson KS, Gevirtz RN, Brown M, Spira J, Guarneri E, StoletniyL. The effect of biofeedback on function in patients with heartfailure. Appl Psychophysiol Biofeedback 2009; 34:71–91.
References
  1. Porges SW. Cardiac vagal tone: a physiological index of stress. Neurosci Biobehav Rev 1995; 19:225–233.
  2. Médigue C, Girard A, Laude D, Monti A, Wargon M, ElghoziJ-L. Relationship between pulse interval and respiratory sinusarrhythmia: a time- and frequency-domain analysis of the effects ofatropine. Eur J Physiol 2001; 441:650–655.
  3. Del Pozo JM, Gevirtz RN, Scher B, Guarneri E. Biofeedbacktreatment increases heart rate variability in patients withknown coronary artery disease. Am Heart J 2004; 147:e11. http://download.journals.elsevierhealth.com/pdfs/journals/0002-8703/PIIS0002870303007191.pdf. Accessed May 2, 2011.
  4. Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart ratevariability and its association with increased mortality after acutemyocardial infarciton. Am J Cardiol 1987; 59:256–262.
  5. van Dixhoorn JV, White A. Relaxation therapy for rehabilitationand prevention in ischaemic heart disease: a systematic review andmeta-analysis. Eur J Cardiovasc Prev Rehabil 2005; 12:193–202.
  6. Karavidas MK, Lehrer PM, Vaschillo E, et al. Preliminary resultsof an open label study of heart rate variability biofeedback for thetreatment of major depression. Appl Psychophysiol Biofeedback2007; 32:19–30.
  7. Zucker TL, Samuelson KW, Muench F, Greenberg MA, GevirtzRN. The effects of respiratory sinus arrhythmia biofeedback onheart rate variability and posttraumatic stress disorder symptoms: apilot study. Appl Psychophysiol Biofeedback 2009; 34:135–143.
  8. Swanson KS, Gevirtz RN, Brown M, Spira J, Guarneri E, StoletniyL. The effect of biofeedback on function in patients with heartfailure. Appl Psychophysiol Biofeedback 2009; 34:71–91.
Page Number
S59-S61
Page Number
S59-S61
Publications
Publications
Article Type
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback in the treatment of stress
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback in the treatment of stress
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S59-S61
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback for extreme stress: Wounded warriors

Article Type
Changed
Tue, 10/02/2018 - 09:32
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback for extreme stress: Wounded warriors

Posttraumatic stress disorder (PTSD) is a severe anxiety disorder whose symptoms emerge following exposure to extreme stress, such as those encountered in the battlefield or as a result of sexual abuse or natural disasters. The ability to employ coping mechanisms affects the disorder’s presentation as well as the frequency, intensity, and duration of the symptoms. The “Wounded Warrior” program at East Carolina University (Greenville, NC) was developed to promote the functional independence of US Marines, including those with PTSD.

STRESS RESPONSE: INTERACTION OF THE BRAIN AND IMMUNE SYSTEM

Walter Cannon coined the “flight or fight” response to stress in the early 20th century, in which he emphasized the importance of the parasympathetic system.1 In 1988, Folkow clarified the description as an immune response to stress.2 The stress response is now understood to be a neuroendocrine function that includes a feedback loop between the hypothalamus and the pituitary and adrenal glands; stimulation of the hypothalamus promotes secretion of corticotropin-releasing hormone (CRH) into the hypophyseal portal system, which supplies the anterior pituitarywith blood. CRH stimulates the secretion of adrenocorticotropic hormone into the bloodstream by the pituitary, prompting the adrenal glands to release the stress hormone cortisol.

Cortisol mobilizes the body’s defenses to meet the challenge of an adverse situation. It modulates the stress response by inhibiting the further release of CRH by the hypothalamus. Cortisol thus protects healthy cells and tissues by inhibiting an overreaction from the immune system. Without this protective effect, the interaction between the brain and the immune system can become dysregulated, increasing the risk of immune disorders.

THE CENTRAL AUTONOMIC NETWORK

The central nervous system that regulates the overall balance of the autonomic nervous system (ANS) has been called the central autonomic network (CAN).3 The CAN helps control executive, social, affective, attentional, and motivational functions. Therefore, the old paradigm of simply decreasing hyperarousal of the ANS to treat negative affective states and dispositions is inadequate. Instead, restoring the appropriate relationship between the ANS and the central nervous system is the aim behind interventions to treat PTSD.

Autonomic, cognitive, and affective functions assist humans in maintaining balance when confronted with external challenges. The CAN controls inhibitory or negative processes that permit specific behavior and redeploy resources needed elsewhere. When negative circuits are compromised, positive circuits develop, resulting in hypervigilance, the symptoms of which can be devastating and, if not ameliorated, can develop into permanent conditions. In one study,Vietnam veterans with PTSD had an 8% reduction in the volume of their right hippocampus compared with veterans without PTSD. Another study calculated a 26% reduction in the left hippocampus and a 22% reduction in the right in veterans with the most severe PTSD compared with veterans who were in combat but had no PTSD symptoms.4

A common subcortical neural system regulates defensive behavior, including autonomic, emotional, and cognitive behavior. When the prefrontal cortex is taken “off line” for whatever reason, parasympathetic inhibitory action is withdrawn, and relative sympathetic dominance, associated with defense, occurs.

CONFRONTING HYPERAROUSAL

The question then arises of how to train the ANS to avoid hypervigilance. Growing evidence supports the use of heart rate variability as a predictor of hypervigilance and inefficient allocation of attentional and cognitive resources.

The overall objective of heart rate variability training is to decrease ANS hyperarousal and to improve its balance. “Wounded warriors” learn to control ANS responses to stress-producing stimuli (eg, thoughts, memories, and images associated with combat). The goal of training is to decrease arousal and maintain ANS balance for increasing lengths of time.

Once it was observed that alpha waves were dysfunctional in vulnerable populations, protocols were developed to train alpha and theta waves as a method of improving function. Peniston and colleagues5–9 showed that increased alpha and theta brain wave production resulted in normalized personality measures and prolonged the period of time before relapse in alcoholics. This protocol has also shown efficacy as an intervention in depression and PTSD.

BIOFEEDBACK TRAINING PROGRAM

The US Department of Defense is studying a combination of central nervous system biofeedback with ANS biofeedback, with the goal of restoring and maintaining tone between the systems.

The training program used in the study lasts 1 month, and starts with a session for preassessment, 16 biofeedback sessions (four per week), a postprogram evaluation, and a 3-month followup. Each week, participants are exposed to stress-producing stimuli that increase in intensity:

  • Week 1: Stroop Color Word Test, math stressor, talk stressor/everyday events
  • Week 2: Talk stressor, combat experiences
  • Week 3: Images and sounds of combat
  • Week 4: Virtual Baghdad or Afghanistan (virtual reality exposure)

Each biofeedback session consists of 5 minutes of baseline evaluation; 5 minutes in which the veteran is subjected to the weekly stressor; 20 minutes of heart rate variability and neurofeedback training; 5 more minutes of training with the weekly stressor; 20 more minutes of heart rate variability and neurofeedback training; and finally 5 minutes of recovery.

Figure. Before (top) and after (bottom) heart rate variability training training. The patient’s heart rate after completing training has markedly less variation.
Preliminary clinical data indicate decreases in ANS hyperarousal and increases in parasympathetic activity (Figure). Reports on the Patient Health Questionnaire Short Form (PHQ SF-36) indicate positive changes in physical symptoms and decreases in symptoms of depression, panic, and anxiety. Outcome measurements will include changes from heart rate variability training; the Posttraumatic Stress Checklist; PHQ SF-36; Profile of Mood States; salivary alpha-amylase changes; a behavioral questionnaire assessing nutrition habits and alcohol, drug, and nicotine use; and the Self-Satisfaction Inventory.

SUMMARY

Dysfunction in the balance of both the ANS and central nervous system is associated with symptoms of PTSD in combat veterans. Methods that are designed to restore balance in these systems are needed to ameliorate these symptoms. Biofeedback and neurofeedback are safe methods with which to achieve these goals.

References
  1. Cannon WB. Bodily Changes in Pain, Hunger, Fear and Rage: An Account of Recent Researches into the Function of Emotional Excitement. 2nd ed. New York, NY: Appleton-Century-Crofts; 1929.
  2. Folkow B. Stress, hypothalamic function and neuroendocrine consequences. Acta Med Scand Suppl 1988; 723:61–69.
  3. Thayer JF, Brosschot JF. Psychosomatics and psychopathology: looking up and down from the brain. Psychoneuroendocrinology 2005; 30:1050–1058.
  4. van der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001; 16:S49–S64.
  5. Peniston EG, Kulkosky PJ. Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcohol Clin Exp Res 1989;13:271–279.
  6. Peniston EG, Kulkosky PJ. Alcoholic personality and alpha-thetabrainwave training. Medical Psychotherapy: An International Journal1990; 3:37–55.
  7. Peniston EG, Kulkosky PJ. Alpha-theta brainwave neurofeedbacktherapy for Vietnam veterans with combat-related posttraumaticstress disorder. Medical Psychotherapy: An International Journal1991; 4:47–60.
  8. Peniston EG, Kulkosky PJ. Alpha-theta EEG biofeedback trainingin alcoholism and posttraumatic stress disorder. The InternationalSociety for the Study of Subtle Energies and Energy Medicines1992; 2:5–7.
  9. Peniston EG, Marrinan DA, Deming WA, Kulkosky PJ. EEGalpha-theta brainwave synchronization in Vietnam theater veteranswith combat-related posttraumatic stress disorder and alcohol abuse.Medical Psychotherapy: An International Journal 1993; 6:37–50.
Article PDF
Author and Disclosure Information

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Correspondence: Carmen V. Russoniello, PhD, Director, Psychophysiology Lab and Biofeedback Clinic, East Carolina University, East Fifth Street, Greenville, NC 27858-4353; russonielloc@mail.ecu.edu

Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of Dr. Russoniello's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Russoniello.

Publications
Page Number
S61-S63
Author and Disclosure Information

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Correspondence: Carmen V. Russoniello, PhD, Director, Psychophysiology Lab and Biofeedback Clinic, East Carolina University, East Fifth Street, Greenville, NC 27858-4353; russonielloc@mail.ecu.edu

Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of Dr. Russoniello's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Russoniello.

Author and Disclosure Information

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Correspondence: Carmen V. Russoniello, PhD, Director, Psychophysiology Lab and Biofeedback Clinic, East Carolina University, East Fifth Street, Greenville, NC 27858-4353; russonielloc@mail.ecu.edu

Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of Dr. Russoniello's presentation and panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Russoniello.

Article PDF
Article PDF

Posttraumatic stress disorder (PTSD) is a severe anxiety disorder whose symptoms emerge following exposure to extreme stress, such as those encountered in the battlefield or as a result of sexual abuse or natural disasters. The ability to employ coping mechanisms affects the disorder’s presentation as well as the frequency, intensity, and duration of the symptoms. The “Wounded Warrior” program at East Carolina University (Greenville, NC) was developed to promote the functional independence of US Marines, including those with PTSD.

STRESS RESPONSE: INTERACTION OF THE BRAIN AND IMMUNE SYSTEM

Walter Cannon coined the “flight or fight” response to stress in the early 20th century, in which he emphasized the importance of the parasympathetic system.1 In 1988, Folkow clarified the description as an immune response to stress.2 The stress response is now understood to be a neuroendocrine function that includes a feedback loop between the hypothalamus and the pituitary and adrenal glands; stimulation of the hypothalamus promotes secretion of corticotropin-releasing hormone (CRH) into the hypophyseal portal system, which supplies the anterior pituitarywith blood. CRH stimulates the secretion of adrenocorticotropic hormone into the bloodstream by the pituitary, prompting the adrenal glands to release the stress hormone cortisol.

Cortisol mobilizes the body’s defenses to meet the challenge of an adverse situation. It modulates the stress response by inhibiting the further release of CRH by the hypothalamus. Cortisol thus protects healthy cells and tissues by inhibiting an overreaction from the immune system. Without this protective effect, the interaction between the brain and the immune system can become dysregulated, increasing the risk of immune disorders.

THE CENTRAL AUTONOMIC NETWORK

The central nervous system that regulates the overall balance of the autonomic nervous system (ANS) has been called the central autonomic network (CAN).3 The CAN helps control executive, social, affective, attentional, and motivational functions. Therefore, the old paradigm of simply decreasing hyperarousal of the ANS to treat negative affective states and dispositions is inadequate. Instead, restoring the appropriate relationship between the ANS and the central nervous system is the aim behind interventions to treat PTSD.

Autonomic, cognitive, and affective functions assist humans in maintaining balance when confronted with external challenges. The CAN controls inhibitory or negative processes that permit specific behavior and redeploy resources needed elsewhere. When negative circuits are compromised, positive circuits develop, resulting in hypervigilance, the symptoms of which can be devastating and, if not ameliorated, can develop into permanent conditions. In one study,Vietnam veterans with PTSD had an 8% reduction in the volume of their right hippocampus compared with veterans without PTSD. Another study calculated a 26% reduction in the left hippocampus and a 22% reduction in the right in veterans with the most severe PTSD compared with veterans who were in combat but had no PTSD symptoms.4

A common subcortical neural system regulates defensive behavior, including autonomic, emotional, and cognitive behavior. When the prefrontal cortex is taken “off line” for whatever reason, parasympathetic inhibitory action is withdrawn, and relative sympathetic dominance, associated with defense, occurs.

CONFRONTING HYPERAROUSAL

The question then arises of how to train the ANS to avoid hypervigilance. Growing evidence supports the use of heart rate variability as a predictor of hypervigilance and inefficient allocation of attentional and cognitive resources.

The overall objective of heart rate variability training is to decrease ANS hyperarousal and to improve its balance. “Wounded warriors” learn to control ANS responses to stress-producing stimuli (eg, thoughts, memories, and images associated with combat). The goal of training is to decrease arousal and maintain ANS balance for increasing lengths of time.

Once it was observed that alpha waves were dysfunctional in vulnerable populations, protocols were developed to train alpha and theta waves as a method of improving function. Peniston and colleagues5–9 showed that increased alpha and theta brain wave production resulted in normalized personality measures and prolonged the period of time before relapse in alcoholics. This protocol has also shown efficacy as an intervention in depression and PTSD.

BIOFEEDBACK TRAINING PROGRAM

The US Department of Defense is studying a combination of central nervous system biofeedback with ANS biofeedback, with the goal of restoring and maintaining tone between the systems.

The training program used in the study lasts 1 month, and starts with a session for preassessment, 16 biofeedback sessions (four per week), a postprogram evaluation, and a 3-month followup. Each week, participants are exposed to stress-producing stimuli that increase in intensity:

  • Week 1: Stroop Color Word Test, math stressor, talk stressor/everyday events
  • Week 2: Talk stressor, combat experiences
  • Week 3: Images and sounds of combat
  • Week 4: Virtual Baghdad or Afghanistan (virtual reality exposure)

Each biofeedback session consists of 5 minutes of baseline evaluation; 5 minutes in which the veteran is subjected to the weekly stressor; 20 minutes of heart rate variability and neurofeedback training; 5 more minutes of training with the weekly stressor; 20 more minutes of heart rate variability and neurofeedback training; and finally 5 minutes of recovery.

Figure. Before (top) and after (bottom) heart rate variability training training. The patient’s heart rate after completing training has markedly less variation.
Preliminary clinical data indicate decreases in ANS hyperarousal and increases in parasympathetic activity (Figure). Reports on the Patient Health Questionnaire Short Form (PHQ SF-36) indicate positive changes in physical symptoms and decreases in symptoms of depression, panic, and anxiety. Outcome measurements will include changes from heart rate variability training; the Posttraumatic Stress Checklist; PHQ SF-36; Profile of Mood States; salivary alpha-amylase changes; a behavioral questionnaire assessing nutrition habits and alcohol, drug, and nicotine use; and the Self-Satisfaction Inventory.

SUMMARY

Dysfunction in the balance of both the ANS and central nervous system is associated with symptoms of PTSD in combat veterans. Methods that are designed to restore balance in these systems are needed to ameliorate these symptoms. Biofeedback and neurofeedback are safe methods with which to achieve these goals.

Posttraumatic stress disorder (PTSD) is a severe anxiety disorder whose symptoms emerge following exposure to extreme stress, such as those encountered in the battlefield or as a result of sexual abuse or natural disasters. The ability to employ coping mechanisms affects the disorder’s presentation as well as the frequency, intensity, and duration of the symptoms. The “Wounded Warrior” program at East Carolina University (Greenville, NC) was developed to promote the functional independence of US Marines, including those with PTSD.

STRESS RESPONSE: INTERACTION OF THE BRAIN AND IMMUNE SYSTEM

Walter Cannon coined the “flight or fight” response to stress in the early 20th century, in which he emphasized the importance of the parasympathetic system.1 In 1988, Folkow clarified the description as an immune response to stress.2 The stress response is now understood to be a neuroendocrine function that includes a feedback loop between the hypothalamus and the pituitary and adrenal glands; stimulation of the hypothalamus promotes secretion of corticotropin-releasing hormone (CRH) into the hypophyseal portal system, which supplies the anterior pituitarywith blood. CRH stimulates the secretion of adrenocorticotropic hormone into the bloodstream by the pituitary, prompting the adrenal glands to release the stress hormone cortisol.

Cortisol mobilizes the body’s defenses to meet the challenge of an adverse situation. It modulates the stress response by inhibiting the further release of CRH by the hypothalamus. Cortisol thus protects healthy cells and tissues by inhibiting an overreaction from the immune system. Without this protective effect, the interaction between the brain and the immune system can become dysregulated, increasing the risk of immune disorders.

THE CENTRAL AUTONOMIC NETWORK

The central nervous system that regulates the overall balance of the autonomic nervous system (ANS) has been called the central autonomic network (CAN).3 The CAN helps control executive, social, affective, attentional, and motivational functions. Therefore, the old paradigm of simply decreasing hyperarousal of the ANS to treat negative affective states and dispositions is inadequate. Instead, restoring the appropriate relationship between the ANS and the central nervous system is the aim behind interventions to treat PTSD.

Autonomic, cognitive, and affective functions assist humans in maintaining balance when confronted with external challenges. The CAN controls inhibitory or negative processes that permit specific behavior and redeploy resources needed elsewhere. When negative circuits are compromised, positive circuits develop, resulting in hypervigilance, the symptoms of which can be devastating and, if not ameliorated, can develop into permanent conditions. In one study,Vietnam veterans with PTSD had an 8% reduction in the volume of their right hippocampus compared with veterans without PTSD. Another study calculated a 26% reduction in the left hippocampus and a 22% reduction in the right in veterans with the most severe PTSD compared with veterans who were in combat but had no PTSD symptoms.4

A common subcortical neural system regulates defensive behavior, including autonomic, emotional, and cognitive behavior. When the prefrontal cortex is taken “off line” for whatever reason, parasympathetic inhibitory action is withdrawn, and relative sympathetic dominance, associated with defense, occurs.

CONFRONTING HYPERAROUSAL

The question then arises of how to train the ANS to avoid hypervigilance. Growing evidence supports the use of heart rate variability as a predictor of hypervigilance and inefficient allocation of attentional and cognitive resources.

The overall objective of heart rate variability training is to decrease ANS hyperarousal and to improve its balance. “Wounded warriors” learn to control ANS responses to stress-producing stimuli (eg, thoughts, memories, and images associated with combat). The goal of training is to decrease arousal and maintain ANS balance for increasing lengths of time.

Once it was observed that alpha waves were dysfunctional in vulnerable populations, protocols were developed to train alpha and theta waves as a method of improving function. Peniston and colleagues5–9 showed that increased alpha and theta brain wave production resulted in normalized personality measures and prolonged the period of time before relapse in alcoholics. This protocol has also shown efficacy as an intervention in depression and PTSD.

BIOFEEDBACK TRAINING PROGRAM

The US Department of Defense is studying a combination of central nervous system biofeedback with ANS biofeedback, with the goal of restoring and maintaining tone between the systems.

The training program used in the study lasts 1 month, and starts with a session for preassessment, 16 biofeedback sessions (four per week), a postprogram evaluation, and a 3-month followup. Each week, participants are exposed to stress-producing stimuli that increase in intensity:

  • Week 1: Stroop Color Word Test, math stressor, talk stressor/everyday events
  • Week 2: Talk stressor, combat experiences
  • Week 3: Images and sounds of combat
  • Week 4: Virtual Baghdad or Afghanistan (virtual reality exposure)

Each biofeedback session consists of 5 minutes of baseline evaluation; 5 minutes in which the veteran is subjected to the weekly stressor; 20 minutes of heart rate variability and neurofeedback training; 5 more minutes of training with the weekly stressor; 20 more minutes of heart rate variability and neurofeedback training; and finally 5 minutes of recovery.

Figure. Before (top) and after (bottom) heart rate variability training training. The patient’s heart rate after completing training has markedly less variation.
Preliminary clinical data indicate decreases in ANS hyperarousal and increases in parasympathetic activity (Figure). Reports on the Patient Health Questionnaire Short Form (PHQ SF-36) indicate positive changes in physical symptoms and decreases in symptoms of depression, panic, and anxiety. Outcome measurements will include changes from heart rate variability training; the Posttraumatic Stress Checklist; PHQ SF-36; Profile of Mood States; salivary alpha-amylase changes; a behavioral questionnaire assessing nutrition habits and alcohol, drug, and nicotine use; and the Self-Satisfaction Inventory.

SUMMARY

Dysfunction in the balance of both the ANS and central nervous system is associated with symptoms of PTSD in combat veterans. Methods that are designed to restore balance in these systems are needed to ameliorate these symptoms. Biofeedback and neurofeedback are safe methods with which to achieve these goals.

References
  1. Cannon WB. Bodily Changes in Pain, Hunger, Fear and Rage: An Account of Recent Researches into the Function of Emotional Excitement. 2nd ed. New York, NY: Appleton-Century-Crofts; 1929.
  2. Folkow B. Stress, hypothalamic function and neuroendocrine consequences. Acta Med Scand Suppl 1988; 723:61–69.
  3. Thayer JF, Brosschot JF. Psychosomatics and psychopathology: looking up and down from the brain. Psychoneuroendocrinology 2005; 30:1050–1058.
  4. van der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001; 16:S49–S64.
  5. Peniston EG, Kulkosky PJ. Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcohol Clin Exp Res 1989;13:271–279.
  6. Peniston EG, Kulkosky PJ. Alcoholic personality and alpha-thetabrainwave training. Medical Psychotherapy: An International Journal1990; 3:37–55.
  7. Peniston EG, Kulkosky PJ. Alpha-theta brainwave neurofeedbacktherapy for Vietnam veterans with combat-related posttraumaticstress disorder. Medical Psychotherapy: An International Journal1991; 4:47–60.
  8. Peniston EG, Kulkosky PJ. Alpha-theta EEG biofeedback trainingin alcoholism and posttraumatic stress disorder. The InternationalSociety for the Study of Subtle Energies and Energy Medicines1992; 2:5–7.
  9. Peniston EG, Marrinan DA, Deming WA, Kulkosky PJ. EEGalpha-theta brainwave synchronization in Vietnam theater veteranswith combat-related posttraumatic stress disorder and alcohol abuse.Medical Psychotherapy: An International Journal 1993; 6:37–50.
References
  1. Cannon WB. Bodily Changes in Pain, Hunger, Fear and Rage: An Account of Recent Researches into the Function of Emotional Excitement. 2nd ed. New York, NY: Appleton-Century-Crofts; 1929.
  2. Folkow B. Stress, hypothalamic function and neuroendocrine consequences. Acta Med Scand Suppl 1988; 723:61–69.
  3. Thayer JF, Brosschot JF. Psychosomatics and psychopathology: looking up and down from the brain. Psychoneuroendocrinology 2005; 30:1050–1058.
  4. van der Kolk BA. The psychobiology and psychopharmacology of PTSD. Hum Psychopharmacol 2001; 16:S49–S64.
  5. Peniston EG, Kulkosky PJ. Alpha-theta brainwave training and beta-endorphin levels in alcoholics. Alcohol Clin Exp Res 1989;13:271–279.
  6. Peniston EG, Kulkosky PJ. Alcoholic personality and alpha-thetabrainwave training. Medical Psychotherapy: An International Journal1990; 3:37–55.
  7. Peniston EG, Kulkosky PJ. Alpha-theta brainwave neurofeedbacktherapy for Vietnam veterans with combat-related posttraumaticstress disorder. Medical Psychotherapy: An International Journal1991; 4:47–60.
  8. Peniston EG, Kulkosky PJ. Alpha-theta EEG biofeedback trainingin alcoholism and posttraumatic stress disorder. The InternationalSociety for the Study of Subtle Energies and Energy Medicines1992; 2:5–7.
  9. Peniston EG, Marrinan DA, Deming WA, Kulkosky PJ. EEGalpha-theta brainwave synchronization in Vietnam theater veteranswith combat-related posttraumatic stress disorder and alcohol abuse.Medical Psychotherapy: An International Journal 1993; 6:37–50.
Page Number
S61-S63
Page Number
S61-S63
Publications
Publications
Article Type
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback for extreme stress: Wounded warriors
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Biofeedback for extreme stress: Wounded warriors
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S61-S63
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Stress in medicine: Strategies for caregivers, patients, clinicians—Panel discussion

Article Type
Changed
Tue, 10/02/2018 - 09:32
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Panel discussion

Question from audience: Why does the Cleveland Clinic start its healing services program preoperatively rather than postoperatively?

Dr. Gillinov: We have a fairly well defined preoperative set of medical tests, and during this process nurses present patients with materials that explain the experience, and nurses and doctors make themselves available in special classes to answer patients’ questions. In doing so, we have increasingly identified patients preoperatively who have stress or problems.

Last week I saw a woman who had a leaking mitral valve, but her symptoms were out of proportion to her disease. She had loss of energy and appetite, and she wasn’t eating much. She was depressed and our team picked that up. She actually never had to undergo surgery. We referred her to a psychologist and, according to her son, she started to feel better. By starting preoperatively, we’re sometimes able to pick out things that we should treat instead of heart disease.

We also provide guided imagery and massage preoperatively.

Dr. Duffy: Healing services is on standing preoperative orders at the hospital. The team goes in proactively and asks, “In addition to your open heart surgery on Wednesday, is there anything we can do to support your emotional and spiritual journey here today?”

Terminology also matters. The term “healing services” is a safe umbrella under which we include biofeedback as one of the services, but it encompasses pastoral care, hospice care, and palliative care. The way it’s integrated into a care model is important. If it’s reserved for end of life, it might be viewed as defective or as a death sentence, so we want the healing services team to be proactive.

Question from audience: How does the primary care physician fit into all of this? I believe that if the physicians in the hospital want to gain patient confidence, they’ll show that they’re communicating well with the primary care physician.

Dr. Gevirtz: The primary care physicians are incredibly open to this idea. They have 12 minutes to deal with people with fibromyalgia, irritable bowel syndrome, chronic pain, noncardiac chest pain, etc. What are they going to do in 12 minutes? They’re grateful if they have a handoff, especially if it’s in the Clinic itself.

Question from audience: Are there any thoughts on making biofeedback part of general training rather than using it just for patients who’ve already experienced trauma?

Dr. Gevirtz: We did a study in which we showed that a biofeedback technician in the primary care setting saved the health maintenance system quite a lot of money, but the administration couldn’t decide whose territory to take to give us an office, so it ended the program.

Dr. Russoniello: How we enable greater access to our intervention is an important question. I see people quit the program if they can’t get access to biofeedback. In an effort to enhance compliance, we’ve incorporated biofeedback into video games, working with a couple of private companies to develop them.The idea is that persons playing the video game can accrue points to enhance their overall score if they perform paced breathing or some other form of biofeedback. Early indications from focus groups are that people will like this.

We have already shown in randomized controlled clinical studies of depression and anxiety that certain video games can improve mood and decrease stress.There is a big movement to get products in people’s hands to help them manage their health.

Question from audience: How much overlap is there between biofeedback methodologies—enhancing heart rate variability, vagal withdrawal, neurofeedback, and electroencephalographic feedback—in the systems you’re targeting and what are the unique contributions of each?

Dr. Gevirtz: We follow a stepped-care model. We start with the simplest and move on to the more complicated technologies. Two published studies with long-term followup showed the effectiveness of a learned breathing technique in alleviating noncardiac chest pain. Simple biofeedback wasn’t even needed. Three years later, the patients were better than they were at the end of the actual training. If you can do it simply, then you do it, and if it doesn’t work, then move on to more and more complicated techniques, with neurofeedback being the last resort.

Question from audience: Has anybody measured the physical impact of stimulating multiple systems on the study subject? In other words, can it be damaging to overstimulate these systems at the same time?

Dr. Gevirtz: We’ve been trying to do that. Recurrent abdominal pain or functional abdominal pain is the most common complaint to pediatric gastroenterologists. We have 1,800 patients a year who make it to the children’s hospital level with this complaint. These are kids who are suffering with very great pain and we we’re pretty sure it’s an autonomically mediated kind of phenomenon. We’re able to measure vagal activity in these kids in ambulatory settings at school and have found very little vagal activity before treatment. After training, they were able to restore vagal activity, and it correlated at the level of 0.63 with a reduction of symptoms. I think it’s important to try to tie the physiology to symptoms. It’s not always easy to do but we’re trying.

Question from audience: I’d like to pick up on two topics that Dr. Duffy raised: the business of medicine and the proposal for informed hope rather than an informed consent before surgery. Something that I see with patients and families at times is this magical expectation promoted by the business side that medicine can do these amazing and wonderful things and doesn’t have any sort of weaknesses. I wonder what role unrealistic expectations promoted by the media, advertising, and others may play in the stress of patients, caregivers, and physicians who need to try to meet the expectations of infallible medicine?

Dr. Duffy: We’ve spun so far the other way with our advanced technology that we’ve lost the human side, especially the concept of a relationship and giving people hope even though they have a terminal condition. It’s a balance between the art and the business of medicine. It’s about setting realistic expectations and realistic hope.

Article PDF
Author and Disclosure Information

Michael G. McKee, PhD
Cleveland Clinic, Cleveland, OH

A. Marc Gillinov, MD
Cleveland Clinic, Cleveland, OH

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Richard N. Gevirtz, PhD
Alliant International University, San Diego, CA

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Drs. McKee, Gillinov, Duffy, and Gevirtz reported that they have no financial relationships that pose a potential conflict of interest with this article. Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of the authors’ panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by each of the authors.

Publications
Page Number
S63-S64
Author and Disclosure Information

Michael G. McKee, PhD
Cleveland Clinic, Cleveland, OH

A. Marc Gillinov, MD
Cleveland Clinic, Cleveland, OH

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Richard N. Gevirtz, PhD
Alliant International University, San Diego, CA

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Drs. McKee, Gillinov, Duffy, and Gevirtz reported that they have no financial relationships that pose a potential conflict of interest with this article. Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of the authors’ panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by each of the authors.

Author and Disclosure Information

Michael G. McKee, PhD
Cleveland Clinic, Cleveland, OH

A. Marc Gillinov, MD
Cleveland Clinic, Cleveland, OH

M. Bridget Duffy, MD
ExperiaHealth, San Francisco, CA

Richard N. Gevirtz, PhD
Alliant International University, San Diego, CA

Carmen V. Russoniello, PhD
East Carolina University, Greenville, NC

Drs. McKee, Gillinov, Duffy, and Gevirtz reported that they have no financial relationships that pose a potential conflict of interest with this article. Dr. Russoniello reported advisory committee membership and ownership interest in Biocom Technologies.

This article was developed from an audio transcript of the authors’ panel discussion at the 2011 Heart-Brain Summit. The transcript was edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by each of the authors.

Article PDF
Article PDF
Related Articles

Question from audience: Why does the Cleveland Clinic start its healing services program preoperatively rather than postoperatively?

Dr. Gillinov: We have a fairly well defined preoperative set of medical tests, and during this process nurses present patients with materials that explain the experience, and nurses and doctors make themselves available in special classes to answer patients’ questions. In doing so, we have increasingly identified patients preoperatively who have stress or problems.

Last week I saw a woman who had a leaking mitral valve, but her symptoms were out of proportion to her disease. She had loss of energy and appetite, and she wasn’t eating much. She was depressed and our team picked that up. She actually never had to undergo surgery. We referred her to a psychologist and, according to her son, she started to feel better. By starting preoperatively, we’re sometimes able to pick out things that we should treat instead of heart disease.

We also provide guided imagery and massage preoperatively.

Dr. Duffy: Healing services is on standing preoperative orders at the hospital. The team goes in proactively and asks, “In addition to your open heart surgery on Wednesday, is there anything we can do to support your emotional and spiritual journey here today?”

Terminology also matters. The term “healing services” is a safe umbrella under which we include biofeedback as one of the services, but it encompasses pastoral care, hospice care, and palliative care. The way it’s integrated into a care model is important. If it’s reserved for end of life, it might be viewed as defective or as a death sentence, so we want the healing services team to be proactive.

Question from audience: How does the primary care physician fit into all of this? I believe that if the physicians in the hospital want to gain patient confidence, they’ll show that they’re communicating well with the primary care physician.

Dr. Gevirtz: The primary care physicians are incredibly open to this idea. They have 12 minutes to deal with people with fibromyalgia, irritable bowel syndrome, chronic pain, noncardiac chest pain, etc. What are they going to do in 12 minutes? They’re grateful if they have a handoff, especially if it’s in the Clinic itself.

Question from audience: Are there any thoughts on making biofeedback part of general training rather than using it just for patients who’ve already experienced trauma?

Dr. Gevirtz: We did a study in which we showed that a biofeedback technician in the primary care setting saved the health maintenance system quite a lot of money, but the administration couldn’t decide whose territory to take to give us an office, so it ended the program.

Dr. Russoniello: How we enable greater access to our intervention is an important question. I see people quit the program if they can’t get access to biofeedback. In an effort to enhance compliance, we’ve incorporated biofeedback into video games, working with a couple of private companies to develop them.The idea is that persons playing the video game can accrue points to enhance their overall score if they perform paced breathing or some other form of biofeedback. Early indications from focus groups are that people will like this.

We have already shown in randomized controlled clinical studies of depression and anxiety that certain video games can improve mood and decrease stress.There is a big movement to get products in people’s hands to help them manage their health.

Question from audience: How much overlap is there between biofeedback methodologies—enhancing heart rate variability, vagal withdrawal, neurofeedback, and electroencephalographic feedback—in the systems you’re targeting and what are the unique contributions of each?

Dr. Gevirtz: We follow a stepped-care model. We start with the simplest and move on to the more complicated technologies. Two published studies with long-term followup showed the effectiveness of a learned breathing technique in alleviating noncardiac chest pain. Simple biofeedback wasn’t even needed. Three years later, the patients were better than they were at the end of the actual training. If you can do it simply, then you do it, and if it doesn’t work, then move on to more and more complicated techniques, with neurofeedback being the last resort.

Question from audience: Has anybody measured the physical impact of stimulating multiple systems on the study subject? In other words, can it be damaging to overstimulate these systems at the same time?

Dr. Gevirtz: We’ve been trying to do that. Recurrent abdominal pain or functional abdominal pain is the most common complaint to pediatric gastroenterologists. We have 1,800 patients a year who make it to the children’s hospital level with this complaint. These are kids who are suffering with very great pain and we we’re pretty sure it’s an autonomically mediated kind of phenomenon. We’re able to measure vagal activity in these kids in ambulatory settings at school and have found very little vagal activity before treatment. After training, they were able to restore vagal activity, and it correlated at the level of 0.63 with a reduction of symptoms. I think it’s important to try to tie the physiology to symptoms. It’s not always easy to do but we’re trying.

Question from audience: I’d like to pick up on two topics that Dr. Duffy raised: the business of medicine and the proposal for informed hope rather than an informed consent before surgery. Something that I see with patients and families at times is this magical expectation promoted by the business side that medicine can do these amazing and wonderful things and doesn’t have any sort of weaknesses. I wonder what role unrealistic expectations promoted by the media, advertising, and others may play in the stress of patients, caregivers, and physicians who need to try to meet the expectations of infallible medicine?

Dr. Duffy: We’ve spun so far the other way with our advanced technology that we’ve lost the human side, especially the concept of a relationship and giving people hope even though they have a terminal condition. It’s a balance between the art and the business of medicine. It’s about setting realistic expectations and realistic hope.

Question from audience: Why does the Cleveland Clinic start its healing services program preoperatively rather than postoperatively?

Dr. Gillinov: We have a fairly well defined preoperative set of medical tests, and during this process nurses present patients with materials that explain the experience, and nurses and doctors make themselves available in special classes to answer patients’ questions. In doing so, we have increasingly identified patients preoperatively who have stress or problems.

Last week I saw a woman who had a leaking mitral valve, but her symptoms were out of proportion to her disease. She had loss of energy and appetite, and she wasn’t eating much. She was depressed and our team picked that up. She actually never had to undergo surgery. We referred her to a psychologist and, according to her son, she started to feel better. By starting preoperatively, we’re sometimes able to pick out things that we should treat instead of heart disease.

We also provide guided imagery and massage preoperatively.

Dr. Duffy: Healing services is on standing preoperative orders at the hospital. The team goes in proactively and asks, “In addition to your open heart surgery on Wednesday, is there anything we can do to support your emotional and spiritual journey here today?”

Terminology also matters. The term “healing services” is a safe umbrella under which we include biofeedback as one of the services, but it encompasses pastoral care, hospice care, and palliative care. The way it’s integrated into a care model is important. If it’s reserved for end of life, it might be viewed as defective or as a death sentence, so we want the healing services team to be proactive.

Question from audience: How does the primary care physician fit into all of this? I believe that if the physicians in the hospital want to gain patient confidence, they’ll show that they’re communicating well with the primary care physician.

Dr. Gevirtz: The primary care physicians are incredibly open to this idea. They have 12 minutes to deal with people with fibromyalgia, irritable bowel syndrome, chronic pain, noncardiac chest pain, etc. What are they going to do in 12 minutes? They’re grateful if they have a handoff, especially if it’s in the Clinic itself.

Question from audience: Are there any thoughts on making biofeedback part of general training rather than using it just for patients who’ve already experienced trauma?

Dr. Gevirtz: We did a study in which we showed that a biofeedback technician in the primary care setting saved the health maintenance system quite a lot of money, but the administration couldn’t decide whose territory to take to give us an office, so it ended the program.

Dr. Russoniello: How we enable greater access to our intervention is an important question. I see people quit the program if they can’t get access to biofeedback. In an effort to enhance compliance, we’ve incorporated biofeedback into video games, working with a couple of private companies to develop them.The idea is that persons playing the video game can accrue points to enhance their overall score if they perform paced breathing or some other form of biofeedback. Early indications from focus groups are that people will like this.

We have already shown in randomized controlled clinical studies of depression and anxiety that certain video games can improve mood and decrease stress.There is a big movement to get products in people’s hands to help them manage their health.

Question from audience: How much overlap is there between biofeedback methodologies—enhancing heart rate variability, vagal withdrawal, neurofeedback, and electroencephalographic feedback—in the systems you’re targeting and what are the unique contributions of each?

Dr. Gevirtz: We follow a stepped-care model. We start with the simplest and move on to the more complicated technologies. Two published studies with long-term followup showed the effectiveness of a learned breathing technique in alleviating noncardiac chest pain. Simple biofeedback wasn’t even needed. Three years later, the patients were better than they were at the end of the actual training. If you can do it simply, then you do it, and if it doesn’t work, then move on to more and more complicated techniques, with neurofeedback being the last resort.

Question from audience: Has anybody measured the physical impact of stimulating multiple systems on the study subject? In other words, can it be damaging to overstimulate these systems at the same time?

Dr. Gevirtz: We’ve been trying to do that. Recurrent abdominal pain or functional abdominal pain is the most common complaint to pediatric gastroenterologists. We have 1,800 patients a year who make it to the children’s hospital level with this complaint. These are kids who are suffering with very great pain and we we’re pretty sure it’s an autonomically mediated kind of phenomenon. We’re able to measure vagal activity in these kids in ambulatory settings at school and have found very little vagal activity before treatment. After training, they were able to restore vagal activity, and it correlated at the level of 0.63 with a reduction of symptoms. I think it’s important to try to tie the physiology to symptoms. It’s not always easy to do but we’re trying.

Question from audience: I’d like to pick up on two topics that Dr. Duffy raised: the business of medicine and the proposal for informed hope rather than an informed consent before surgery. Something that I see with patients and families at times is this magical expectation promoted by the business side that medicine can do these amazing and wonderful things and doesn’t have any sort of weaknesses. I wonder what role unrealistic expectations promoted by the media, advertising, and others may play in the stress of patients, caregivers, and physicians who need to try to meet the expectations of infallible medicine?

Dr. Duffy: We’ve spun so far the other way with our advanced technology that we’ve lost the human side, especially the concept of a relationship and giving people hope even though they have a terminal condition. It’s a balance between the art and the business of medicine. It’s about setting realistic expectations and realistic hope.

Page Number
S63-S64
Page Number
S63-S64
Publications
Publications
Article Type
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Panel discussion
Display Headline
Stress in medicine: Strategies for caregivers, patients, clinicians—Panel discussion
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Key 2010 publications in behavioral medicine

Article Type
Changed
Tue, 10/02/2018 - 09:33
Display Headline
Key 2010 publications in behavioral medicine

The effect of emotion on the heart is not confined to depression, but extends to a variety of mental states; as William Harvey described in 1628, “A mental disturbance provoking pain, excessive joy, hope or anxiety extends to the heart, where it affects its temper and rate, impairing general nutrition and vigor.”

In going beyond the well-established role of depression as a risk factor for heart disease, 2010 delivered several important publications recognizing anxiety, anger, and other forms of distress as key factors in the etiology of coronary heart disease (CHD). Other papers of merit elucidated new and overlooked insights into the pathways linking psychosocial stress and cardiovascular risk, and also considered psychologic states that appear to promote healthy functioning.

IMPACT OF NEGATIVE EMOTIONS ON RISK OF INCIDENT CORONARY HEART DISEASE

In a meta-analysis of 20 prospective studies that included 249,846 persons with a mean follow-up of 11.2 years, Roest et al1 examined the impact of anxiety characterized by the presence of anxiety symptoms or a diagnosis of anxiety disorder on incident CHD. Most of the studies adjusted for a broad array of relevant potential confounders. Findings suggest the presence of anxiety increases the risk of incident CHD by 26% (P P = .003).

In a meta-analysis of 25 prospective studies of 7,160 persons with a mean follow-up exceeding 10 years, Chida and Steptoe2 found that anger increased the risk of incident CHD by 19%, after adjustment for standard coronary risk factors. The effect was less stable than that associated with anxiety and depression, and when stratified by gender, the harmful effects of anger were more evident in men than in women. The effect of anger was attenuated when controlling for behavioral covariates. The association between anger and CHD did not hold for all ways of measuring anger, which suggests that the type of anger or the ability to regulate anger may be relevant to the relationship.

A study that did account for the type of anger expression on the risk of incident CHD was conducted by Davidson and Mostofsky.3 The independent effect of three distinct types of anger expression (constructive anger, destructive anger justification, and destructive anger rumination) on 10-year incident CHD was examined, controlling for other psychosocial factors. In men, higher scores for constructive anger were associated with a lower rate of CHD; in both men and women, higher scores for destructive anger justification were associated with an increased risk of CHD.

Insights gained from these studies are as follows:

  • The impact of anxiety appears to be comparable to depression, and the effects of anxiety and depression are largely independent.
  • If anxiety and depression co-occur, the effect on CHD is synergistic.
  • The effects of anger are less clear; its impact may be independent of or dependent on other forms of psychologic distress.
  • Distress in general appears to serve as a signal that something is wrong and needs to be addressed. If ignored, it may become chronic and unremitting; because symptoms of distress may lead to systemic dysregulation and increased CHD risk, they may indicate the need for increased surveillance and intervention.

WHY FOCUS ON THE BIOLOGY OF EMOTIONS?

A clear biologic explanation for the influence of emotional factors on physical health would serve to assuage skeptics who doubt that such a link exists or who attribute a common underlying genetic trait to both negative affect and heart disease. Further, focusing on the biology may help answer key questions with respect to emotions and disease processes: What is the damage incurred by negative emotional states and is it reversible? Can compensatory pathways be activated to bypass the mechanisms causing damage or slow the progression of disease?

Cardiac response to worry and stress

In one study attempting to shed light on relevant emotion-related biologic process, the prolonged physiologic effects of worry were examined. Worry episodes and stressful events were recorded hourly along with ambulatory heart rate and heart rate variability in 73 teachers for 4 days.4 Autonomic activity, as reflected by a concurrent elevation in heart rate and a decrease in heart rate variability, was increased up to 2 hours after a worry episode. The findings also suggested that the prolonged cardiac effects of separate worry episodes were independent.

Another study sought to determine whether heightened reactivity or delayed recovery to acute stress increases risk of cardiovascular disease.5 This meta-analysis included 36 studies to assess whether acute cardiovascular response to various laboratory stressors (ie, cognitive tasks, stress interviews, public speaking). Findings indicated that heightened cardiovascular reactivity was associated with worse cardiovascular outcomes, such as incident hypertension, coronary calcification, carotid intima-media thickness, and cardiovascular events over time.

Role of aldosterone overlooked

Reprinted from Neuroscience and Biobehavioral Reviews (Kubzansky LD, et al. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 2010; 34:80–86), © 2010, with permission from Elsevier.
Figure 1. A model of aldosterone as a mediator of the relationship between distress and heart disease. ACTH = adrenocorticotropic hormone; HPA = hypothalamic-pituitary-adrenal; MR = mineralocorticoid receptor; SNS = sympathetic-adrenomedullary system
Although identified by Selye as a stress-related hormone that may be relevant when considering health, few studies have considered aldosterone as a potential pathway linking emotional distress and heart disease. Aldosterone is an adrenocorticosteroid hormone that is released by activation of the hypothalamic-pituitaryadrenal (HPA) axis and the renin-angiotensin system in response to stress. Aldosterone, which activates the mineralocorticoid receptors, has widespread cardiovascular and metabolic effects beyond its effects on fluid and electrolyte balance. Clinical trials have shown that blocking activation of mineralocorticoid receptors in patients with heart failure reduces the incidence of cardiovascular mortality. Pharmacologic blockade of the renin-angiotensin system is also known to improve mood, leading to speculation that by activating the HPA axis and sympathetic nervous system, psychosocial distress may trigger the release of angiotensin II and aldosterone and activate mineralocorticoid receptors, thereby promoting pathophysiologic processes that can lead to heart disease (Figure 1).

 

 

WHY CONSIDER RESILIENCE?

Because the absence of a deficit is not the same as the presence of an asset, greater insight into dysfunction may be gained by explicitly considering what promotes healthy functioning. Ameliorating distress has proven difficult; so, in studying resilience (including the ability to regulate affect), new targets for prevention and intervention may be identified. Although no meta-analysis of resilience factors has been published to date owing to the paucity of data, the studies that have been performed are generally rigorous and have demonstrated consistent findings.

For example, one prospective, well-controlled study of 1,739 men and women demonstrated a protective effect of positive affect (as ascertained by structured interview) against 10-year incident CHD.6 The risk of fatal or nonfatal ischemic heart disease events was reduced by 22% (P = .02) for each 1-point increase in positive affect, even after controlling for depression and negative emotions.

Reprinted, with permission, from Archives of General Psychiatry (Kubzansky LD, et al. Arch Gen Psychiatry 2011; 68:400–408), Copyright © 2011 American Medical Association. All rights reserved.
Figure 2. Kaplan-Meier survival curve for self-regulation and incident total coronary heart disease. The participant numbers in the self-regulation groups included 355 with low, 426 with medium, and 361 with high self-regulation.7
Recent work may suggest that considering the ability to regulate affect and behavior may provide further insight into why or how positive and negative affect levels per se influence CHD risk. For example, in one recent prospective study, a single measure of self-regulation in healthy men at baseline predicted the development of disease over 12.7 years, with higher levels of self-regulation associated with rates of disease-free survival (Figure 2).7 This finding held after adjusting for standard coronary risk factors, as well as negative and positive affect. This study suggests that effective self-regulation may reduce the risk of CHD by maintaining emotional flexibility and preventing chronic negative states.

Biology of resilience: Counteracting cellular damage

Genomic changes can be induced by the relaxation response, as evidenced by the differential gene expression profiles of long-term daily practitioners of relaxation (ie, meditation, yoga), short-term (8-week) practitioners of relaxation, and healthy controls.8 Alterations in cellular metabolism, oxidative phosphorylation, and generation of reactive oxygen species that counteract proinflammatory responses, indicative of an adaptive response, were observed in both groups that practiced relaxation.

FUTURE DIRECTIONS

Whether and how the sources and effects of psychosocial stress and response to treatment differ across men and women deserves closer examination. A review by Low et al9 summarizes the current state of knowledge with respect to psychosocial factors and heart disease in women, noting that the sources of stress associated with increased CHD risk differ across men and women; psychosocial risk factors like depression and anxiety appear to increase risk for both men and women; work-related stress has larger effects in men while stress related to relationships and family responsibilities appear to have larger effects in women.

Although responses to psychosocial stress are not clearly different between men and women, intervention targeted at reducing distress is much less effective in reducing the risk of adverse events in women versus men. The mechanism to explain this difference in effectiveness of intervention urgently requires further exploration.

In conducting this work, several factors are important. The best time to intervene to reduce psychosocial distress is unknown; a key consideration will be, what is the best etiologic window for intervention? Perhaps a life-course approach that targets individuals with chronically high levels of emotional distress who also have multiple coronary risk factors, and that enhances their capacity to regulate emotions would prove superior to waiting until late in the disease process.

Another area that may prove fruitful is to consider in more depth the biology of the placebo effect and whether and how it may inform our understanding of resilience.

More generally, considering why interventions seem to influence outcomes so differently across men and women, applying a life course approach to determine the best etiologic window for prevention and intervention strategies, and conducting a more in-depth exploration of the biology of resilience may lead to improved capacity for population-based approaches to reducing the burden of CHD.

References
  1. Roest AM, Martens E, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010; 56:3846.
  2. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53:936946.
  3. Davidson KW, Mostofsky E. Anger expression and risk of coronary heart disease: evidence from the Nova Scotia Health Survey. Am Heart J 2010; 159:199206.
  4. Pieper S, Brosschot JF, van der Leeden R, Thayer J. Prolonged cardiac effects of momentary assessed stressful events and worry episodes. Psychosom Med 2010; 72:570577.
  5. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. Hypertension 2010; 55:10261032.
  6. Davidson KW, Mostofsky E, Whang W. Don’t worry, be happy: positive affect and reduced 10-year incident coronary heart disease: the Canadian Nova Scotia Health Survey. Eur Heart J 2010; 31:10651070.
  7. Kubzansky LD, Park N, Peterson C, Vokonas P, Sparrow D. Healthy psychological functioning and incident coronary heart disease. Arch Gen Psychiatry 2000; 68:400408.
  8. Dusek JA, Out HH, Wohlhueter AL, et al Genomic counterstress changes induced by the relaxation response. PLoS One 2008; 3:e2576.
  9. Low CA, Thurston RC, Matthews KA. Psychosocial factors in the development of heart disease in women: current research and future directions. Psychosom Med 2010; 72:842854.
Article PDF
Author and Disclosure Information

Laura D. Kubzansky, PhD, MPH
Department of Society, Human Development, and Health, Harvard School of Public Health, Boston, MA

Correspondence: Laura D. Kubzansky, PhD, MPH, Department of Society, Human Development, and Health, Harvard School of Public Health, 677 Huntington Avenue, Kresge Building, Room 714, Boston, MA 02115; lkubzans@hsph.harvard.edu

Dr. Kubzansky reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Kubzansky’s lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Kubzansky.

Publications
Page Number
S65-S68
Author and Disclosure Information

Laura D. Kubzansky, PhD, MPH
Department of Society, Human Development, and Health, Harvard School of Public Health, Boston, MA

Correspondence: Laura D. Kubzansky, PhD, MPH, Department of Society, Human Development, and Health, Harvard School of Public Health, 677 Huntington Avenue, Kresge Building, Room 714, Boston, MA 02115; lkubzans@hsph.harvard.edu

Dr. Kubzansky reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Kubzansky’s lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Kubzansky.

Author and Disclosure Information

Laura D. Kubzansky, PhD, MPH
Department of Society, Human Development, and Health, Harvard School of Public Health, Boston, MA

Correspondence: Laura D. Kubzansky, PhD, MPH, Department of Society, Human Development, and Health, Harvard School of Public Health, 677 Huntington Avenue, Kresge Building, Room 714, Boston, MA 02115; lkubzans@hsph.harvard.edu

Dr. Kubzansky reported that she has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Kubzansky’s lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Kubzansky.

Article PDF
Article PDF

The effect of emotion on the heart is not confined to depression, but extends to a variety of mental states; as William Harvey described in 1628, “A mental disturbance provoking pain, excessive joy, hope or anxiety extends to the heart, where it affects its temper and rate, impairing general nutrition and vigor.”

In going beyond the well-established role of depression as a risk factor for heart disease, 2010 delivered several important publications recognizing anxiety, anger, and other forms of distress as key factors in the etiology of coronary heart disease (CHD). Other papers of merit elucidated new and overlooked insights into the pathways linking psychosocial stress and cardiovascular risk, and also considered psychologic states that appear to promote healthy functioning.

IMPACT OF NEGATIVE EMOTIONS ON RISK OF INCIDENT CORONARY HEART DISEASE

In a meta-analysis of 20 prospective studies that included 249,846 persons with a mean follow-up of 11.2 years, Roest et al1 examined the impact of anxiety characterized by the presence of anxiety symptoms or a diagnosis of anxiety disorder on incident CHD. Most of the studies adjusted for a broad array of relevant potential confounders. Findings suggest the presence of anxiety increases the risk of incident CHD by 26% (P P = .003).

In a meta-analysis of 25 prospective studies of 7,160 persons with a mean follow-up exceeding 10 years, Chida and Steptoe2 found that anger increased the risk of incident CHD by 19%, after adjustment for standard coronary risk factors. The effect was less stable than that associated with anxiety and depression, and when stratified by gender, the harmful effects of anger were more evident in men than in women. The effect of anger was attenuated when controlling for behavioral covariates. The association between anger and CHD did not hold for all ways of measuring anger, which suggests that the type of anger or the ability to regulate anger may be relevant to the relationship.

A study that did account for the type of anger expression on the risk of incident CHD was conducted by Davidson and Mostofsky.3 The independent effect of three distinct types of anger expression (constructive anger, destructive anger justification, and destructive anger rumination) on 10-year incident CHD was examined, controlling for other psychosocial factors. In men, higher scores for constructive anger were associated with a lower rate of CHD; in both men and women, higher scores for destructive anger justification were associated with an increased risk of CHD.

Insights gained from these studies are as follows:

  • The impact of anxiety appears to be comparable to depression, and the effects of anxiety and depression are largely independent.
  • If anxiety and depression co-occur, the effect on CHD is synergistic.
  • The effects of anger are less clear; its impact may be independent of or dependent on other forms of psychologic distress.
  • Distress in general appears to serve as a signal that something is wrong and needs to be addressed. If ignored, it may become chronic and unremitting; because symptoms of distress may lead to systemic dysregulation and increased CHD risk, they may indicate the need for increased surveillance and intervention.

WHY FOCUS ON THE BIOLOGY OF EMOTIONS?

A clear biologic explanation for the influence of emotional factors on physical health would serve to assuage skeptics who doubt that such a link exists or who attribute a common underlying genetic trait to both negative affect and heart disease. Further, focusing on the biology may help answer key questions with respect to emotions and disease processes: What is the damage incurred by negative emotional states and is it reversible? Can compensatory pathways be activated to bypass the mechanisms causing damage or slow the progression of disease?

Cardiac response to worry and stress

In one study attempting to shed light on relevant emotion-related biologic process, the prolonged physiologic effects of worry were examined. Worry episodes and stressful events were recorded hourly along with ambulatory heart rate and heart rate variability in 73 teachers for 4 days.4 Autonomic activity, as reflected by a concurrent elevation in heart rate and a decrease in heart rate variability, was increased up to 2 hours after a worry episode. The findings also suggested that the prolonged cardiac effects of separate worry episodes were independent.

Another study sought to determine whether heightened reactivity or delayed recovery to acute stress increases risk of cardiovascular disease.5 This meta-analysis included 36 studies to assess whether acute cardiovascular response to various laboratory stressors (ie, cognitive tasks, stress interviews, public speaking). Findings indicated that heightened cardiovascular reactivity was associated with worse cardiovascular outcomes, such as incident hypertension, coronary calcification, carotid intima-media thickness, and cardiovascular events over time.

Role of aldosterone overlooked

Reprinted from Neuroscience and Biobehavioral Reviews (Kubzansky LD, et al. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 2010; 34:80–86), © 2010, with permission from Elsevier.
Figure 1. A model of aldosterone as a mediator of the relationship between distress and heart disease. ACTH = adrenocorticotropic hormone; HPA = hypothalamic-pituitary-adrenal; MR = mineralocorticoid receptor; SNS = sympathetic-adrenomedullary system
Although identified by Selye as a stress-related hormone that may be relevant when considering health, few studies have considered aldosterone as a potential pathway linking emotional distress and heart disease. Aldosterone is an adrenocorticosteroid hormone that is released by activation of the hypothalamic-pituitaryadrenal (HPA) axis and the renin-angiotensin system in response to stress. Aldosterone, which activates the mineralocorticoid receptors, has widespread cardiovascular and metabolic effects beyond its effects on fluid and electrolyte balance. Clinical trials have shown that blocking activation of mineralocorticoid receptors in patients with heart failure reduces the incidence of cardiovascular mortality. Pharmacologic blockade of the renin-angiotensin system is also known to improve mood, leading to speculation that by activating the HPA axis and sympathetic nervous system, psychosocial distress may trigger the release of angiotensin II and aldosterone and activate mineralocorticoid receptors, thereby promoting pathophysiologic processes that can lead to heart disease (Figure 1).

 

 

WHY CONSIDER RESILIENCE?

Because the absence of a deficit is not the same as the presence of an asset, greater insight into dysfunction may be gained by explicitly considering what promotes healthy functioning. Ameliorating distress has proven difficult; so, in studying resilience (including the ability to regulate affect), new targets for prevention and intervention may be identified. Although no meta-analysis of resilience factors has been published to date owing to the paucity of data, the studies that have been performed are generally rigorous and have demonstrated consistent findings.

For example, one prospective, well-controlled study of 1,739 men and women demonstrated a protective effect of positive affect (as ascertained by structured interview) against 10-year incident CHD.6 The risk of fatal or nonfatal ischemic heart disease events was reduced by 22% (P = .02) for each 1-point increase in positive affect, even after controlling for depression and negative emotions.

Reprinted, with permission, from Archives of General Psychiatry (Kubzansky LD, et al. Arch Gen Psychiatry 2011; 68:400–408), Copyright © 2011 American Medical Association. All rights reserved.
Figure 2. Kaplan-Meier survival curve for self-regulation and incident total coronary heart disease. The participant numbers in the self-regulation groups included 355 with low, 426 with medium, and 361 with high self-regulation.7
Recent work may suggest that considering the ability to regulate affect and behavior may provide further insight into why or how positive and negative affect levels per se influence CHD risk. For example, in one recent prospective study, a single measure of self-regulation in healthy men at baseline predicted the development of disease over 12.7 years, with higher levels of self-regulation associated with rates of disease-free survival (Figure 2).7 This finding held after adjusting for standard coronary risk factors, as well as negative and positive affect. This study suggests that effective self-regulation may reduce the risk of CHD by maintaining emotional flexibility and preventing chronic negative states.

Biology of resilience: Counteracting cellular damage

Genomic changes can be induced by the relaxation response, as evidenced by the differential gene expression profiles of long-term daily practitioners of relaxation (ie, meditation, yoga), short-term (8-week) practitioners of relaxation, and healthy controls.8 Alterations in cellular metabolism, oxidative phosphorylation, and generation of reactive oxygen species that counteract proinflammatory responses, indicative of an adaptive response, were observed in both groups that practiced relaxation.

FUTURE DIRECTIONS

Whether and how the sources and effects of psychosocial stress and response to treatment differ across men and women deserves closer examination. A review by Low et al9 summarizes the current state of knowledge with respect to psychosocial factors and heart disease in women, noting that the sources of stress associated with increased CHD risk differ across men and women; psychosocial risk factors like depression and anxiety appear to increase risk for both men and women; work-related stress has larger effects in men while stress related to relationships and family responsibilities appear to have larger effects in women.

Although responses to psychosocial stress are not clearly different between men and women, intervention targeted at reducing distress is much less effective in reducing the risk of adverse events in women versus men. The mechanism to explain this difference in effectiveness of intervention urgently requires further exploration.

In conducting this work, several factors are important. The best time to intervene to reduce psychosocial distress is unknown; a key consideration will be, what is the best etiologic window for intervention? Perhaps a life-course approach that targets individuals with chronically high levels of emotional distress who also have multiple coronary risk factors, and that enhances their capacity to regulate emotions would prove superior to waiting until late in the disease process.

Another area that may prove fruitful is to consider in more depth the biology of the placebo effect and whether and how it may inform our understanding of resilience.

More generally, considering why interventions seem to influence outcomes so differently across men and women, applying a life course approach to determine the best etiologic window for prevention and intervention strategies, and conducting a more in-depth exploration of the biology of resilience may lead to improved capacity for population-based approaches to reducing the burden of CHD.

The effect of emotion on the heart is not confined to depression, but extends to a variety of mental states; as William Harvey described in 1628, “A mental disturbance provoking pain, excessive joy, hope or anxiety extends to the heart, where it affects its temper and rate, impairing general nutrition and vigor.”

In going beyond the well-established role of depression as a risk factor for heart disease, 2010 delivered several important publications recognizing anxiety, anger, and other forms of distress as key factors in the etiology of coronary heart disease (CHD). Other papers of merit elucidated new and overlooked insights into the pathways linking psychosocial stress and cardiovascular risk, and also considered psychologic states that appear to promote healthy functioning.

IMPACT OF NEGATIVE EMOTIONS ON RISK OF INCIDENT CORONARY HEART DISEASE

In a meta-analysis of 20 prospective studies that included 249,846 persons with a mean follow-up of 11.2 years, Roest et al1 examined the impact of anxiety characterized by the presence of anxiety symptoms or a diagnosis of anxiety disorder on incident CHD. Most of the studies adjusted for a broad array of relevant potential confounders. Findings suggest the presence of anxiety increases the risk of incident CHD by 26% (P P = .003).

In a meta-analysis of 25 prospective studies of 7,160 persons with a mean follow-up exceeding 10 years, Chida and Steptoe2 found that anger increased the risk of incident CHD by 19%, after adjustment for standard coronary risk factors. The effect was less stable than that associated with anxiety and depression, and when stratified by gender, the harmful effects of anger were more evident in men than in women. The effect of anger was attenuated when controlling for behavioral covariates. The association between anger and CHD did not hold for all ways of measuring anger, which suggests that the type of anger or the ability to regulate anger may be relevant to the relationship.

A study that did account for the type of anger expression on the risk of incident CHD was conducted by Davidson and Mostofsky.3 The independent effect of three distinct types of anger expression (constructive anger, destructive anger justification, and destructive anger rumination) on 10-year incident CHD was examined, controlling for other psychosocial factors. In men, higher scores for constructive anger were associated with a lower rate of CHD; in both men and women, higher scores for destructive anger justification were associated with an increased risk of CHD.

Insights gained from these studies are as follows:

  • The impact of anxiety appears to be comparable to depression, and the effects of anxiety and depression are largely independent.
  • If anxiety and depression co-occur, the effect on CHD is synergistic.
  • The effects of anger are less clear; its impact may be independent of or dependent on other forms of psychologic distress.
  • Distress in general appears to serve as a signal that something is wrong and needs to be addressed. If ignored, it may become chronic and unremitting; because symptoms of distress may lead to systemic dysregulation and increased CHD risk, they may indicate the need for increased surveillance and intervention.

WHY FOCUS ON THE BIOLOGY OF EMOTIONS?

A clear biologic explanation for the influence of emotional factors on physical health would serve to assuage skeptics who doubt that such a link exists or who attribute a common underlying genetic trait to both negative affect and heart disease. Further, focusing on the biology may help answer key questions with respect to emotions and disease processes: What is the damage incurred by negative emotional states and is it reversible? Can compensatory pathways be activated to bypass the mechanisms causing damage or slow the progression of disease?

Cardiac response to worry and stress

In one study attempting to shed light on relevant emotion-related biologic process, the prolonged physiologic effects of worry were examined. Worry episodes and stressful events were recorded hourly along with ambulatory heart rate and heart rate variability in 73 teachers for 4 days.4 Autonomic activity, as reflected by a concurrent elevation in heart rate and a decrease in heart rate variability, was increased up to 2 hours after a worry episode. The findings also suggested that the prolonged cardiac effects of separate worry episodes were independent.

Another study sought to determine whether heightened reactivity or delayed recovery to acute stress increases risk of cardiovascular disease.5 This meta-analysis included 36 studies to assess whether acute cardiovascular response to various laboratory stressors (ie, cognitive tasks, stress interviews, public speaking). Findings indicated that heightened cardiovascular reactivity was associated with worse cardiovascular outcomes, such as incident hypertension, coronary calcification, carotid intima-media thickness, and cardiovascular events over time.

Role of aldosterone overlooked

Reprinted from Neuroscience and Biobehavioral Reviews (Kubzansky LD, et al. Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 2010; 34:80–86), © 2010, with permission from Elsevier.
Figure 1. A model of aldosterone as a mediator of the relationship between distress and heart disease. ACTH = adrenocorticotropic hormone; HPA = hypothalamic-pituitary-adrenal; MR = mineralocorticoid receptor; SNS = sympathetic-adrenomedullary system
Although identified by Selye as a stress-related hormone that may be relevant when considering health, few studies have considered aldosterone as a potential pathway linking emotional distress and heart disease. Aldosterone is an adrenocorticosteroid hormone that is released by activation of the hypothalamic-pituitaryadrenal (HPA) axis and the renin-angiotensin system in response to stress. Aldosterone, which activates the mineralocorticoid receptors, has widespread cardiovascular and metabolic effects beyond its effects on fluid and electrolyte balance. Clinical trials have shown that blocking activation of mineralocorticoid receptors in patients with heart failure reduces the incidence of cardiovascular mortality. Pharmacologic blockade of the renin-angiotensin system is also known to improve mood, leading to speculation that by activating the HPA axis and sympathetic nervous system, psychosocial distress may trigger the release of angiotensin II and aldosterone and activate mineralocorticoid receptors, thereby promoting pathophysiologic processes that can lead to heart disease (Figure 1).

 

 

WHY CONSIDER RESILIENCE?

Because the absence of a deficit is not the same as the presence of an asset, greater insight into dysfunction may be gained by explicitly considering what promotes healthy functioning. Ameliorating distress has proven difficult; so, in studying resilience (including the ability to regulate affect), new targets for prevention and intervention may be identified. Although no meta-analysis of resilience factors has been published to date owing to the paucity of data, the studies that have been performed are generally rigorous and have demonstrated consistent findings.

For example, one prospective, well-controlled study of 1,739 men and women demonstrated a protective effect of positive affect (as ascertained by structured interview) against 10-year incident CHD.6 The risk of fatal or nonfatal ischemic heart disease events was reduced by 22% (P = .02) for each 1-point increase in positive affect, even after controlling for depression and negative emotions.

Reprinted, with permission, from Archives of General Psychiatry (Kubzansky LD, et al. Arch Gen Psychiatry 2011; 68:400–408), Copyright © 2011 American Medical Association. All rights reserved.
Figure 2. Kaplan-Meier survival curve for self-regulation and incident total coronary heart disease. The participant numbers in the self-regulation groups included 355 with low, 426 with medium, and 361 with high self-regulation.7
Recent work may suggest that considering the ability to regulate affect and behavior may provide further insight into why or how positive and negative affect levels per se influence CHD risk. For example, in one recent prospective study, a single measure of self-regulation in healthy men at baseline predicted the development of disease over 12.7 years, with higher levels of self-regulation associated with rates of disease-free survival (Figure 2).7 This finding held after adjusting for standard coronary risk factors, as well as negative and positive affect. This study suggests that effective self-regulation may reduce the risk of CHD by maintaining emotional flexibility and preventing chronic negative states.

Biology of resilience: Counteracting cellular damage

Genomic changes can be induced by the relaxation response, as evidenced by the differential gene expression profiles of long-term daily practitioners of relaxation (ie, meditation, yoga), short-term (8-week) practitioners of relaxation, and healthy controls.8 Alterations in cellular metabolism, oxidative phosphorylation, and generation of reactive oxygen species that counteract proinflammatory responses, indicative of an adaptive response, were observed in both groups that practiced relaxation.

FUTURE DIRECTIONS

Whether and how the sources and effects of psychosocial stress and response to treatment differ across men and women deserves closer examination. A review by Low et al9 summarizes the current state of knowledge with respect to psychosocial factors and heart disease in women, noting that the sources of stress associated with increased CHD risk differ across men and women; psychosocial risk factors like depression and anxiety appear to increase risk for both men and women; work-related stress has larger effects in men while stress related to relationships and family responsibilities appear to have larger effects in women.

Although responses to psychosocial stress are not clearly different between men and women, intervention targeted at reducing distress is much less effective in reducing the risk of adverse events in women versus men. The mechanism to explain this difference in effectiveness of intervention urgently requires further exploration.

In conducting this work, several factors are important. The best time to intervene to reduce psychosocial distress is unknown; a key consideration will be, what is the best etiologic window for intervention? Perhaps a life-course approach that targets individuals with chronically high levels of emotional distress who also have multiple coronary risk factors, and that enhances their capacity to regulate emotions would prove superior to waiting until late in the disease process.

Another area that may prove fruitful is to consider in more depth the biology of the placebo effect and whether and how it may inform our understanding of resilience.

More generally, considering why interventions seem to influence outcomes so differently across men and women, applying a life course approach to determine the best etiologic window for prevention and intervention strategies, and conducting a more in-depth exploration of the biology of resilience may lead to improved capacity for population-based approaches to reducing the burden of CHD.

References
  1. Roest AM, Martens E, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010; 56:3846.
  2. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53:936946.
  3. Davidson KW, Mostofsky E. Anger expression and risk of coronary heart disease: evidence from the Nova Scotia Health Survey. Am Heart J 2010; 159:199206.
  4. Pieper S, Brosschot JF, van der Leeden R, Thayer J. Prolonged cardiac effects of momentary assessed stressful events and worry episodes. Psychosom Med 2010; 72:570577.
  5. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. Hypertension 2010; 55:10261032.
  6. Davidson KW, Mostofsky E, Whang W. Don’t worry, be happy: positive affect and reduced 10-year incident coronary heart disease: the Canadian Nova Scotia Health Survey. Eur Heart J 2010; 31:10651070.
  7. Kubzansky LD, Park N, Peterson C, Vokonas P, Sparrow D. Healthy psychological functioning and incident coronary heart disease. Arch Gen Psychiatry 2000; 68:400408.
  8. Dusek JA, Out HH, Wohlhueter AL, et al Genomic counterstress changes induced by the relaxation response. PLoS One 2008; 3:e2576.
  9. Low CA, Thurston RC, Matthews KA. Psychosocial factors in the development of heart disease in women: current research and future directions. Psychosom Med 2010; 72:842854.
References
  1. Roest AM, Martens E, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010; 56:3846.
  2. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009; 53:936946.
  3. Davidson KW, Mostofsky E. Anger expression and risk of coronary heart disease: evidence from the Nova Scotia Health Survey. Am Heart J 2010; 159:199206.
  4. Pieper S, Brosschot JF, van der Leeden R, Thayer J. Prolonged cardiac effects of momentary assessed stressful events and worry episodes. Psychosom Med 2010; 72:570577.
  5. Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. Hypertension 2010; 55:10261032.
  6. Davidson KW, Mostofsky E, Whang W. Don’t worry, be happy: positive affect and reduced 10-year incident coronary heart disease: the Canadian Nova Scotia Health Survey. Eur Heart J 2010; 31:10651070.
  7. Kubzansky LD, Park N, Peterson C, Vokonas P, Sparrow D. Healthy psychological functioning and incident coronary heart disease. Arch Gen Psychiatry 2000; 68:400408.
  8. Dusek JA, Out HH, Wohlhueter AL, et al Genomic counterstress changes induced by the relaxation response. PLoS One 2008; 3:e2576.
  9. Low CA, Thurston RC, Matthews KA. Psychosocial factors in the development of heart disease in women: current research and future directions. Psychosom Med 2010; 72:842854.
Page Number
S65-S68
Page Number
S65-S68
Publications
Publications
Article Type
Display Headline
Key 2010 publications in behavioral medicine
Display Headline
Key 2010 publications in behavioral medicine
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S65-S68
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Imaging for autonomic dysfunction

Article Type
Changed
Tue, 10/02/2018 - 09:33
Display Headline
Imaging for autonomic dysfunction

The autonomic nervous system (ANS), composed of the sympathetic and parasympathetic nervous systems, governs our adaptation to changing environments such as physical threats or changes in temperature. It has been difficult to elucidate this process in humans, however, because of limitations in neuroimaging caused by artifacts from cardiorespiratory sources. This article reviews structural and functional imaging that can provide insights into the ANS.

STRUCTURAL IMAGING

Figure 1. With a coronal view, regions of cortical control of the autonomic nervous system are visible on magnetic resonance imaging.
For purposes of imaging, it is helpful to visualize the neural anatomy at a primitive level. If we imagine the neural tube bisected and flayed open, and the folds smoothed out, we would see a simplified topology of the brain, revealing the forebrain (cerebral cortex, thalamus, and hypothalamus), midbrain, hindbrain (pons, medulla, cerebellum), and spinal cord. As the brain develops and appears more complicated, these simple underlying relationships are preserved. Of particular note are the relationships of the cingulate, insula, and amygdala, all of which share proximity to the basal ganglia and the gateways into and out of the brain. These regions control and influence the ANS, many of which are visible on a single coronal view, including the cingulate cortex, prefrontal cortex, insular cortex, amygdala, and hypothalamus (Figure 1). However, the smaller individual hypothalamic and brainstem nuclei are typically not visible on conventional magnetic resonance imaging (MRI).

Similar to cortical and subcortical pathology (or stimulation) in areas of the brain that manifest as non-autonomic symptoms such as weakness, parasthesias, or seizures, pathology or stimulation in ANS areas of the brain manifest as autonomic symptoms. For example (Table), electrical stimulation of the right insular cortex of animals and humans causes ANS manifestations in the form of changes in heart rate and blood pressure, whereas left-sided stimulation of the insular cortex causes a decrease in heart rate and depressor responses. Stimulation of the basolateral amygdalian nucleus increases blood pressure and decreases heart rate; stimulation of the rostral amygdalian nucleus results in depressor effects and variable changes in heart rate. Stimulation of the cingulated gyrus and some other regions within the prefrontal cortex causes decreases in heart rate and blood pressure.

The two main subcortical areas of interest for imaging are the lateral hypothalamic area and the paraventricular nucleus, but visualization is difficult. The hypothalamus occupies a volumetric area of the brain no larger than 20 voxels; individual substructures of the hypothalamus therefore cannot easily be viewed by conventional imaging. The larger voxel size of functional MRI (fMRI) mean that fMRI of the hypothalamus can display 1 voxel at most.

Most brainstem nuclei are motor nuclei that affect autonomic responses, either sympathetic or parasympathetic. These nuclei are difficult to visualize on conventional MRI for two reasons: the nuclei are small, and may be the size of only 1 to 2 voxels. More important, MRI contrast between these nuclei and surrounding parenchyma is minimal because these structures “blend in” with the surrounding brain and are difficult to visualize singly. Examples of these major brainstem sympathetic nuclei are the periaqueductal gray substance, parabrachial nuclei, solitary nucleus, and the hypothalamospinal tract; examples of the major brainstem parasympathetic nuclei are the dorsal nucleus of the vagus nerve and the nucleus ambiguus.

The areas of the ANS under cortical control are more integrative, with influence from higher cognitive function—for example, the panic or fear associated with public speaking. Regions of subcortical control involve the basal ganglia and hypothalamus, which regulate primitive, subconscious activity, such as “fight or flight” response, pain reaction, and fear of snakes, all of which affect multiple motor nuclei. Several specific sympathetic and parasympathetic motor nuclei directly affect heart rate and blood pressure and act as relay stations for sensory impulses that reach the cerebral cortex.

NEUROLOGIC PROCESSES AND CARDIAC EFFECTS

Figure 2. Magnetic resonance imaging in a patient with Shy-Drager (left) is normal; a “hot cross buns” sign may be evident in patients with multiple-system atrophy (right).
Significant cardiac effects stemming from brain injury are well known, including alteration of cardiac rhythms, cardiac variability, and blood pressure regulation. Neurologic diseases such as parkinsonism, multiple sclerosis (MS), stroke, epilepsy, and tumors can have cardiac effects, although structural abnormalities on conventional MRI may be lacking. One notable exception is multiple systems atrophy, which can have strong autonomic symptoms and has a characteristic MRI finding called “hot cross buns” (Figure 2). An example is a subtype formally known as Shy-Drager syndrome.

MS is classically a disease of white matter, although it can also affect gray matter. Autonomic dysfunction is common, affecting as many as 50% of MS patients with symptoms that include orthostatic dizziness, bladder disturbances, temperature instability, gastrointestinal disturbances, and sweating.1–4 The effect of autonomic dysfunction on disease activity is unclear. Multiple brainstem lesions are evident on MRI, and may be linked to cardiac autonomic dysfunction. The variability of MS contributes to the difficulty of using imaging to identify culprit lesions.

Stroke causes autonomic dysfunction, with the specific manifestations dependent on the region of the brain involved. In cases of right middle cerebral artery infarct affecting the right insula, an increased incidence of cardiac arrhythmias, cardiac death, and catecholamine production ensues.5–7 Medullary infarcts have been shown to produce significant autonomic dysfunction.8,9

Ictal and interictal cardiac manifestations in epilepsy often precede seizure onset.1 Common cardiac changes are ictal tachycardia or ictal bradycardia, or both, with no clear relationship to the location or type of seizure. Evidence suggests that heart rate variability changes in epilepsy result from interictal autonomic alterations, including sympathetic or parasympathetic dominance. Investigation of baroreflex responses with temporal lobe epilepsy has uncovered decreased baroreflex sensitivity. There is no reliable correlation between sympathetic or parasympathetic upregulation or downregulation and brain MRI findings, however.

Autonomic dysfunction in the form of orthostatic hypotension has been documented in patients with mass effect from tumors, for example posterior fossa epidermoid tumors, wherein tumor resection results in improved autonomic function.10

 

 

FUNCTIONAL BRAIN IMAGING IN GENERAL

Direct visualization of heart-brain interactions is the goal when assessing ANS function. Positron emission tomography (PET) produces quantitative images, but spatial and temporal resolutions are vastly superior with fMRI.11 Further, radiation exposure is low with fMRI, allowing for safe repeat imaging.

Ogawa et al12 first demonstrated that in vivo images of brain microvasculature are affected by blood oxygen level, and that blood oxygenation reduced vascular signal loss. Therefore, blood oxygenation level–dependent (BOLD) contrast added to MRI could complement PET-like measurements in the study of regional brain activity.

Figure 3. Examples of magnetic resonance imaging susceptibility to motion artifacts before and after filtering in an electrocardiogram and a photoplethysmogram.
The relationship between neural activity and cerebral blood flow is indirect. Functional MRI has been used to locate the brain regions that are involved in simple tasks; for example, bilateral finger tapping results in increased cerebral blood flow that is detected by fMRI after a delay of several seconds. The increase in cerebral blood flow causes decreased intravascular deoxyhemoglobin which causes decreased extravascular susceptibility signal loss, which all together result in a net enhancement of the MRI signal. The signal-to-noise ratio is very low, with a signal change on the order of 1% to 3%.

Bilateral finger tapping with intermittent periods of rest is associated with a pattern of increasing and decreasing intensity of fMRI signals in involved brain regions that reflect the periods of activity and rest. This technique has been used to locate brain voxels with similar patterns of activity, enabling the creation of familiar color brain mapping. A challenge posed by autonomic fMRI in such brain mapping is that fMRI is susceptible to artifacts (Figure 3). For example, a movement of the head as little as 1 mm inside the MRI scanner—a distance comparable to the size of autonomic structures—can produce a motion artifact (false activation of brain regions) that can affect statistical significance. In addition, many ANS regions of the brain are near osseous structures (for example the brainstem and skull base) that cause signal distortion and loss.

REQUIREMENTS FOR AUTONOMIC fMRI

The tasks chosen to visualize brain control of autonomic function must naturally elicit an autonomic response. The difficulty is that untrained persons have little or no volitional control over autonomic functions, so the task and its analysis must be designed carefully and be MRI-compatible. Any motion will degrade the image; further, the capacity for the MRI environment to corrupt the measurements can limit the potential tasks for measurement.

Possible stimuli for eliciting a sympathetic response include pain, fear, anticipation, anxiety, concentration or memory, cold pressor, Stroop test, breathing tests, and maximal hand grip. Examples of parasympathetic stimuli are the Valsalva maneuver and paced breathing. The responses to stimuli (ie, heart rate, heart rate variability, blood pressure, galvanic skin response, papillary response) must be monitored to compare the data obtained from fMRI. MRI-compatible equipment is now available for measuring many of these responses.

Identifying areas activated during tasks

Functional neuroimaging with PET and fMRI has shown consistently that the anterior cingulate is activated during multiple tasks designed to elicit an autonomic response (gambling anticipation, emotional response to faces, Stroop test).11

In a study designed to test autonomic interoceptive awareness, subjects underwent fMRI while they were asked to judge the timing of their heartbeats to auditory tones that were either synchronized with their heartbeat or delayed by 500 msec.13 Areas of enhanced activity during the task were the right insular cortex, anterior cingulate, parietal lobes, and operculum.

Characterizing brainstem sites

It is difficult to achieve visualization of areas within the brainstem that govern autonomic responses. These regions are small and motion artifacts are common because of brainstem movement with the cardiac pulse. With fMRI, Topolovec et al14 were able to characterize brainstem sites involved in autonomic control, demonstrating activation of the nucleus of the solitary tract and parabrachial nucleus.

Reprinted from NeuroImage (Napadow V, et al. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuro-Image 2008; 42:169–177), Copyright © 2008, with permission from Elsevier.
Figure 4. Despite the difficulty of visualizing brainstem areas that govern autonomic response, functional magnetic resonance imaging and electrocardiographic data demonstrated brainstem regions that correlated with autonomic involvement during a handgrip task.16
Using fMRI and electrocardiographic data obtained simultaneously, Napadow et al15 attempted to assess brain correlates of autonomic function in subjects performing an MRI-compatible handgrip task. Brainstem regions that co-localized with expected areas of autonomic involvement were the parabrachial nucleus, amygdala, hypothalamus, periaquaductal gray area, posterior insula, and prefrontal cortex (Figure 4).

A review of four fMRI studies of stressor-evoked blood pressure reactivity demonstrated activation in corticolimbic areas, including the cingulate cortex, insula, amygdala, and cortical and subcortical areas that are involved in hemodynamic and metabolic support for stress-related behavioral responses.16

 

 

FUNCTIONAL BRAIN IMAGING IN DISEASE STATES

There are few studies of functional brain imaging in patients with disease because of the challenges involved. The studies are difficult to perform on sick patients because of the unfriendly MRI environment, with struct requirements for attention and participation. Furthermore, autonomic responses may be blunted, making physiologic comparisons difficult. In addition, there is evidence that BOLD may be intrinsically impaired in disease states. Unlike fMRI studies to locate brain regions involved in simple tasks such as finger tapping, which can be performed in a single subject, detecting changes in autonomic responses in disease states requires averaging over studies of multiple patients.

Woo et al17 used fMRI to compare brain regions of activation in six patients with heart failure and 16 controls upon a forehead cold pressor challenge. Increases in heart rate were measured in the patients with heart failure with application of the cold stimulus. Larger neural fMRI signal responses in patients with heart failure were observed in 14 brain regions, whereas reduced fMRI activity was observed in 15 other brain regions in the heart failure patients. Based on the results, the investigators suggested that heart failure may be associated with altered sympathetic and parasympathetic activity, and that these dysfunctions might contribute to the progression of heart failure.

Gianaros et al18 found fMRI evidence for a correlation between carotid artery intima-media thickness, a surrogate measure for carotid artery or coronary artery disease, and altered ANS reaction to fear using a fearful faces paradigm.

CONCLUSION

Functional MRI of heart-brain interactions has strong potential for normal subjects, in whom the BOLD effect is small, within the limits of motion and susceptibility artifacts. Typically, such applications require averaging results over multiple subjects. Its potential utility in disease states is less significant because of the additional limitations of MRI with sick patients (the MRI environment, blunting of autonomic response in disease, possible impairment of BOLD), but continued investigation is warranted.

References
  1. Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia 2010; 51:725737.
  2. Kodounis A, Stamboulis E, Constantinidis TS, Liolios A. Measurement of autonomic dysregulation in multiple sclerosis. Acta Neurol Scand 2005; 112:403408.
  3. Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999; 246:578586.
  4. Kulcu DG, Akbas B, Citci B, Cihangiroglu M. Autonomic dysreflexia in a man with multiple sclerosis. J Spinal Cord Med 2009; 32:198203.
  5. Abboud H, Berroir S, Labreuche J, Orjuele K, Amarenco O. Insular involvement in brain infarction increases risk for cardiac arrhythmia and death. Ann Neurol 2006; 59:691699.
  6. Tokgozoglu SL, Batur MK, Topcuoglu MA, Saribas O, Kes S, Oto A. Effects of stroke localization on cardiac autonomic balance and sudden death. Stroke 1999; 30:13011311.
  7. Strittmatter M, Meyer S, Fischer C, Georg T, Schmitz B. Location-dependent patterns in cardio-autonomic dysfunction in ischaemic stroke. Eur Neurol 2003; 50:3038.
  8. Lassman AB, Mayer SA. Paroxysmal apnea and vasomotor instability following medullary infarction. Arch Neurol 2005; 62:12861288.
  9. Deluca C, Tinazzi M, Bovi P, Rizzuto N, Moretto G. Limb ataxia and proximal intracranial territory brain infarcts: clinical and topographical correlations. J Neurol Neurosurg Psychiatry 2007; 78:832835.
  10. Gómez-Esteban JC, Berganzo K, Tijero B, Barcena J, Zarranz JJ. Orthostatic hypotension associated with an epidermoid tumor of the IV ventricle. J Neurol 2009; 256:13571359.
  11. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005; 493:154166.
  12. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87:98689872.
  13. Critchley HD. The human cortex responds to an interoceptive challenge. Proc Natl Acad Sci USA 2004; 101:63336334.
  14. Topolovec JC, Gati JS, Menon RS, Shoemaker JK, Cechetto DF. Human cardiovascular and gustatory brainstem sites observed by functional magnetic resonance imaging. J Comp Neurol 2004; 471:446461.
  15. Napadow V, Dhond R, Conti G, Makris N, Brown EN, Barbieri R. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuroimage 2008; 42:169177.
  16. Gianaros PJ, Sheu LK. A review of neuroimaging studies of stressor-evoked blood pressure reactivity: emerging evidence for a brain-body pathway to coronary heart disease risk. Neuroimage 2009; 47:922936.
  17. Woo MA, Macey PM, Keens PT, et al Functional abnormalities in brain areas that mediate autonomic nervous system control in advanced heart failure. J Card Fail 2005; 11:437446.
  18. Gianaros PJ, Hariri AR, Sheu LK, et al Preclinical atherosclerosis covaries with individual differences in reactivity and functional connectivity of the amygdala. Biol Psych 2009; 65:943950.
Article PDF
Author and Disclosure Information

Stephen E. Jones, MD, PhD
Department of Neuroradiology, Cleveland Clinic, Cleveland, OH

Correspondence: Stephen E. Jones, MD, PhD, Department of Neuroradiology, Cleveland Clinic, 9500 Euclid Avenue, U15, Cleveland, OH 44195; joness19@ccf.org

Dr. Jones reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Jones’ lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Jones.

Publications
Page Number
S69-S74
Author and Disclosure Information

Stephen E. Jones, MD, PhD
Department of Neuroradiology, Cleveland Clinic, Cleveland, OH

Correspondence: Stephen E. Jones, MD, PhD, Department of Neuroradiology, Cleveland Clinic, 9500 Euclid Avenue, U15, Cleveland, OH 44195; joness19@ccf.org

Dr. Jones reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Jones’ lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Jones.

Author and Disclosure Information

Stephen E. Jones, MD, PhD
Department of Neuroradiology, Cleveland Clinic, Cleveland, OH

Correspondence: Stephen E. Jones, MD, PhD, Department of Neuroradiology, Cleveland Clinic, 9500 Euclid Avenue, U15, Cleveland, OH 44195; joness19@ccf.org

Dr. Jones reported that he has no financial relationships that pose a potential conflict of interest with this article.

This article was developed from an audio transcript of Dr. Jones’ lecture at the 2010 Heart-Brain Summit. The transcript was formatted and edited by the Cleveland Clinic Journal of Medicine staff for clarity and conciseness, and was then reviewed, revised, and approved by Dr. Jones.

Article PDF
Article PDF

The autonomic nervous system (ANS), composed of the sympathetic and parasympathetic nervous systems, governs our adaptation to changing environments such as physical threats or changes in temperature. It has been difficult to elucidate this process in humans, however, because of limitations in neuroimaging caused by artifacts from cardiorespiratory sources. This article reviews structural and functional imaging that can provide insights into the ANS.

STRUCTURAL IMAGING

Figure 1. With a coronal view, regions of cortical control of the autonomic nervous system are visible on magnetic resonance imaging.
For purposes of imaging, it is helpful to visualize the neural anatomy at a primitive level. If we imagine the neural tube bisected and flayed open, and the folds smoothed out, we would see a simplified topology of the brain, revealing the forebrain (cerebral cortex, thalamus, and hypothalamus), midbrain, hindbrain (pons, medulla, cerebellum), and spinal cord. As the brain develops and appears more complicated, these simple underlying relationships are preserved. Of particular note are the relationships of the cingulate, insula, and amygdala, all of which share proximity to the basal ganglia and the gateways into and out of the brain. These regions control and influence the ANS, many of which are visible on a single coronal view, including the cingulate cortex, prefrontal cortex, insular cortex, amygdala, and hypothalamus (Figure 1). However, the smaller individual hypothalamic and brainstem nuclei are typically not visible on conventional magnetic resonance imaging (MRI).

Similar to cortical and subcortical pathology (or stimulation) in areas of the brain that manifest as non-autonomic symptoms such as weakness, parasthesias, or seizures, pathology or stimulation in ANS areas of the brain manifest as autonomic symptoms. For example (Table), electrical stimulation of the right insular cortex of animals and humans causes ANS manifestations in the form of changes in heart rate and blood pressure, whereas left-sided stimulation of the insular cortex causes a decrease in heart rate and depressor responses. Stimulation of the basolateral amygdalian nucleus increases blood pressure and decreases heart rate; stimulation of the rostral amygdalian nucleus results in depressor effects and variable changes in heart rate. Stimulation of the cingulated gyrus and some other regions within the prefrontal cortex causes decreases in heart rate and blood pressure.

The two main subcortical areas of interest for imaging are the lateral hypothalamic area and the paraventricular nucleus, but visualization is difficult. The hypothalamus occupies a volumetric area of the brain no larger than 20 voxels; individual substructures of the hypothalamus therefore cannot easily be viewed by conventional imaging. The larger voxel size of functional MRI (fMRI) mean that fMRI of the hypothalamus can display 1 voxel at most.

Most brainstem nuclei are motor nuclei that affect autonomic responses, either sympathetic or parasympathetic. These nuclei are difficult to visualize on conventional MRI for two reasons: the nuclei are small, and may be the size of only 1 to 2 voxels. More important, MRI contrast between these nuclei and surrounding parenchyma is minimal because these structures “blend in” with the surrounding brain and are difficult to visualize singly. Examples of these major brainstem sympathetic nuclei are the periaqueductal gray substance, parabrachial nuclei, solitary nucleus, and the hypothalamospinal tract; examples of the major brainstem parasympathetic nuclei are the dorsal nucleus of the vagus nerve and the nucleus ambiguus.

The areas of the ANS under cortical control are more integrative, with influence from higher cognitive function—for example, the panic or fear associated with public speaking. Regions of subcortical control involve the basal ganglia and hypothalamus, which regulate primitive, subconscious activity, such as “fight or flight” response, pain reaction, and fear of snakes, all of which affect multiple motor nuclei. Several specific sympathetic and parasympathetic motor nuclei directly affect heart rate and blood pressure and act as relay stations for sensory impulses that reach the cerebral cortex.

NEUROLOGIC PROCESSES AND CARDIAC EFFECTS

Figure 2. Magnetic resonance imaging in a patient with Shy-Drager (left) is normal; a “hot cross buns” sign may be evident in patients with multiple-system atrophy (right).
Significant cardiac effects stemming from brain injury are well known, including alteration of cardiac rhythms, cardiac variability, and blood pressure regulation. Neurologic diseases such as parkinsonism, multiple sclerosis (MS), stroke, epilepsy, and tumors can have cardiac effects, although structural abnormalities on conventional MRI may be lacking. One notable exception is multiple systems atrophy, which can have strong autonomic symptoms and has a characteristic MRI finding called “hot cross buns” (Figure 2). An example is a subtype formally known as Shy-Drager syndrome.

MS is classically a disease of white matter, although it can also affect gray matter. Autonomic dysfunction is common, affecting as many as 50% of MS patients with symptoms that include orthostatic dizziness, bladder disturbances, temperature instability, gastrointestinal disturbances, and sweating.1–4 The effect of autonomic dysfunction on disease activity is unclear. Multiple brainstem lesions are evident on MRI, and may be linked to cardiac autonomic dysfunction. The variability of MS contributes to the difficulty of using imaging to identify culprit lesions.

Stroke causes autonomic dysfunction, with the specific manifestations dependent on the region of the brain involved. In cases of right middle cerebral artery infarct affecting the right insula, an increased incidence of cardiac arrhythmias, cardiac death, and catecholamine production ensues.5–7 Medullary infarcts have been shown to produce significant autonomic dysfunction.8,9

Ictal and interictal cardiac manifestations in epilepsy often precede seizure onset.1 Common cardiac changes are ictal tachycardia or ictal bradycardia, or both, with no clear relationship to the location or type of seizure. Evidence suggests that heart rate variability changes in epilepsy result from interictal autonomic alterations, including sympathetic or parasympathetic dominance. Investigation of baroreflex responses with temporal lobe epilepsy has uncovered decreased baroreflex sensitivity. There is no reliable correlation between sympathetic or parasympathetic upregulation or downregulation and brain MRI findings, however.

Autonomic dysfunction in the form of orthostatic hypotension has been documented in patients with mass effect from tumors, for example posterior fossa epidermoid tumors, wherein tumor resection results in improved autonomic function.10

 

 

FUNCTIONAL BRAIN IMAGING IN GENERAL

Direct visualization of heart-brain interactions is the goal when assessing ANS function. Positron emission tomography (PET) produces quantitative images, but spatial and temporal resolutions are vastly superior with fMRI.11 Further, radiation exposure is low with fMRI, allowing for safe repeat imaging.

Ogawa et al12 first demonstrated that in vivo images of brain microvasculature are affected by blood oxygen level, and that blood oxygenation reduced vascular signal loss. Therefore, blood oxygenation level–dependent (BOLD) contrast added to MRI could complement PET-like measurements in the study of regional brain activity.

Figure 3. Examples of magnetic resonance imaging susceptibility to motion artifacts before and after filtering in an electrocardiogram and a photoplethysmogram.
The relationship between neural activity and cerebral blood flow is indirect. Functional MRI has been used to locate the brain regions that are involved in simple tasks; for example, bilateral finger tapping results in increased cerebral blood flow that is detected by fMRI after a delay of several seconds. The increase in cerebral blood flow causes decreased intravascular deoxyhemoglobin which causes decreased extravascular susceptibility signal loss, which all together result in a net enhancement of the MRI signal. The signal-to-noise ratio is very low, with a signal change on the order of 1% to 3%.

Bilateral finger tapping with intermittent periods of rest is associated with a pattern of increasing and decreasing intensity of fMRI signals in involved brain regions that reflect the periods of activity and rest. This technique has been used to locate brain voxels with similar patterns of activity, enabling the creation of familiar color brain mapping. A challenge posed by autonomic fMRI in such brain mapping is that fMRI is susceptible to artifacts (Figure 3). For example, a movement of the head as little as 1 mm inside the MRI scanner—a distance comparable to the size of autonomic structures—can produce a motion artifact (false activation of brain regions) that can affect statistical significance. In addition, many ANS regions of the brain are near osseous structures (for example the brainstem and skull base) that cause signal distortion and loss.

REQUIREMENTS FOR AUTONOMIC fMRI

The tasks chosen to visualize brain control of autonomic function must naturally elicit an autonomic response. The difficulty is that untrained persons have little or no volitional control over autonomic functions, so the task and its analysis must be designed carefully and be MRI-compatible. Any motion will degrade the image; further, the capacity for the MRI environment to corrupt the measurements can limit the potential tasks for measurement.

Possible stimuli for eliciting a sympathetic response include pain, fear, anticipation, anxiety, concentration or memory, cold pressor, Stroop test, breathing tests, and maximal hand grip. Examples of parasympathetic stimuli are the Valsalva maneuver and paced breathing. The responses to stimuli (ie, heart rate, heart rate variability, blood pressure, galvanic skin response, papillary response) must be monitored to compare the data obtained from fMRI. MRI-compatible equipment is now available for measuring many of these responses.

Identifying areas activated during tasks

Functional neuroimaging with PET and fMRI has shown consistently that the anterior cingulate is activated during multiple tasks designed to elicit an autonomic response (gambling anticipation, emotional response to faces, Stroop test).11

In a study designed to test autonomic interoceptive awareness, subjects underwent fMRI while they were asked to judge the timing of their heartbeats to auditory tones that were either synchronized with their heartbeat or delayed by 500 msec.13 Areas of enhanced activity during the task were the right insular cortex, anterior cingulate, parietal lobes, and operculum.

Characterizing brainstem sites

It is difficult to achieve visualization of areas within the brainstem that govern autonomic responses. These regions are small and motion artifacts are common because of brainstem movement with the cardiac pulse. With fMRI, Topolovec et al14 were able to characterize brainstem sites involved in autonomic control, demonstrating activation of the nucleus of the solitary tract and parabrachial nucleus.

Reprinted from NeuroImage (Napadow V, et al. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuro-Image 2008; 42:169–177), Copyright © 2008, with permission from Elsevier.
Figure 4. Despite the difficulty of visualizing brainstem areas that govern autonomic response, functional magnetic resonance imaging and electrocardiographic data demonstrated brainstem regions that correlated with autonomic involvement during a handgrip task.16
Using fMRI and electrocardiographic data obtained simultaneously, Napadow et al15 attempted to assess brain correlates of autonomic function in subjects performing an MRI-compatible handgrip task. Brainstem regions that co-localized with expected areas of autonomic involvement were the parabrachial nucleus, amygdala, hypothalamus, periaquaductal gray area, posterior insula, and prefrontal cortex (Figure 4).

A review of four fMRI studies of stressor-evoked blood pressure reactivity demonstrated activation in corticolimbic areas, including the cingulate cortex, insula, amygdala, and cortical and subcortical areas that are involved in hemodynamic and metabolic support for stress-related behavioral responses.16

 

 

FUNCTIONAL BRAIN IMAGING IN DISEASE STATES

There are few studies of functional brain imaging in patients with disease because of the challenges involved. The studies are difficult to perform on sick patients because of the unfriendly MRI environment, with struct requirements for attention and participation. Furthermore, autonomic responses may be blunted, making physiologic comparisons difficult. In addition, there is evidence that BOLD may be intrinsically impaired in disease states. Unlike fMRI studies to locate brain regions involved in simple tasks such as finger tapping, which can be performed in a single subject, detecting changes in autonomic responses in disease states requires averaging over studies of multiple patients.

Woo et al17 used fMRI to compare brain regions of activation in six patients with heart failure and 16 controls upon a forehead cold pressor challenge. Increases in heart rate were measured in the patients with heart failure with application of the cold stimulus. Larger neural fMRI signal responses in patients with heart failure were observed in 14 brain regions, whereas reduced fMRI activity was observed in 15 other brain regions in the heart failure patients. Based on the results, the investigators suggested that heart failure may be associated with altered sympathetic and parasympathetic activity, and that these dysfunctions might contribute to the progression of heart failure.

Gianaros et al18 found fMRI evidence for a correlation between carotid artery intima-media thickness, a surrogate measure for carotid artery or coronary artery disease, and altered ANS reaction to fear using a fearful faces paradigm.

CONCLUSION

Functional MRI of heart-brain interactions has strong potential for normal subjects, in whom the BOLD effect is small, within the limits of motion and susceptibility artifacts. Typically, such applications require averaging results over multiple subjects. Its potential utility in disease states is less significant because of the additional limitations of MRI with sick patients (the MRI environment, blunting of autonomic response in disease, possible impairment of BOLD), but continued investigation is warranted.

The autonomic nervous system (ANS), composed of the sympathetic and parasympathetic nervous systems, governs our adaptation to changing environments such as physical threats or changes in temperature. It has been difficult to elucidate this process in humans, however, because of limitations in neuroimaging caused by artifacts from cardiorespiratory sources. This article reviews structural and functional imaging that can provide insights into the ANS.

STRUCTURAL IMAGING

Figure 1. With a coronal view, regions of cortical control of the autonomic nervous system are visible on magnetic resonance imaging.
For purposes of imaging, it is helpful to visualize the neural anatomy at a primitive level. If we imagine the neural tube bisected and flayed open, and the folds smoothed out, we would see a simplified topology of the brain, revealing the forebrain (cerebral cortex, thalamus, and hypothalamus), midbrain, hindbrain (pons, medulla, cerebellum), and spinal cord. As the brain develops and appears more complicated, these simple underlying relationships are preserved. Of particular note are the relationships of the cingulate, insula, and amygdala, all of which share proximity to the basal ganglia and the gateways into and out of the brain. These regions control and influence the ANS, many of which are visible on a single coronal view, including the cingulate cortex, prefrontal cortex, insular cortex, amygdala, and hypothalamus (Figure 1). However, the smaller individual hypothalamic and brainstem nuclei are typically not visible on conventional magnetic resonance imaging (MRI).

Similar to cortical and subcortical pathology (or stimulation) in areas of the brain that manifest as non-autonomic symptoms such as weakness, parasthesias, or seizures, pathology or stimulation in ANS areas of the brain manifest as autonomic symptoms. For example (Table), electrical stimulation of the right insular cortex of animals and humans causes ANS manifestations in the form of changes in heart rate and blood pressure, whereas left-sided stimulation of the insular cortex causes a decrease in heart rate and depressor responses. Stimulation of the basolateral amygdalian nucleus increases blood pressure and decreases heart rate; stimulation of the rostral amygdalian nucleus results in depressor effects and variable changes in heart rate. Stimulation of the cingulated gyrus and some other regions within the prefrontal cortex causes decreases in heart rate and blood pressure.

The two main subcortical areas of interest for imaging are the lateral hypothalamic area and the paraventricular nucleus, but visualization is difficult. The hypothalamus occupies a volumetric area of the brain no larger than 20 voxels; individual substructures of the hypothalamus therefore cannot easily be viewed by conventional imaging. The larger voxel size of functional MRI (fMRI) mean that fMRI of the hypothalamus can display 1 voxel at most.

Most brainstem nuclei are motor nuclei that affect autonomic responses, either sympathetic or parasympathetic. These nuclei are difficult to visualize on conventional MRI for two reasons: the nuclei are small, and may be the size of only 1 to 2 voxels. More important, MRI contrast between these nuclei and surrounding parenchyma is minimal because these structures “blend in” with the surrounding brain and are difficult to visualize singly. Examples of these major brainstem sympathetic nuclei are the periaqueductal gray substance, parabrachial nuclei, solitary nucleus, and the hypothalamospinal tract; examples of the major brainstem parasympathetic nuclei are the dorsal nucleus of the vagus nerve and the nucleus ambiguus.

The areas of the ANS under cortical control are more integrative, with influence from higher cognitive function—for example, the panic or fear associated with public speaking. Regions of subcortical control involve the basal ganglia and hypothalamus, which regulate primitive, subconscious activity, such as “fight or flight” response, pain reaction, and fear of snakes, all of which affect multiple motor nuclei. Several specific sympathetic and parasympathetic motor nuclei directly affect heart rate and blood pressure and act as relay stations for sensory impulses that reach the cerebral cortex.

NEUROLOGIC PROCESSES AND CARDIAC EFFECTS

Figure 2. Magnetic resonance imaging in a patient with Shy-Drager (left) is normal; a “hot cross buns” sign may be evident in patients with multiple-system atrophy (right).
Significant cardiac effects stemming from brain injury are well known, including alteration of cardiac rhythms, cardiac variability, and blood pressure regulation. Neurologic diseases such as parkinsonism, multiple sclerosis (MS), stroke, epilepsy, and tumors can have cardiac effects, although structural abnormalities on conventional MRI may be lacking. One notable exception is multiple systems atrophy, which can have strong autonomic symptoms and has a characteristic MRI finding called “hot cross buns” (Figure 2). An example is a subtype formally known as Shy-Drager syndrome.

MS is classically a disease of white matter, although it can also affect gray matter. Autonomic dysfunction is common, affecting as many as 50% of MS patients with symptoms that include orthostatic dizziness, bladder disturbances, temperature instability, gastrointestinal disturbances, and sweating.1–4 The effect of autonomic dysfunction on disease activity is unclear. Multiple brainstem lesions are evident on MRI, and may be linked to cardiac autonomic dysfunction. The variability of MS contributes to the difficulty of using imaging to identify culprit lesions.

Stroke causes autonomic dysfunction, with the specific manifestations dependent on the region of the brain involved. In cases of right middle cerebral artery infarct affecting the right insula, an increased incidence of cardiac arrhythmias, cardiac death, and catecholamine production ensues.5–7 Medullary infarcts have been shown to produce significant autonomic dysfunction.8,9

Ictal and interictal cardiac manifestations in epilepsy often precede seizure onset.1 Common cardiac changes are ictal tachycardia or ictal bradycardia, or both, with no clear relationship to the location or type of seizure. Evidence suggests that heart rate variability changes in epilepsy result from interictal autonomic alterations, including sympathetic or parasympathetic dominance. Investigation of baroreflex responses with temporal lobe epilepsy has uncovered decreased baroreflex sensitivity. There is no reliable correlation between sympathetic or parasympathetic upregulation or downregulation and brain MRI findings, however.

Autonomic dysfunction in the form of orthostatic hypotension has been documented in patients with mass effect from tumors, for example posterior fossa epidermoid tumors, wherein tumor resection results in improved autonomic function.10

 

 

FUNCTIONAL BRAIN IMAGING IN GENERAL

Direct visualization of heart-brain interactions is the goal when assessing ANS function. Positron emission tomography (PET) produces quantitative images, but spatial and temporal resolutions are vastly superior with fMRI.11 Further, radiation exposure is low with fMRI, allowing for safe repeat imaging.

Ogawa et al12 first demonstrated that in vivo images of brain microvasculature are affected by blood oxygen level, and that blood oxygenation reduced vascular signal loss. Therefore, blood oxygenation level–dependent (BOLD) contrast added to MRI could complement PET-like measurements in the study of regional brain activity.

Figure 3. Examples of magnetic resonance imaging susceptibility to motion artifacts before and after filtering in an electrocardiogram and a photoplethysmogram.
The relationship between neural activity and cerebral blood flow is indirect. Functional MRI has been used to locate the brain regions that are involved in simple tasks; for example, bilateral finger tapping results in increased cerebral blood flow that is detected by fMRI after a delay of several seconds. The increase in cerebral blood flow causes decreased intravascular deoxyhemoglobin which causes decreased extravascular susceptibility signal loss, which all together result in a net enhancement of the MRI signal. The signal-to-noise ratio is very low, with a signal change on the order of 1% to 3%.

Bilateral finger tapping with intermittent periods of rest is associated with a pattern of increasing and decreasing intensity of fMRI signals in involved brain regions that reflect the periods of activity and rest. This technique has been used to locate brain voxels with similar patterns of activity, enabling the creation of familiar color brain mapping. A challenge posed by autonomic fMRI in such brain mapping is that fMRI is susceptible to artifacts (Figure 3). For example, a movement of the head as little as 1 mm inside the MRI scanner—a distance comparable to the size of autonomic structures—can produce a motion artifact (false activation of brain regions) that can affect statistical significance. In addition, many ANS regions of the brain are near osseous structures (for example the brainstem and skull base) that cause signal distortion and loss.

REQUIREMENTS FOR AUTONOMIC fMRI

The tasks chosen to visualize brain control of autonomic function must naturally elicit an autonomic response. The difficulty is that untrained persons have little or no volitional control over autonomic functions, so the task and its analysis must be designed carefully and be MRI-compatible. Any motion will degrade the image; further, the capacity for the MRI environment to corrupt the measurements can limit the potential tasks for measurement.

Possible stimuli for eliciting a sympathetic response include pain, fear, anticipation, anxiety, concentration or memory, cold pressor, Stroop test, breathing tests, and maximal hand grip. Examples of parasympathetic stimuli are the Valsalva maneuver and paced breathing. The responses to stimuli (ie, heart rate, heart rate variability, blood pressure, galvanic skin response, papillary response) must be monitored to compare the data obtained from fMRI. MRI-compatible equipment is now available for measuring many of these responses.

Identifying areas activated during tasks

Functional neuroimaging with PET and fMRI has shown consistently that the anterior cingulate is activated during multiple tasks designed to elicit an autonomic response (gambling anticipation, emotional response to faces, Stroop test).11

In a study designed to test autonomic interoceptive awareness, subjects underwent fMRI while they were asked to judge the timing of their heartbeats to auditory tones that were either synchronized with their heartbeat or delayed by 500 msec.13 Areas of enhanced activity during the task were the right insular cortex, anterior cingulate, parietal lobes, and operculum.

Characterizing brainstem sites

It is difficult to achieve visualization of areas within the brainstem that govern autonomic responses. These regions are small and motion artifacts are common because of brainstem movement with the cardiac pulse. With fMRI, Topolovec et al14 were able to characterize brainstem sites involved in autonomic control, demonstrating activation of the nucleus of the solitary tract and parabrachial nucleus.

Reprinted from NeuroImage (Napadow V, et al. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuro-Image 2008; 42:169–177), Copyright © 2008, with permission from Elsevier.
Figure 4. Despite the difficulty of visualizing brainstem areas that govern autonomic response, functional magnetic resonance imaging and electrocardiographic data demonstrated brainstem regions that correlated with autonomic involvement during a handgrip task.16
Using fMRI and electrocardiographic data obtained simultaneously, Napadow et al15 attempted to assess brain correlates of autonomic function in subjects performing an MRI-compatible handgrip task. Brainstem regions that co-localized with expected areas of autonomic involvement were the parabrachial nucleus, amygdala, hypothalamus, periaquaductal gray area, posterior insula, and prefrontal cortex (Figure 4).

A review of four fMRI studies of stressor-evoked blood pressure reactivity demonstrated activation in corticolimbic areas, including the cingulate cortex, insula, amygdala, and cortical and subcortical areas that are involved in hemodynamic and metabolic support for stress-related behavioral responses.16

 

 

FUNCTIONAL BRAIN IMAGING IN DISEASE STATES

There are few studies of functional brain imaging in patients with disease because of the challenges involved. The studies are difficult to perform on sick patients because of the unfriendly MRI environment, with struct requirements for attention and participation. Furthermore, autonomic responses may be blunted, making physiologic comparisons difficult. In addition, there is evidence that BOLD may be intrinsically impaired in disease states. Unlike fMRI studies to locate brain regions involved in simple tasks such as finger tapping, which can be performed in a single subject, detecting changes in autonomic responses in disease states requires averaging over studies of multiple patients.

Woo et al17 used fMRI to compare brain regions of activation in six patients with heart failure and 16 controls upon a forehead cold pressor challenge. Increases in heart rate were measured in the patients with heart failure with application of the cold stimulus. Larger neural fMRI signal responses in patients with heart failure were observed in 14 brain regions, whereas reduced fMRI activity was observed in 15 other brain regions in the heart failure patients. Based on the results, the investigators suggested that heart failure may be associated with altered sympathetic and parasympathetic activity, and that these dysfunctions might contribute to the progression of heart failure.

Gianaros et al18 found fMRI evidence for a correlation between carotid artery intima-media thickness, a surrogate measure for carotid artery or coronary artery disease, and altered ANS reaction to fear using a fearful faces paradigm.

CONCLUSION

Functional MRI of heart-brain interactions has strong potential for normal subjects, in whom the BOLD effect is small, within the limits of motion and susceptibility artifacts. Typically, such applications require averaging results over multiple subjects. Its potential utility in disease states is less significant because of the additional limitations of MRI with sick patients (the MRI environment, blunting of autonomic response in disease, possible impairment of BOLD), but continued investigation is warranted.

References
  1. Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia 2010; 51:725737.
  2. Kodounis A, Stamboulis E, Constantinidis TS, Liolios A. Measurement of autonomic dysregulation in multiple sclerosis. Acta Neurol Scand 2005; 112:403408.
  3. Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999; 246:578586.
  4. Kulcu DG, Akbas B, Citci B, Cihangiroglu M. Autonomic dysreflexia in a man with multiple sclerosis. J Spinal Cord Med 2009; 32:198203.
  5. Abboud H, Berroir S, Labreuche J, Orjuele K, Amarenco O. Insular involvement in brain infarction increases risk for cardiac arrhythmia and death. Ann Neurol 2006; 59:691699.
  6. Tokgozoglu SL, Batur MK, Topcuoglu MA, Saribas O, Kes S, Oto A. Effects of stroke localization on cardiac autonomic balance and sudden death. Stroke 1999; 30:13011311.
  7. Strittmatter M, Meyer S, Fischer C, Georg T, Schmitz B. Location-dependent patterns in cardio-autonomic dysfunction in ischaemic stroke. Eur Neurol 2003; 50:3038.
  8. Lassman AB, Mayer SA. Paroxysmal apnea and vasomotor instability following medullary infarction. Arch Neurol 2005; 62:12861288.
  9. Deluca C, Tinazzi M, Bovi P, Rizzuto N, Moretto G. Limb ataxia and proximal intracranial territory brain infarcts: clinical and topographical correlations. J Neurol Neurosurg Psychiatry 2007; 78:832835.
  10. Gómez-Esteban JC, Berganzo K, Tijero B, Barcena J, Zarranz JJ. Orthostatic hypotension associated with an epidermoid tumor of the IV ventricle. J Neurol 2009; 256:13571359.
  11. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005; 493:154166.
  12. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87:98689872.
  13. Critchley HD. The human cortex responds to an interoceptive challenge. Proc Natl Acad Sci USA 2004; 101:63336334.
  14. Topolovec JC, Gati JS, Menon RS, Shoemaker JK, Cechetto DF. Human cardiovascular and gustatory brainstem sites observed by functional magnetic resonance imaging. J Comp Neurol 2004; 471:446461.
  15. Napadow V, Dhond R, Conti G, Makris N, Brown EN, Barbieri R. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuroimage 2008; 42:169177.
  16. Gianaros PJ, Sheu LK. A review of neuroimaging studies of stressor-evoked blood pressure reactivity: emerging evidence for a brain-body pathway to coronary heart disease risk. Neuroimage 2009; 47:922936.
  17. Woo MA, Macey PM, Keens PT, et al Functional abnormalities in brain areas that mediate autonomic nervous system control in advanced heart failure. J Card Fail 2005; 11:437446.
  18. Gianaros PJ, Hariri AR, Sheu LK, et al Preclinical atherosclerosis covaries with individual differences in reactivity and functional connectivity of the amygdala. Biol Psych 2009; 65:943950.
References
  1. Sevcencu C, Struijk JJ. Autonomic alterations and cardiac changes in epilepsy. Epilepsia 2010; 51:725737.
  2. Kodounis A, Stamboulis E, Constantinidis TS, Liolios A. Measurement of autonomic dysregulation in multiple sclerosis. Acta Neurol Scand 2005; 112:403408.
  3. Flachenecker P, Wolf A, Krauser M, Hartung HP, Reiners K. Cardiovascular autonomic dysfunction in multiple sclerosis: correlation with orthostatic intolerance. J Neurol 1999; 246:578586.
  4. Kulcu DG, Akbas B, Citci B, Cihangiroglu M. Autonomic dysreflexia in a man with multiple sclerosis. J Spinal Cord Med 2009; 32:198203.
  5. Abboud H, Berroir S, Labreuche J, Orjuele K, Amarenco O. Insular involvement in brain infarction increases risk for cardiac arrhythmia and death. Ann Neurol 2006; 59:691699.
  6. Tokgozoglu SL, Batur MK, Topcuoglu MA, Saribas O, Kes S, Oto A. Effects of stroke localization on cardiac autonomic balance and sudden death. Stroke 1999; 30:13011311.
  7. Strittmatter M, Meyer S, Fischer C, Georg T, Schmitz B. Location-dependent patterns in cardio-autonomic dysfunction in ischaemic stroke. Eur Neurol 2003; 50:3038.
  8. Lassman AB, Mayer SA. Paroxysmal apnea and vasomotor instability following medullary infarction. Arch Neurol 2005; 62:12861288.
  9. Deluca C, Tinazzi M, Bovi P, Rizzuto N, Moretto G. Limb ataxia and proximal intracranial territory brain infarcts: clinical and topographical correlations. J Neurol Neurosurg Psychiatry 2007; 78:832835.
  10. Gómez-Esteban JC, Berganzo K, Tijero B, Barcena J, Zarranz JJ. Orthostatic hypotension associated with an epidermoid tumor of the IV ventricle. J Neurol 2009; 256:13571359.
  11. Critchley HD. Neural mechanisms of autonomic, affective, and cognitive integration. J Comp Neurol 2005; 493:154166.
  12. Ogawa S, Lee TM, Kay AR, Tank DW. Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci USA 1990; 87:98689872.
  13. Critchley HD. The human cortex responds to an interoceptive challenge. Proc Natl Acad Sci USA 2004; 101:63336334.
  14. Topolovec JC, Gati JS, Menon RS, Shoemaker JK, Cechetto DF. Human cardiovascular and gustatory brainstem sites observed by functional magnetic resonance imaging. J Comp Neurol 2004; 471:446461.
  15. Napadow V, Dhond R, Conti G, Makris N, Brown EN, Barbieri R. Brain correlates of autonomic modulation: combining heart rate variability with fMRI. Neuroimage 2008; 42:169177.
  16. Gianaros PJ, Sheu LK. A review of neuroimaging studies of stressor-evoked blood pressure reactivity: emerging evidence for a brain-body pathway to coronary heart disease risk. Neuroimage 2009; 47:922936.
  17. Woo MA, Macey PM, Keens PT, et al Functional abnormalities in brain areas that mediate autonomic nervous system control in advanced heart failure. J Card Fail 2005; 11:437446.
  18. Gianaros PJ, Hariri AR, Sheu LK, et al Preclinical atherosclerosis covaries with individual differences in reactivity and functional connectivity of the amygdala. Biol Psych 2009; 65:943950.
Page Number
S69-S74
Page Number
S69-S74
Publications
Publications
Article Type
Display Headline
Imaging for autonomic dysfunction
Display Headline
Imaging for autonomic dysfunction
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S69-S74
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Neurohormonal control of heart failure

Article Type
Changed
Tue, 10/02/2018 - 09:33
Display Headline
Neurohormonal control of heart failure

We have known for more than 100 years that heart failure is characterized by excessive sympathetic nervous system (SNS) activity. Thanks to refinement of this concept in the 1980s and 1990s, we now have a good understanding of SNS activity in both experimental and clinical heart failure. During those two decades, we also realized the pathophysiologic importance of the renin-angiotensin-aldosterone system (RAAS) in patients with heart failure.1 By 2000, it was obvious that heart failure was inextricably intertwined with excessive neurohormonal activity.2,3 This understanding of the pathophysiology of heart failure took on greater importance with the ability to pharmacologically block these neurohormonal systems, thereby demonstrating the detrimental role of neurohormones in the onset and progression of heart failure.

This article is a brief historical and personal description of the study of neurohormonal control mechanisms as they relate to the clinical syndrome of heart failure. The article includes a personal account of how the story unfolded in the cardiology research laboratories at the University of Minnesota.

THE EARLY YEARS: NEUROHORMONAL HYPOTHESIS

A hypothesis emerged gradually in the 1980s suggesting that progression of heart failure was in part a product of excessive SNS and RAAS activity. Many believed that pharmacologic inhibition of these systems might mitigate against progressive cardiac remodeling and thereby reduce symptoms and extend life—the so called neurohormonal hypothesis.4 SNS blockers and RAAS blockers are now widely used in tandem as first-line therapy to treat patients with heart failure,5–11 but in 1980 we were just beginning to consider their therapeutic effects.

This major shift in thinking about neurohormonal systems and heart failure did not come about quickly. Early success was driven by the ability to quickly and precisely measure neurohormones in the laboratory coupled with the availability of drugs specifically designed to block the SNS and RAAS. It was also critically important to embrace the power of randomized controlled trials to test new therapies. Investigators, research nurses, and patients from many medical centers and laboratories should be credited with this astonishing success. I am proud to have been a part of this activity at the University of Minnesota.

THE COHN LABORATORY

Early work done in the 1960s by numerous investigators noted that the failing left ventricle (LV) was exquisitely sensitive to afterload conditions.12–15 John Ross and Eugene Braunwald explored this observation in patients in 1964.15 Jay Cohn, with his unique background in hypertension and hemodynamics, brought the concept back into the laboratory in the early 1970s, where he explored the mechanisms responsible for increased sensitivity to afterload in patients with heart failure.16

I had the good fortune to join Cohn’s laboratory in 1979, when this avenue of heart failure research was in full bloom. A team of investigators was gradually assembled that included Maria Teresa Olivari, who relocated from the Cardiovascular Research Institute in Milan, Italy, directed by Maurizio D. Guazzi. Also joining the group were T. Barry Levine from the University of Michigan, Ann Arbor; Steven Goldsmith from Ohio State University, Columbus; Susan Ziesche from the Minneapolis Veterans Affairs (VA) Medical Center; Thomas Rector, an expert statistician and pharmacologist at the University of Minnesota; and many research fellows, visitors, students, biochemists, statisticians, and research nurses. Joseph Franciosa joined the University of Minnesota group in 1974 and, after completing several important trials, left in 1979 to lead the cardiology group at the Philadelphia VA Medical Center.

The Cohn group developed a working hypothesis that activation of the SNS and RAAS in heart failure was most likely an adaptive mechanism intended for short-term circulatory support, such as in the setting of blood loss, dehydration, shock, volume depletion, or flight response. In patients with heart failure, according to the hypothesis, the SNS and RAAS activity persisted beyond that needed for adaptation, with chronic release of norepinephrine (NE), renin, angiotensin II, aldosterone, and other neurohormones. The neurohormones ultimately became “maladaptive.” Thanks to the assaying skills of Ada Simon, we had the early advantage of precise and rapid radioenzyme measurement of plasma norepinephrine and renin activity in the blood of patients and animals.

We believed that neurohormonal activation contributed in part to the excessive afterload conditions observed in heart failure. We also thought that excessive neurohormonal activation directly impaired cardiac systolic function. The obvious next step was to explore whether neurohormonal antagonists would improve myocardial performance.

Under the leadership of Steven Goldsmith, many studies were performed to investigate reflex control mechanisms and their pathogenic role in patients with heart failure. The accumulating data suggested that persistent, excessive neurohormonal activity was characteristic of heart failure and that it was associated with a poor prognosis.17 The precise mechanism that drives activation of the SNS remained elusive, however, and is poorly defined even today. In that era, when β-adrenergic blockers were believed to be contraindicated, we inhibited the central SNS with bromocriptine, clonidine, and guanfacine with modestly favorable responses. We inhibited circulating arginine vasopressin antibody (thanks to Prof. Alan Cowley for noting an acute favorable response).

 

 

THE PHARMACOLOGIC ERA

The 1980s and 1990s saw the availability of several pharmacologic tools for assessing the roles of the SNS and RAAS in heart failure. The hypotensive effects of angiotensin-converting enzyme (ACE) inhibitors and, later, angiotensin-receptor blockers (ARBs) were sources of concern, since many patients with advanced heart failure had low- to normal-range blood pressures before they received RAAS blockers. However, our group as well as others observed that abrupt blood pressure reduction occurred primarily in patients with very hyperreninemic responses to intravenous diuretics (ie, volume-depleted patients). Eventually, we learned that low baseline blood pressure did not adversely affect outcomes when vasodilators were used in patients with heart failure,18,19 leading us to titrate these drugs upward over days to weeks.

Several different combinations of vasodilators were used successfully to treat heart failure, including hydralazine, isosorbide dinitrate,20 ACE inhibitors,21,22 and ARBs.8,23–28 Direct-acting calcium channel blocking vasodilators, such as amlodipine, did not improve survival in patients with systolic heart failure, although they appeared to be safe in this setting.29 The aldosterone receptor blockers spironolactone30 and eplerenone31 were later demonstrated to improve survival of patients with advanced systolic heart failure when added to vasodilator therapy.

By the end of the 1990s, it was evident that drugs that blocked the SNS and RAAS were not just vasodilators or “afterload reducers,” similar to α-blockers, hydralazine, nitrates, and amlodipine. Neurohormonal blockers were doing something profoundly beneficial not observed with more direct-acting vasodilators.32–37 Simple afterload reduction was not enough in patients with systolic heart failure.

Neurohormonal antagonists were acting more directly on the myocardium. They were preventing the progression of LV remodeling and, in some cases, promoting reverse remodeling, thus improving myocardial function and favorably influencing the natural history of heart failure.31–39 We were astonished to discover that the failing, dilated heart could revert to normal size in response to neurohormone blockade with ACE inhibitors and β-adrenergic blockers; these findings were soon reported by other laboratories as well.

Contrary to our concept of heart failure in the 1970s, we now understood that the heart has inherent plasticity. It can dilate in response to abnormal loading conditions or myocardial injury, and it can restore itself to normal size when neurohormones are blocked and perverse loading conditions are improved. This reversal can occur spontaneously if an offending agent such as chronic alcohol use or inflammation is removed, but it is likely facilitated by SNS and RAAS blockers.

THE REMODELING ERA

Ken McDonald joined the University of Minnesota lab in 1989 as a research fellow. His skill in conducting both animal and clinical mechanistic studies was pivotal to our achieving our research goals. The inspired animal work by Boston-based Marc and Janice Pfeffer revealed the significance of the LV remodeling concept in the development of heart failure36: ventricular remodeling was a hallmark of systolic heart failure, and pharmacologic inhibition of LV remodeling by blocking neurohormones had profound clinical implications.

Under the direction of Wenda Carlyle, a molecular biology laboratory was established at the University of Minnesota whose work was dedicated solely to exploration of remodeling at a very basic level. Alan Hirsch was recruited from Victor Dzau’s laboratory at Brigham and Women’s Hospital in Boston to extend our efforts to understand the molecular basis of cardiac remodeling. Ken McDonald guided the use of magnetic resonance imaging to study remodeling in dogs.

The late 1970s saw the initiation and eventual execution of several important clinical trials, including the Vasodilator Heart Failure Trials (V-HeFT I and V-HeFT II)40,41 under our leadership, and Studies of Left Ventricular Dysfunction (SOLVD)5,6 under the leadership of Salim Yusuf and others at the National Heart Lung and Blood Institute (NHLBI). Many neuro hormonal and remodeling substudies sprang from these large clinical trials. Spencer Kubo joined our group from the Medical College of Cornell University in the mid-1980s, and he immediately demonstrated his prowess in clinical research. He also recruited Alan Bank to study the endothelium in both experimental and human heart failure.

Integrating the molecular, animal, and clinical laboratories allowed us to pursue many mechanistic studies. Laboratory meetings, often held on Saturday mornings, generated ideas for program projects that were subsequently funded by NHLBI. Birthday parties and other social events with laboratory staff and their families were part of our fabric. Late-night trips to the Post Office to send off abstracts for national meetings before the midnight deadline were a regular feature.

Our coordination of and participation in the large clinical trials allowed us to meet frequently in Bethesda with colleagues from other major centers, fostering many collaborations and friendships that continue to thrive. Susan Ziesche deserves much of the credit for coordinating many groups that were part of these large, complex trials. Cheryl Yano, our administrator, also played a key role. All National Institutes of Health (NIH) grants passed through Cheryl, and she worked tirelessly to ensure that the proposals were in the best possible shape before we submitted them. Inder Anand joined our group in the early 1990s and became a major analytical force. Jay Cohn was the intellectual leader of the group, as well as our soul and inspiration. People worked hard for him, and he taught us much in a setting that valued creativity and new ideas above all.

 

 

THE LATER YEARS

By 1997, the face of heart failure had changed. New treatments were effective, but there were new challenges to face. I moved that year to the Cleveland Clinic, where I spent 11 enjoyable and productive years. I returned to Minnesota in 2008 to help build a new cardiovascular division.

It is gratifying to look back and see what has become of the “neurohormonal hypothesis.” Today, nearly all major medical centers have heart failure programs, and certification in advanced heart failure/heart transplantation is a reality. Training programs in advanced heart failure and heart transplant are common. The Heart Failure Society of America sprang up in the early 1990s, dedicated to patients with heart failure. Jay Cohn founded the Journal of Cardiac Failure, which flourished under his leadership. Neurohormonal blockers are now considered standard, conventional therapy and are widely used throughout the world.

CONCLUSIONS

Still, there is much work to do. An increasing number of devices are being developed, largely for patients with more advanced heart failure, but attention is also being directed to prevention of heart failure. Identification and possible treatment of patients at risk for the development of heart failure, and identification of those who already have some early structural and functional perturbation without advanced symptoms, are critically important. Since event rates are so low in these patients, we need to create new strategies for studying interventions. In the long term, the best treatment for nearly any condition is early diagnosis and perhaps early treatment with a goal of prevention.

One consequence of our progress over the years may be that heart failure now primarily affects a more elderly group—patients who often have many associated comorbidities. The consequences include more frequent readmissions, large numbers of patients with intractable signs and symptoms, and the emergence of difficult end-of-life decisions. If we could truly prevent heart failure rather than forestall its emergence to a later point in life, perhaps we could do more good.

For me, the study of neurohormonal mechanisms in the setting of heart failure was the centerpiece of my early career. Jay Cohn had asked several of us early in our laboratory experience to choose a neurohormonal system and learn about it in great depth and detail. My assignment was the SNS. Since then, I have never tired of learning about its control mechanisms, how it achieves circulatory homeostasis, how its excess quantities can be directly toxic to the heart, and the variety of pharmacologic ways that we can control it. I am indeed fortunate to have been part of this amazing study group.

References
  1. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645651.
  2. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370377.
  3. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49:16591666.
  4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248254.
  5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325:293302.
  6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685691.
  7. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  8. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  9. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:17651773.
  10. Hjalmarson A, Goldstein S, Fagerberg B, et al Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERITHF). JAMA 2000; 283:12951302.
  11. Packer M, Fowler MB, Roecker EB, et al Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:21942199.
  12. Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ Res 1961; 9:11481155.
  13. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol 1963; 204:604610.
  14. Wilcken DE, Charlier AA, Hoffman JI. Effects of alterations in aortic impedance on the performance of the ventricles. Circ Res 1964; 14:283293.
  15. Ross J, Braunwald E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 1964; 29:739749.
  16. Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351361.
  17. Cohn JN, Levine TB, Olivari MT, et al Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819823.
  18. Anand IS, Tam SW, Rector TS, et al Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49:3239.
  19. Rouleau JL, Roecker EB, Tendra M, et al Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43:14231429.
  20. Taylor AL, Ziesche S, Yancy C, et al Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:20492057.
  21. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2:755763.
  22. Pfeffer MA, Braunwald E, Moyé LA, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial—the SAVE Investigators. N Eng J Med 1992; 327:669677.
  23. Curtiss C, Cohn JN, Vrobel T, Franciosa J. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58:763770.
  24. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:16671675.
  25. Young JB, Dunlap ME, Pfeffer MA, et al Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection trials. Circulation 2004; 110:26182626.
  26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:18931906.
  27. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  28. Konstam MA, Neaton JD, Dickstein K, et al Effects of high-dose versus lose-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 2009; 374:18401848.
  29. Packer M. Prospective randomized amlodipine survival evaluation 2. Presented at: 49th American College of Cardiology meeting; March 2000; Anaheim, CA.
  30. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  31. Pitt B, Remme W, Zannand F, et al Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:13091321.
  32. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  33. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569581.
  34. Konstam MA, Kronenberg MW, Rousseau MF, et al Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88:22772283.
  35. Greenberg B, Quinones MA, Koilpillai C, et al Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91:25732581.
  36. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57:8495.
  37. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  38. McDonald KM, Garr M, Carlyle PF, et al Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II sub-type 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:30343046.
  39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:11611172.
  40. Cohn JN, Archibald DG, Ziesche S, et al Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:15471552.
  41. Cohn JN, Johnson G, Ziesche S, et al A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303310.
Article PDF
Author and Disclosure Information

Gary S. Francis, MD
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN

Correspondence: Gary S. Francis, MD, University of Minnesota Medical School, 284 VCRC, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455; franc354@umn.edu.

Dr. Francis reported that he has served on advisory boards for Sanofi-Aventis and on data safety monitoring boards for Novartis and Corthera.

 

Publications
Page Number
S75-S79
Author and Disclosure Information

Gary S. Francis, MD
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN

Correspondence: Gary S. Francis, MD, University of Minnesota Medical School, 284 VCRC, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455; franc354@umn.edu.

Dr. Francis reported that he has served on advisory boards for Sanofi-Aventis and on data safety monitoring boards for Novartis and Corthera.

 

Author and Disclosure Information

Gary S. Francis, MD
Cardiovascular Division, University of Minnesota Medical School, Minneapolis, MN

Correspondence: Gary S. Francis, MD, University of Minnesota Medical School, 284 VCRC, 420 Delaware Street SE, MMC 508, Minneapolis, MN 55455; franc354@umn.edu.

Dr. Francis reported that he has served on advisory boards for Sanofi-Aventis and on data safety monitoring boards for Novartis and Corthera.

 

Article PDF
Article PDF

We have known for more than 100 years that heart failure is characterized by excessive sympathetic nervous system (SNS) activity. Thanks to refinement of this concept in the 1980s and 1990s, we now have a good understanding of SNS activity in both experimental and clinical heart failure. During those two decades, we also realized the pathophysiologic importance of the renin-angiotensin-aldosterone system (RAAS) in patients with heart failure.1 By 2000, it was obvious that heart failure was inextricably intertwined with excessive neurohormonal activity.2,3 This understanding of the pathophysiology of heart failure took on greater importance with the ability to pharmacologically block these neurohormonal systems, thereby demonstrating the detrimental role of neurohormones in the onset and progression of heart failure.

This article is a brief historical and personal description of the study of neurohormonal control mechanisms as they relate to the clinical syndrome of heart failure. The article includes a personal account of how the story unfolded in the cardiology research laboratories at the University of Minnesota.

THE EARLY YEARS: NEUROHORMONAL HYPOTHESIS

A hypothesis emerged gradually in the 1980s suggesting that progression of heart failure was in part a product of excessive SNS and RAAS activity. Many believed that pharmacologic inhibition of these systems might mitigate against progressive cardiac remodeling and thereby reduce symptoms and extend life—the so called neurohormonal hypothesis.4 SNS blockers and RAAS blockers are now widely used in tandem as first-line therapy to treat patients with heart failure,5–11 but in 1980 we were just beginning to consider their therapeutic effects.

This major shift in thinking about neurohormonal systems and heart failure did not come about quickly. Early success was driven by the ability to quickly and precisely measure neurohormones in the laboratory coupled with the availability of drugs specifically designed to block the SNS and RAAS. It was also critically important to embrace the power of randomized controlled trials to test new therapies. Investigators, research nurses, and patients from many medical centers and laboratories should be credited with this astonishing success. I am proud to have been a part of this activity at the University of Minnesota.

THE COHN LABORATORY

Early work done in the 1960s by numerous investigators noted that the failing left ventricle (LV) was exquisitely sensitive to afterload conditions.12–15 John Ross and Eugene Braunwald explored this observation in patients in 1964.15 Jay Cohn, with his unique background in hypertension and hemodynamics, brought the concept back into the laboratory in the early 1970s, where he explored the mechanisms responsible for increased sensitivity to afterload in patients with heart failure.16

I had the good fortune to join Cohn’s laboratory in 1979, when this avenue of heart failure research was in full bloom. A team of investigators was gradually assembled that included Maria Teresa Olivari, who relocated from the Cardiovascular Research Institute in Milan, Italy, directed by Maurizio D. Guazzi. Also joining the group were T. Barry Levine from the University of Michigan, Ann Arbor; Steven Goldsmith from Ohio State University, Columbus; Susan Ziesche from the Minneapolis Veterans Affairs (VA) Medical Center; Thomas Rector, an expert statistician and pharmacologist at the University of Minnesota; and many research fellows, visitors, students, biochemists, statisticians, and research nurses. Joseph Franciosa joined the University of Minnesota group in 1974 and, after completing several important trials, left in 1979 to lead the cardiology group at the Philadelphia VA Medical Center.

The Cohn group developed a working hypothesis that activation of the SNS and RAAS in heart failure was most likely an adaptive mechanism intended for short-term circulatory support, such as in the setting of blood loss, dehydration, shock, volume depletion, or flight response. In patients with heart failure, according to the hypothesis, the SNS and RAAS activity persisted beyond that needed for adaptation, with chronic release of norepinephrine (NE), renin, angiotensin II, aldosterone, and other neurohormones. The neurohormones ultimately became “maladaptive.” Thanks to the assaying skills of Ada Simon, we had the early advantage of precise and rapid radioenzyme measurement of plasma norepinephrine and renin activity in the blood of patients and animals.

We believed that neurohormonal activation contributed in part to the excessive afterload conditions observed in heart failure. We also thought that excessive neurohormonal activation directly impaired cardiac systolic function. The obvious next step was to explore whether neurohormonal antagonists would improve myocardial performance.

Under the leadership of Steven Goldsmith, many studies were performed to investigate reflex control mechanisms and their pathogenic role in patients with heart failure. The accumulating data suggested that persistent, excessive neurohormonal activity was characteristic of heart failure and that it was associated with a poor prognosis.17 The precise mechanism that drives activation of the SNS remained elusive, however, and is poorly defined even today. In that era, when β-adrenergic blockers were believed to be contraindicated, we inhibited the central SNS with bromocriptine, clonidine, and guanfacine with modestly favorable responses. We inhibited circulating arginine vasopressin antibody (thanks to Prof. Alan Cowley for noting an acute favorable response).

 

 

THE PHARMACOLOGIC ERA

The 1980s and 1990s saw the availability of several pharmacologic tools for assessing the roles of the SNS and RAAS in heart failure. The hypotensive effects of angiotensin-converting enzyme (ACE) inhibitors and, later, angiotensin-receptor blockers (ARBs) were sources of concern, since many patients with advanced heart failure had low- to normal-range blood pressures before they received RAAS blockers. However, our group as well as others observed that abrupt blood pressure reduction occurred primarily in patients with very hyperreninemic responses to intravenous diuretics (ie, volume-depleted patients). Eventually, we learned that low baseline blood pressure did not adversely affect outcomes when vasodilators were used in patients with heart failure,18,19 leading us to titrate these drugs upward over days to weeks.

Several different combinations of vasodilators were used successfully to treat heart failure, including hydralazine, isosorbide dinitrate,20 ACE inhibitors,21,22 and ARBs.8,23–28 Direct-acting calcium channel blocking vasodilators, such as amlodipine, did not improve survival in patients with systolic heart failure, although they appeared to be safe in this setting.29 The aldosterone receptor blockers spironolactone30 and eplerenone31 were later demonstrated to improve survival of patients with advanced systolic heart failure when added to vasodilator therapy.

By the end of the 1990s, it was evident that drugs that blocked the SNS and RAAS were not just vasodilators or “afterload reducers,” similar to α-blockers, hydralazine, nitrates, and amlodipine. Neurohormonal blockers were doing something profoundly beneficial not observed with more direct-acting vasodilators.32–37 Simple afterload reduction was not enough in patients with systolic heart failure.

Neurohormonal antagonists were acting more directly on the myocardium. They were preventing the progression of LV remodeling and, in some cases, promoting reverse remodeling, thus improving myocardial function and favorably influencing the natural history of heart failure.31–39 We were astonished to discover that the failing, dilated heart could revert to normal size in response to neurohormone blockade with ACE inhibitors and β-adrenergic blockers; these findings were soon reported by other laboratories as well.

Contrary to our concept of heart failure in the 1970s, we now understood that the heart has inherent plasticity. It can dilate in response to abnormal loading conditions or myocardial injury, and it can restore itself to normal size when neurohormones are blocked and perverse loading conditions are improved. This reversal can occur spontaneously if an offending agent such as chronic alcohol use or inflammation is removed, but it is likely facilitated by SNS and RAAS blockers.

THE REMODELING ERA

Ken McDonald joined the University of Minnesota lab in 1989 as a research fellow. His skill in conducting both animal and clinical mechanistic studies was pivotal to our achieving our research goals. The inspired animal work by Boston-based Marc and Janice Pfeffer revealed the significance of the LV remodeling concept in the development of heart failure36: ventricular remodeling was a hallmark of systolic heart failure, and pharmacologic inhibition of LV remodeling by blocking neurohormones had profound clinical implications.

Under the direction of Wenda Carlyle, a molecular biology laboratory was established at the University of Minnesota whose work was dedicated solely to exploration of remodeling at a very basic level. Alan Hirsch was recruited from Victor Dzau’s laboratory at Brigham and Women’s Hospital in Boston to extend our efforts to understand the molecular basis of cardiac remodeling. Ken McDonald guided the use of magnetic resonance imaging to study remodeling in dogs.

The late 1970s saw the initiation and eventual execution of several important clinical trials, including the Vasodilator Heart Failure Trials (V-HeFT I and V-HeFT II)40,41 under our leadership, and Studies of Left Ventricular Dysfunction (SOLVD)5,6 under the leadership of Salim Yusuf and others at the National Heart Lung and Blood Institute (NHLBI). Many neuro hormonal and remodeling substudies sprang from these large clinical trials. Spencer Kubo joined our group from the Medical College of Cornell University in the mid-1980s, and he immediately demonstrated his prowess in clinical research. He also recruited Alan Bank to study the endothelium in both experimental and human heart failure.

Integrating the molecular, animal, and clinical laboratories allowed us to pursue many mechanistic studies. Laboratory meetings, often held on Saturday mornings, generated ideas for program projects that were subsequently funded by NHLBI. Birthday parties and other social events with laboratory staff and their families were part of our fabric. Late-night trips to the Post Office to send off abstracts for national meetings before the midnight deadline were a regular feature.

Our coordination of and participation in the large clinical trials allowed us to meet frequently in Bethesda with colleagues from other major centers, fostering many collaborations and friendships that continue to thrive. Susan Ziesche deserves much of the credit for coordinating many groups that were part of these large, complex trials. Cheryl Yano, our administrator, also played a key role. All National Institutes of Health (NIH) grants passed through Cheryl, and she worked tirelessly to ensure that the proposals were in the best possible shape before we submitted them. Inder Anand joined our group in the early 1990s and became a major analytical force. Jay Cohn was the intellectual leader of the group, as well as our soul and inspiration. People worked hard for him, and he taught us much in a setting that valued creativity and new ideas above all.

 

 

THE LATER YEARS

By 1997, the face of heart failure had changed. New treatments were effective, but there were new challenges to face. I moved that year to the Cleveland Clinic, where I spent 11 enjoyable and productive years. I returned to Minnesota in 2008 to help build a new cardiovascular division.

It is gratifying to look back and see what has become of the “neurohormonal hypothesis.” Today, nearly all major medical centers have heart failure programs, and certification in advanced heart failure/heart transplantation is a reality. Training programs in advanced heart failure and heart transplant are common. The Heart Failure Society of America sprang up in the early 1990s, dedicated to patients with heart failure. Jay Cohn founded the Journal of Cardiac Failure, which flourished under his leadership. Neurohormonal blockers are now considered standard, conventional therapy and are widely used throughout the world.

CONCLUSIONS

Still, there is much work to do. An increasing number of devices are being developed, largely for patients with more advanced heart failure, but attention is also being directed to prevention of heart failure. Identification and possible treatment of patients at risk for the development of heart failure, and identification of those who already have some early structural and functional perturbation without advanced symptoms, are critically important. Since event rates are so low in these patients, we need to create new strategies for studying interventions. In the long term, the best treatment for nearly any condition is early diagnosis and perhaps early treatment with a goal of prevention.

One consequence of our progress over the years may be that heart failure now primarily affects a more elderly group—patients who often have many associated comorbidities. The consequences include more frequent readmissions, large numbers of patients with intractable signs and symptoms, and the emergence of difficult end-of-life decisions. If we could truly prevent heart failure rather than forestall its emergence to a later point in life, perhaps we could do more good.

For me, the study of neurohormonal mechanisms in the setting of heart failure was the centerpiece of my early career. Jay Cohn had asked several of us early in our laboratory experience to choose a neurohormonal system and learn about it in great depth and detail. My assignment was the SNS. Since then, I have never tired of learning about its control mechanisms, how it achieves circulatory homeostasis, how its excess quantities can be directly toxic to the heart, and the variety of pharmacologic ways that we can control it. I am indeed fortunate to have been part of this amazing study group.

We have known for more than 100 years that heart failure is characterized by excessive sympathetic nervous system (SNS) activity. Thanks to refinement of this concept in the 1980s and 1990s, we now have a good understanding of SNS activity in both experimental and clinical heart failure. During those two decades, we also realized the pathophysiologic importance of the renin-angiotensin-aldosterone system (RAAS) in patients with heart failure.1 By 2000, it was obvious that heart failure was inextricably intertwined with excessive neurohormonal activity.2,3 This understanding of the pathophysiology of heart failure took on greater importance with the ability to pharmacologically block these neurohormonal systems, thereby demonstrating the detrimental role of neurohormones in the onset and progression of heart failure.

This article is a brief historical and personal description of the study of neurohormonal control mechanisms as they relate to the clinical syndrome of heart failure. The article includes a personal account of how the story unfolded in the cardiology research laboratories at the University of Minnesota.

THE EARLY YEARS: NEUROHORMONAL HYPOTHESIS

A hypothesis emerged gradually in the 1980s suggesting that progression of heart failure was in part a product of excessive SNS and RAAS activity. Many believed that pharmacologic inhibition of these systems might mitigate against progressive cardiac remodeling and thereby reduce symptoms and extend life—the so called neurohormonal hypothesis.4 SNS blockers and RAAS blockers are now widely used in tandem as first-line therapy to treat patients with heart failure,5–11 but in 1980 we were just beginning to consider their therapeutic effects.

This major shift in thinking about neurohormonal systems and heart failure did not come about quickly. Early success was driven by the ability to quickly and precisely measure neurohormones in the laboratory coupled with the availability of drugs specifically designed to block the SNS and RAAS. It was also critically important to embrace the power of randomized controlled trials to test new therapies. Investigators, research nurses, and patients from many medical centers and laboratories should be credited with this astonishing success. I am proud to have been a part of this activity at the University of Minnesota.

THE COHN LABORATORY

Early work done in the 1960s by numerous investigators noted that the failing left ventricle (LV) was exquisitely sensitive to afterload conditions.12–15 John Ross and Eugene Braunwald explored this observation in patients in 1964.15 Jay Cohn, with his unique background in hypertension and hemodynamics, brought the concept back into the laboratory in the early 1970s, where he explored the mechanisms responsible for increased sensitivity to afterload in patients with heart failure.16

I had the good fortune to join Cohn’s laboratory in 1979, when this avenue of heart failure research was in full bloom. A team of investigators was gradually assembled that included Maria Teresa Olivari, who relocated from the Cardiovascular Research Institute in Milan, Italy, directed by Maurizio D. Guazzi. Also joining the group were T. Barry Levine from the University of Michigan, Ann Arbor; Steven Goldsmith from Ohio State University, Columbus; Susan Ziesche from the Minneapolis Veterans Affairs (VA) Medical Center; Thomas Rector, an expert statistician and pharmacologist at the University of Minnesota; and many research fellows, visitors, students, biochemists, statisticians, and research nurses. Joseph Franciosa joined the University of Minnesota group in 1974 and, after completing several important trials, left in 1979 to lead the cardiology group at the Philadelphia VA Medical Center.

The Cohn group developed a working hypothesis that activation of the SNS and RAAS in heart failure was most likely an adaptive mechanism intended for short-term circulatory support, such as in the setting of blood loss, dehydration, shock, volume depletion, or flight response. In patients with heart failure, according to the hypothesis, the SNS and RAAS activity persisted beyond that needed for adaptation, with chronic release of norepinephrine (NE), renin, angiotensin II, aldosterone, and other neurohormones. The neurohormones ultimately became “maladaptive.” Thanks to the assaying skills of Ada Simon, we had the early advantage of precise and rapid radioenzyme measurement of plasma norepinephrine and renin activity in the blood of patients and animals.

We believed that neurohormonal activation contributed in part to the excessive afterload conditions observed in heart failure. We also thought that excessive neurohormonal activation directly impaired cardiac systolic function. The obvious next step was to explore whether neurohormonal antagonists would improve myocardial performance.

Under the leadership of Steven Goldsmith, many studies were performed to investigate reflex control mechanisms and their pathogenic role in patients with heart failure. The accumulating data suggested that persistent, excessive neurohormonal activity was characteristic of heart failure and that it was associated with a poor prognosis.17 The precise mechanism that drives activation of the SNS remained elusive, however, and is poorly defined even today. In that era, when β-adrenergic blockers were believed to be contraindicated, we inhibited the central SNS with bromocriptine, clonidine, and guanfacine with modestly favorable responses. We inhibited circulating arginine vasopressin antibody (thanks to Prof. Alan Cowley for noting an acute favorable response).

 

 

THE PHARMACOLOGIC ERA

The 1980s and 1990s saw the availability of several pharmacologic tools for assessing the roles of the SNS and RAAS in heart failure. The hypotensive effects of angiotensin-converting enzyme (ACE) inhibitors and, later, angiotensin-receptor blockers (ARBs) were sources of concern, since many patients with advanced heart failure had low- to normal-range blood pressures before they received RAAS blockers. However, our group as well as others observed that abrupt blood pressure reduction occurred primarily in patients with very hyperreninemic responses to intravenous diuretics (ie, volume-depleted patients). Eventually, we learned that low baseline blood pressure did not adversely affect outcomes when vasodilators were used in patients with heart failure,18,19 leading us to titrate these drugs upward over days to weeks.

Several different combinations of vasodilators were used successfully to treat heart failure, including hydralazine, isosorbide dinitrate,20 ACE inhibitors,21,22 and ARBs.8,23–28 Direct-acting calcium channel blocking vasodilators, such as amlodipine, did not improve survival in patients with systolic heart failure, although they appeared to be safe in this setting.29 The aldosterone receptor blockers spironolactone30 and eplerenone31 were later demonstrated to improve survival of patients with advanced systolic heart failure when added to vasodilator therapy.

By the end of the 1990s, it was evident that drugs that blocked the SNS and RAAS were not just vasodilators or “afterload reducers,” similar to α-blockers, hydralazine, nitrates, and amlodipine. Neurohormonal blockers were doing something profoundly beneficial not observed with more direct-acting vasodilators.32–37 Simple afterload reduction was not enough in patients with systolic heart failure.

Neurohormonal antagonists were acting more directly on the myocardium. They were preventing the progression of LV remodeling and, in some cases, promoting reverse remodeling, thus improving myocardial function and favorably influencing the natural history of heart failure.31–39 We were astonished to discover that the failing, dilated heart could revert to normal size in response to neurohormone blockade with ACE inhibitors and β-adrenergic blockers; these findings were soon reported by other laboratories as well.

Contrary to our concept of heart failure in the 1970s, we now understood that the heart has inherent plasticity. It can dilate in response to abnormal loading conditions or myocardial injury, and it can restore itself to normal size when neurohormones are blocked and perverse loading conditions are improved. This reversal can occur spontaneously if an offending agent such as chronic alcohol use or inflammation is removed, but it is likely facilitated by SNS and RAAS blockers.

THE REMODELING ERA

Ken McDonald joined the University of Minnesota lab in 1989 as a research fellow. His skill in conducting both animal and clinical mechanistic studies was pivotal to our achieving our research goals. The inspired animal work by Boston-based Marc and Janice Pfeffer revealed the significance of the LV remodeling concept in the development of heart failure36: ventricular remodeling was a hallmark of systolic heart failure, and pharmacologic inhibition of LV remodeling by blocking neurohormones had profound clinical implications.

Under the direction of Wenda Carlyle, a molecular biology laboratory was established at the University of Minnesota whose work was dedicated solely to exploration of remodeling at a very basic level. Alan Hirsch was recruited from Victor Dzau’s laboratory at Brigham and Women’s Hospital in Boston to extend our efforts to understand the molecular basis of cardiac remodeling. Ken McDonald guided the use of magnetic resonance imaging to study remodeling in dogs.

The late 1970s saw the initiation and eventual execution of several important clinical trials, including the Vasodilator Heart Failure Trials (V-HeFT I and V-HeFT II)40,41 under our leadership, and Studies of Left Ventricular Dysfunction (SOLVD)5,6 under the leadership of Salim Yusuf and others at the National Heart Lung and Blood Institute (NHLBI). Many neuro hormonal and remodeling substudies sprang from these large clinical trials. Spencer Kubo joined our group from the Medical College of Cornell University in the mid-1980s, and he immediately demonstrated his prowess in clinical research. He also recruited Alan Bank to study the endothelium in both experimental and human heart failure.

Integrating the molecular, animal, and clinical laboratories allowed us to pursue many mechanistic studies. Laboratory meetings, often held on Saturday mornings, generated ideas for program projects that were subsequently funded by NHLBI. Birthday parties and other social events with laboratory staff and their families were part of our fabric. Late-night trips to the Post Office to send off abstracts for national meetings before the midnight deadline were a regular feature.

Our coordination of and participation in the large clinical trials allowed us to meet frequently in Bethesda with colleagues from other major centers, fostering many collaborations and friendships that continue to thrive. Susan Ziesche deserves much of the credit for coordinating many groups that were part of these large, complex trials. Cheryl Yano, our administrator, also played a key role. All National Institutes of Health (NIH) grants passed through Cheryl, and she worked tirelessly to ensure that the proposals were in the best possible shape before we submitted them. Inder Anand joined our group in the early 1990s and became a major analytical force. Jay Cohn was the intellectual leader of the group, as well as our soul and inspiration. People worked hard for him, and he taught us much in a setting that valued creativity and new ideas above all.

 

 

THE LATER YEARS

By 1997, the face of heart failure had changed. New treatments were effective, but there were new challenges to face. I moved that year to the Cleveland Clinic, where I spent 11 enjoyable and productive years. I returned to Minnesota in 2008 to help build a new cardiovascular division.

It is gratifying to look back and see what has become of the “neurohormonal hypothesis.” Today, nearly all major medical centers have heart failure programs, and certification in advanced heart failure/heart transplantation is a reality. Training programs in advanced heart failure and heart transplant are common. The Heart Failure Society of America sprang up in the early 1990s, dedicated to patients with heart failure. Jay Cohn founded the Journal of Cardiac Failure, which flourished under his leadership. Neurohormonal blockers are now considered standard, conventional therapy and are widely used throughout the world.

CONCLUSIONS

Still, there is much work to do. An increasing number of devices are being developed, largely for patients with more advanced heart failure, but attention is also being directed to prevention of heart failure. Identification and possible treatment of patients at risk for the development of heart failure, and identification of those who already have some early structural and functional perturbation without advanced symptoms, are critically important. Since event rates are so low in these patients, we need to create new strategies for studying interventions. In the long term, the best treatment for nearly any condition is early diagnosis and perhaps early treatment with a goal of prevention.

One consequence of our progress over the years may be that heart failure now primarily affects a more elderly group—patients who often have many associated comorbidities. The consequences include more frequent readmissions, large numbers of patients with intractable signs and symptoms, and the emergence of difficult end-of-life decisions. If we could truly prevent heart failure rather than forestall its emergence to a later point in life, perhaps we could do more good.

For me, the study of neurohormonal mechanisms in the setting of heart failure was the centerpiece of my early career. Jay Cohn had asked several of us early in our laboratory experience to choose a neurohormonal system and learn about it in great depth and detail. My assignment was the SNS. Since then, I have never tired of learning about its control mechanisms, how it achieves circulatory homeostasis, how its excess quantities can be directly toxic to the heart, and the variety of pharmacologic ways that we can control it. I am indeed fortunate to have been part of this amazing study group.

References
  1. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645651.
  2. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370377.
  3. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49:16591666.
  4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248254.
  5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325:293302.
  6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685691.
  7. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  8. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  9. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:17651773.
  10. Hjalmarson A, Goldstein S, Fagerberg B, et al Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERITHF). JAMA 2000; 283:12951302.
  11. Packer M, Fowler MB, Roecker EB, et al Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:21942199.
  12. Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ Res 1961; 9:11481155.
  13. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol 1963; 204:604610.
  14. Wilcken DE, Charlier AA, Hoffman JI. Effects of alterations in aortic impedance on the performance of the ventricles. Circ Res 1964; 14:283293.
  15. Ross J, Braunwald E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 1964; 29:739749.
  16. Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351361.
  17. Cohn JN, Levine TB, Olivari MT, et al Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819823.
  18. Anand IS, Tam SW, Rector TS, et al Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49:3239.
  19. Rouleau JL, Roecker EB, Tendra M, et al Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43:14231429.
  20. Taylor AL, Ziesche S, Yancy C, et al Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:20492057.
  21. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2:755763.
  22. Pfeffer MA, Braunwald E, Moyé LA, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial—the SAVE Investigators. N Eng J Med 1992; 327:669677.
  23. Curtiss C, Cohn JN, Vrobel T, Franciosa J. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58:763770.
  24. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:16671675.
  25. Young JB, Dunlap ME, Pfeffer MA, et al Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection trials. Circulation 2004; 110:26182626.
  26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:18931906.
  27. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  28. Konstam MA, Neaton JD, Dickstein K, et al Effects of high-dose versus lose-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 2009; 374:18401848.
  29. Packer M. Prospective randomized amlodipine survival evaluation 2. Presented at: 49th American College of Cardiology meeting; March 2000; Anaheim, CA.
  30. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  31. Pitt B, Remme W, Zannand F, et al Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:13091321.
  32. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  33. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569581.
  34. Konstam MA, Kronenberg MW, Rousseau MF, et al Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88:22772283.
  35. Greenberg B, Quinones MA, Koilpillai C, et al Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91:25732581.
  36. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57:8495.
  37. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  38. McDonald KM, Garr M, Carlyle PF, et al Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II sub-type 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:30343046.
  39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:11611172.
  40. Cohn JN, Archibald DG, Ziesche S, et al Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:15471552.
  41. Cohn JN, Johnson G, Ziesche S, et al A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303310.
References
  1. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63:645651.
  2. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101:370377.
  3. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 1982; 49:16591666.
  4. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248254.
  5. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991; 325:293302.
  6. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327:685691.
  7. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  8. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  9. CIBIS Investigators and Committees. A randomized trial of β-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:17651773.
  10. Hjalmarson A, Goldstein S, Fagerberg B, et al Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERITHF). JAMA 2000; 283:12951302.
  11. Packer M, Fowler MB, Roecker EB, et al Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106:21942199.
  12. Imperial ES, Levy MN, Zieske H. Outflow resistance as an independent determinant of cardiac performance. Circ Res 1961; 9:11481155.
  13. Sonnenblick EH, Downing SE. Afterload as a primary determinant of ventricular performance. Am J Physiol 1963; 204:604610.
  14. Wilcken DE, Charlier AA, Hoffman JI. Effects of alterations in aortic impedance on the performance of the ventricles. Circ Res 1964; 14:283293.
  15. Ross J, Braunwald E. The study of left ventricular function in man by increasing resistance to ventricular ejection with angiotensin. Circulation 1964; 29:739749.
  16. Cohn JN. Blood pressure and cardiac performance. Am J Med 1973; 55:351361.
  17. Cohn JN, Levine TB, Olivari MT, et al Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819823.
  18. Anand IS, Tam SW, Rector TS, et al Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 2007; 49:3239.
  19. Rouleau JL, Roecker EB, Tendra M, et al Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 2004; 43:14231429.
  20. Taylor AL, Ziesche S, Yancy C, et al Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351:20492057.
  21. Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 1983; 2:755763.
  22. Pfeffer MA, Braunwald E, Moyé LA, et al Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial—the SAVE Investigators. N Eng J Med 1992; 327:669677.
  23. Curtiss C, Cohn JN, Vrobel T, Franciosa J. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 1978; 58:763770.
  24. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:16671675.
  25. Young JB, Dunlap ME, Pfeffer MA, et al Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection trials. Circulation 2004; 110:26182626.
  26. Pfeffer MA, McMurray JJ, Velazquez EJ, et al Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:18931906.
  27. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:15471559.
  28. Konstam MA, Neaton JD, Dickstein K, et al Effects of high-dose versus lose-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 2009; 374:18401848.
  29. Packer M. Prospective randomized amlodipine survival evaluation 2. Presented at: 49th American College of Cardiology meeting; March 2000; Anaheim, CA.
  30. Pitt B, Zannand F, Remme WJ, et al The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709717.
  31. Pitt B, Remme W, Zannand F, et al Eplerenone, a selective aldosterone blocker in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:13091321.
  32. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  33. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. J Am Coll Cardiol 2000; 35:569581.
  34. Konstam MA, Kronenberg MW, Rousseau MF, et al Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilation in patients with asymptomatic systolic dysfunction. Circulation 1993; 88:22772283.
  35. Greenberg B, Quinones MA, Koilpillai C, et al Effects of long-term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction: results of the SOLVD echocardiography substudy. Circulation 1995; 91:25732581.
  36. Pfeffer JM, Pfeffer MA, Braunwald E. Influence of chronic captopril therapy on the infarcted left ventricle of the rat. Circ Res 1985; 57:8495.
  37. Cohn JN. Structural basis for heart failure: ventricular remodeling and its pharmacological inhibition. Circulation 1995; 91:25042507.
  38. McDonald KM, Garr M, Carlyle PF, et al Relative effects of α1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II sub-type 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90:30343046.
  39. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81:11611172.
  40. Cohn JN, Archibald DG, Ziesche S, et al Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314:15471552.
  41. Cohn JN, Johnson G, Ziesche S, et al A comparison of enalapril with hydralazine–isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303310.
Page Number
S75-S79
Page Number
S75-S79
Publications
Publications
Article Type
Display Headline
Neurohormonal control of heart failure
Display Headline
Neurohormonal control of heart failure
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S75-S79
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Biofeedback in coronary artery disease, type 2 diabetes, and multiple sclerosis

Article Type
Changed
Tue, 10/02/2018 - 09:34
Display Headline
Biofeedback in coronary artery disease, type 2 diabetes, and multiple sclerosis
Article PDF
Author and Disclosure Information

Matt Baumann, BS
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Dana L. Frank, PhDc
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael Liebenstein, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leo Pozuelo, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leslie Cho, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Gordon Blackburn, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Francois Bethoux, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Mary Rensel, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Betul Hatipoglu, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jim Young, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Publications
Page Number
S80
Author and Disclosure Information

Matt Baumann, BS
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Dana L. Frank, PhDc
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael Liebenstein, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leo Pozuelo, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leslie Cho, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Gordon Blackburn, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Francois Bethoux, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Mary Rensel, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Betul Hatipoglu, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jim Young, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Author and Disclosure Information

Matt Baumann, BS
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Dana L. Frank, PhDc
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael Liebenstein, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leo Pozuelo, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Leslie Cho, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Gordon Blackburn, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Francois Bethoux, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Mary Rensel, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Betul Hatipoglu, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jim Young, MD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine, Department of Psychiatry and Psychology, Department of Neurology, and Department of Endocrinology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Article PDF
Article PDF
Page Number
S80
Page Number
S80
Publications
Publications
Article Type
Display Headline
Biofeedback in coronary artery disease, type 2 diabetes, and multiple sclerosis
Display Headline
Biofeedback in coronary artery disease, type 2 diabetes, and multiple sclerosis
Citation Override
Cleveland Clinic Journal of Medicine 2011 August; 78(suppl 1):S80
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Biofeedback in heart failure patients awaiting transplantation

Article Type
Changed
Tue, 10/02/2018 - 09:34
Display Headline
Biofeedback in heart failure patients awaiting transplantation
Article PDF
Author and Disclosure Information

Dana L. Frank, PhDc
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Matt Baumann, BS
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Lamees Khorshid, PsyD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Alex Grossman-McKee
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Wilson Tang, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Randall C. Starling, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Publications
Page Number
S80a
Author and Disclosure Information

Dana L. Frank, PhDc
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Matt Baumann, BS
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Lamees Khorshid, PsyD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Alex Grossman-McKee
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Wilson Tang, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Randall C. Starling, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Author and Disclosure Information

Dana L. Frank, PhDc
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Matt Baumann, BS
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Lamees Khorshid, PsyD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Alex Grossman-McKee
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Jerry Kiffer, MA
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Wilson Tang, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Randall C. Starling, MD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Michael G. McKee, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Christine S. Moravec, PhD
Department of Cardiovascular Medicine and Department of Psychiatry and Psychology, Bakken Heart-Brain Institute, Cleveland Clinic, Cleveland, OH

Article PDF
Article PDF
Page Number
S80a
Page Number
S80a
Publications
Publications
Article Type
Display Headline
Biofeedback in heart failure patients awaiting transplantation
Display Headline
Biofeedback in heart failure patients awaiting transplantation
Citation Override
Cleveland Clinic Journal of Medicine 2011 August;78(suppl 1):S80a
Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media